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Cytochalasans are one type of PKS-NRPS secondary metabolites. The tailoring steps involved in 
cytochalasan biosynthesis are almost clear, but the formation of the isoindolone core is still mysterious. 
The ACE1 metabolite probably belongs to the cytochalasan family based on the biosynthetic gene cluster 
(BGC) analysis, even though the structure is not yet elucidated. Heterologous expression of ace1 
(PKS-NRPS) and rap1 (trans-ER) in A. oryzae produced an unexpected alcohol, which is unlikely to 
undergo further Knoevenagel reaction. Therefore it is deduced to be a shunt metabolite during 
heterologous expression. To investigate the biosynthesis of the cytochalasan skeleton including reductive 
release, putative Knoevenagel condensation and Diels-Alder reaction, three model compounds mimicking 
the ACE1 metabolite precursor were designed, prepared and applied for in vitro assays. 
 
Model A was designed and synthesized for over-reduction investigation. In vitro assays confirmed that 
model A can be reduced to the corresponding primary alcohol by A. oryzae cell free extract. This 
indicates that the alcohol is a shunt metabolite and A. oryzae is not a suitable host for cytochalasan 
heterologous expression. 
Model B was designed and prepared to study Knoevenagel condensation. In vitro assays with model B 
suggested model B can possibly form pyrrolinone spontaneously in buffer, while pyrrolinone was 
converted rapidly to alcohols. However, no enzyme activity was observed. 
Besides, pyrrolinone tautomerism was further investigated by comparing tautomerized pyrrolinone and 
non-tautomerised pyrrolinone. From NMR and UV analysis, it is confirmed that pyrrolinones 
tautomerises and are no longer competitive for the following Diels-Alder reaction. 
Model C was designed for both Knoevenagel condensation and Diels-Alder reaction tests. In vitro Assays 
showed that pyrrolinone was formed spontaneously, further confirming the Knoevenagel condensation is 
spontaneous. But its corresponding pyrrolinone also tautomerised and is no longer suitable for the 
following Diels-Alder reaction. 





Cytochalasane sind eine Art von PKS-NRPS-Sekundärmetaboliten. Die einzelnen Schritte der 
Cytochalasan-Biosynthese sind nahezu klar, aber die Bildung des Isoindolon-Kerns ist immer noch 
rätselhaft. Basierend auf einer Analyse des biosynthetischen Genclusters (BGC) gehört der 
ACE1-Metabolit wahrscheinlich zur Cytochalasan-Familie, obwohl dessen Struktur noch nicht aufgeklärt 
wurde. Die heterologe Expression von ace1 (PKS-NRPS) und rap1 (trans-ER) in A. oryzae resultierte in 
der unerwarteten Produktion eines Alkohol, der wahrscheinlich keine weitere Knoevenagel-Reaktion 
eingeht. Daher wird davon ausgegangen, dass es sich um einen Shunt-Metaboliten handelt. Um die 
Biosynthese des Cytochalasan-Gerüsts einschließlich reduktiver Freisetzung, mutmaßlicher 
Knoevenagel-Kondensation und Diels-Alder-Reaktion zu untersuchen wurden drei Modellverbindungen, 
die den ACE1-Metabolitenvorläufer imitieren, entworfen, hergestellt und anschließend für in-vitro Tests 
verwendet. 
 
Modell A wurde für Untersuchungen zur Überreduktion entworfen und synthetisiert. In-vitro Tests 
bestätigten, dass Modell A durch zellfreien Extrakt von A. oryzae zu dem entsprechenden primären 
Alkohol reduziert werden kann. Dies zeigt, dass der Alkohol ein Shunt-Metabolit ist und A. oryzae kein 
geeigneter Wirt für die heterologe Produktion von Cytochalasanen ist. 
Modell B wurde entwickelt und hergestellt, um die Knoevenagel-Kondensation zu untersuchen. In-vitro 
Tests mit Modell B deuteten darauf hin, dass Modell B möglicherweise spontan Pyrrolinon in Puffer 
bilden kann, welches schnell zu Alkoholen degradiert. Es wurde jedoch keine Enzymaktivität beobachtet. 
Außerdem wurde die Pyrrolinon-Tautomerie weiter untersucht, indem tautomerisiertes Pyrrolinon und 
nicht-tautomerisiertes Pyrrolinon verglichen wurden. Aus der NMR- und UV-Analyse wurde bestätigt, 
dass Pyrrolinone tautomerisieren und für die folgende Diels-Alder-Reaktion nicht mehr geeignet sind. 
Modell C wurde sowohl für Knoevenagel-Kondensationstests als auch für Diels-Alder-Reaktionstests 
entwickelt. In-vitro Tests zeigten, dass Pyrrolinon spontan gebildet wurde, was weiter bestätigt, dass die 
Knoevenagel-Kondensation spontan ist. Das entsprechende Pyrrolinon ist jedoch ebenfalls tautomerisiert 
und für die folgenden Diels-Alder Reaktion nicht mehr geeignet. 
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Abbreviations and Units 
[ɑ] specific rotation KS ketosynthase 
ACE Avirulence Conferring Enzyme LCMS Liquid chromatography–mass 
spectrometry AcOH Acetic acid 
ACP acyl carrier protein LDA Lithium diisopropylamine 
AT acyl transferase m multiplet 
n-BuLi n-butyl lithium M molar 
c concentration in g/mL (optical rotation) M+ Molecular ion 
C condensation domain m/z mass to charge ratio 
°C Degrees Celsius MAT malonyl-CoA:ACP transacylase 
CFE Cell free extract Me methyl 
CoA Co-enzyme A MeOH methanol 
COSY Correlation Spectroscopy min minute 
δ chemical shift in ppm mM millimolar 
d doublet MS Molecular sieve 
DA Diels-Alder MeT methyltransferase domain 
DAase Diels-Alderase NADPH β-nicotinamide adenine dinucleotide 
phosphate DCC N,N'-Dicyclohexylcarbodiimide 
DH dehydratase NMR nuclear magnetic resonance 
DIPEA N, N-diisopropylethylamine NRPS non-ribosomal peptide synthetase 
DMAP 4-(dimethylamino)pyridine ORF open reading frame 
DMF Dimethylformamide p-TsOH p-toluenesulfonic acid 
DMP Dess-Martin periodinane PCC Pyridinium chlorochromate 
DMSO dimethyl sulfoxide PDC pyridinium dichromate 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodii
mide 
PKS polyketide synthase 
PKS-NRPS polyketide synthase-non ribosomal 
peptide synthetase e.g. for example 
ELSD Evaporative Light Scattering Detector PMB p-Methoxybenzyl 
eq. equivalents ppm parts per million 
ER enoyl reductase prep-LCMS Preparative LCMS 
ES Electrospray q quartet 
EtOAc ethyl acetate R reductase domain 
EtOH ethanol Rf Retention factor 
Abbreviations and Units 
v 
FADH2 flavin adenine dinucleotide (reduced) RT room temperature 
FAS fatty acid synthase SAM S-adenosylmethionine 
FMO FAD-dependent monooxygenase sat. Saturated 
g Grams sp. species 
h hour T thiolation domain 
HMBC Heteronuclear Multiple Bond Correlation TBS tert-butyldimethylsilyl 
TE thiolesterase domain 
HRMS High Resolution Mass Sprectrometry TF transcription factor 
HSQC Heteronuclear Single Quantum Coherence 
spectroscopy 
TFA trifluoroacetic acid 
THF Tetrahydrofuran 
HWE Horner-Wadsworth Emmons TLC Thin layer chromatography 
IR infrared spectroscopy μl Microlitres 
IMDA Intramolecular Diels-Alder reaction UV Ultraviolet spectroscopy 
J coupling constant in Hertz v Wavenumber 
KR ketoreductase   
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1.1 Cytochalasan Discoveries 
Cytochalasans are large family of secondary metabolites produced by fungal polyketide 
synthase-non ribosomal peptide synthetase (PKS-NRPS) enzymes with a wide range of 
distinctive biological functions. In 1966, the first two cytochalasans, cytochalasin A 1 
and B 2 were discovered by two research groups almost simultaneously and 
independently of each other by Tamm in Basel
1
 and by the Aldridge et al.
2
 in the research 
laboratories of ICI Ltd. in England from Phoma sp. S298 and Helminthosporium 
dematioideum respectively. Tamm named them as dehydrophomin and phomin 
respectively because of their origin, while Aldridge group named them cytochalasin A 1 





 the structures of cytochalasin C 3 and D 4 were elucidated by the Aldridge 
group after their isolation in 1967
2
 from Metarrhizium anisopliae. Then in 1968, Monato 
and co-workers
4
 from Japan described a new antibiotic isolated from cultures of 
Zygosporium masonii and named it zygosporin A 4. Soon afterwards, zygosporin A 4 was 









 reported the final two cytochalasins at that time. Cytochalasin E 5, 
a metabolic product of Rosellinia necatrix, is the first member of the cyclic carbonate 
group of cytochalasans. Cytochalasin F 6 was obtained from cultures of 
Helminthosporium demafioideum, which is a double-bond isomer of cytochalasin B 2 
(Figure 1.1). 
Later, other structurally intriguing cytochalasans have been isolated from various 





 They are widespread in fungi from different habitats 
including terrestrial, endophytic,
8
 and insect-derived fungi,
9
 as well as fungi from marine 




 and even jelly-fish.
12
 
1.2 Cytochalasan Structures and Bioactivities 
The hallmark of cytochalasans includes a substituted octahydro isoindole-1-one scaffold 
fused to a macrocyclic ring derived from a highly reduced polyketide backbone and an 
amino acid. As for the amino acid moiety, tryptophan (e.g. chaetoglobosin A 7)
13
 and 
phenylalanine (e.g. cytochalasin E 5)
14 
are the most commonly observed. However, some 
other amino acids like tyrosine (e.g. phenochalasin A 8),
15
 leucine (e.g. periconiasin A 
9),
16
 valine (e.g. trichalasin A 10)
17
 and alanine (e.g. alachalasin F 11)
18
 can also be 
incorporated into cytochalasans. With regard to the polyketide backbone, it can be a 
hexaketide (e.g. periconiasin G 12),
16
 a heptaketide (e.g. periconiasin A 9), an octaketide 
(e.g. cytochalasin E 5) or a nonaketide (e.g. chaetoglobosin A 7). The macrocyle can be 
carbocyclic (e.g. chaetoglobosin A 7), lactone-containing (e.g. trichalasin A 10) or a 
carbonate (e.g. cytochalasin E 5, Figure1.2). Cytochalasan structures can be further 
diversified during a set of tailoring steps including hydroxylation (e.g. chaetoglobosin A 
7), epoxidation (e.g. alachalasin F 11) and Baeyer-Villiger oxidation (e.g. phenochalasin 




Figure 1.2 Structural diversity of cytochalasans. 
Cytochalasans exhibit a wide range of biological activities such as cytotoxic, 
antimicrobial, antiviral and phytotoxic activities.
19
 As was mentioned above, the most 
well-known bioactivity of cytochalasans is the ability to bind to actin filaments and block 
polymerization and the elongation of actin. After inhibition of actin polymerization, 
cytochalasans can change cellular morphology, inhibit cellular processes such as cell 
division, and even cause cells to undergo apoptosis.
20
 
1.3 Cytochalasan Biosynthesis 
Since the first discovery of cytochalasans, they have attracted great interests among 
scientists because of their structural complexity and strong bioactivity. For biologically 
oriented chemists, how nature biosynthesizes these complex secondary metabolites is an 
intriguing puzzle. However, the complete biosynthetic pathway has not yet been fully 
elucidated especially the assembly of the cytochalasan perhydroisoindole core despite 
the first discovery 50 years ago. 
1.3.1 Isotope Labelling Experiments 
During the 1970s isotope labelling studies were the main tools for investigating 
biosynthesis. Cytochalasin B 2, cytochalasin D 4 and chaetoglobosin A 7 were well 
studied at that time by isotopic feeding experiments. 
Introduction 
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1.3.1.1 Cytochalasin B Isotope Labelling Experiments 
The investigation of cytochalasan biosynthesis started from isotope labelling studies of 
cytochalasin B 2 in 1970 by Tamm and co-workers.
21





H-labelled precursors to the growing culture of Phoma sp. (strain S298). After 
incubation for 12 days, the percentage incorporation into cytochalasin B 2 of the 
precursors was calculated and the obtained radioactive cytochalasin B 2 was 
investigated by chemical degradation experiments. 




C] malonate and [2-
14
C] malonate all 
showed alternating distribution of the radio-activity which suggested a polyketide-like 
biosynthetic pathway (Scheme 1.1). Moreover, compared with activities obtained in 
[2-
14
C] malonate feeding experiments, the radioactivity measured for [1-
14
C] malonate 
incorporation into cytochalasin B 2 was reduced to 50%, which is in accord with the 
decarboxylation of malonate at C-1 during polyketide chain elongation (Table 1.1). 
Table 1.1 The precursors and percentages (absolute) incorporated into the cytochalasin B 2.
22
 
Precursor Activity  Incorporation (absolute)% 
[1-14C]-DL-phenylalanine  0.1 4.9 
[2-14C]-DL-phenylalanine 0.1 6.7 
[U14C]-L-phenylalanine 0.1 10.4 
[4’-3H]-L-phenylalanine 1.0 10.4 
[1-14C]-Na propionate 0.1 0.29 
[2-14C]-Na propionate 0.1 0.4 
[1-14C]-Na malonate 0.1 0.33 
[2-14C]-Na malonate 0.1 1.04 
[1-14C]-Na acetate  1.0 0.123 
[methyl-14C]-L-methionine 0.1 1.96 
[2-14C]-mevalonate 0.25 0.007 
In addition, [2-
14
C]-propionate also caused an alternating distribution of 
radioactivity identical to that of [1-
14
C] acetate and malonate, which is in accord with 
the well-known enzyme catalyzed oxidative fission of propionate to acetate 
(ɑ-oxidation), which means propionate does not account for the methyl branches. 
Introduction 
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Instead, Tamm and co-workers found high absolute incorporation rates of 
[
14
C-methyl]-methionine, revealing SAM is the methyl donor of the methyl branches in 
cytochalasan B (green in scheme 1.1). 
Feeding experiments with racemic phenylalanine (
14
C-labelled at C-1 or C-2) also 





H] phenylalanine confirmed its intact incorporation into cytochalasin B 2 without the 
loss of the carboxyl group. These results demonstrate that the cytochalasan B backbone 
is composed of one unit of phenylalanine, nine units of acetate/malonate, and two 
methyl groups from methionine (Scheme 1.1). 
 
Scheme 1.1 Cytochalasin B 2 feeding experiments by Tamm et al.
21
 
Although the position of incorporation of radioactive phenylalanine and methionine 
could be completely determined by degradation experiments, it is not accessible to 
detect all the position of [
14
C]-acetate especially the carbons on the lactam ring. The 
detectable carbons are indicated with coloured dots in scheme 1.1. Therefore, in 1974,
23
 
Tamm and co-workers fed stable isotope precursors labelled with 2-
13
C acetate to 




C-NMR spectroscopy using sequential single frequency decoupling and partially 
relaxed Fourier transform (PRFT). By comparison of the mass spectra of labelled and 
unlabelled products, the absolute incorporation rate and the expected average 
enhancement of the 
13
C NMR integral per labelled atom were determined. The results 
confirmed their previous proposals for the biosynthesis of cytochalasans and showed the 
C-1 and C-9 positions on the lactam ring are the terminus of a C18-polyketide 
intermediate. The full isotope labelling pattern is shown in scheme 1.2. 
 
Scheme 1.2 Cytochalasin B 2 feeding experiments with 
13
C-precursor. 
In 1975, Tamm and co-workers
24
 further proved that cytochalasin B 2 is a 
nonaketide by feeding radioactive deoxaphomin to Phoma sp. S298. Deoxaphomin 13, 
is a possible cytochalasin B 2 precursor isolated from S298 culture, which has a 
13-membered carbocyclic ring system.
25





C]-L-phenylalanine to cultures of Phoma sp. to obtain radioactive deoxaphomin 13. 
Subsequent feeding experiments demonstrated its intact incorporation into cytochalasin 
B 2. This suggests that deoxaphomin 13 is the precursor for the biosynthesis of 
cytochalasin B 2 and an acetate unit is split as a result of an oxygen insertion (Scheme 
1.3). This possible Baeyer-Villiger oxygenation in cytochalasin B 2 tailoring steps 
remains to be proven. However, the Tang group has recently proved the involvement of 





Scheme 1.3 Radioactive deoxaphomin 13 feeding experiments. 
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1.3.1.2 Cytochalasin D Isotope Labelling Experiments 












C]-cytochalasin D 4, the distribution of the radioactivity 
was determined and the results demonstrated that cytochalasin D 4 is composed of 1 




Scheme 1.4 Cytochalasin D 4 feeding experiments by Tamm et al.
27
 
Almost at the same time, Tamm and co-workers
23
 reported a feeding experiment 
using stable isotope labelling precursors with 
13
C-sodium acetate (at C-1 or C-2) to 
growing cultures of Zygosporium masonii and detected the distribution of precursors 
with 
13
C-NMR spectroscopy (scheme 1.5). Feeding experiment with [1-
13
C]-sodium 
acetate shows the enhancement of 
13
C atoms in an alternating distribution, as well as the 
carbonyl group on the O-acetyl group. Another feeding experiment with [2-
13
C]-sodium 









Further feeding experiments by Tamm and co-workers showed that both DL- and 
L-phenylalanine were equally well incorporated into cytochalasin D 4 due to a rapid 
equilibrium of D- and L-phenylalanines via phenylpyruvic acid. However, the 








H3] acetate to cytochalasin B 2 and D 4; B, possible reason for 









H3] acetate into cytochalasin B 2 and D 4 by Phoma exigua and Zygosporium 
masonii respectively.
30
 The metabolites were analyzed by 
13
C NMR and 
2
H NMR and 
the results showed that the deuterium was exclusively present at carbon atoms which are 
in polyketide chain-initiating units and O-acetyls that are introduced after the assembly 
of the cytochalasin D 4 core structure (scheme 1.6A). Apart from the one deuterium 
from acetate that is definitely lost during the incorporation into malonate, substantial 
deuterium leakage was observed, probably because of the non-stereoselective hydrogen 
exchange of acidic C-H at ɑ-position at a post-malonate stage (Scheme 1.6B). This 
feeding experiment verifies acetate is the starter unit of the polyketide chain assembly. 
1.3.1.3 Chaetoglobosin A Isotope Labelling Experiments 
Chaetoglobosin A 7 together with 19-O-acetylchaetoglosobin A 13 were isolated in 
1973 from Chaetomlum globosum in which a tryptophan rather than phenylalanine was 
introduced.
31
 Therefore the investigation of its biosynthesis gained great interest. In 
1981,
13












Chaetomium globosum showed high incorporation rates of acetate, methionine and 
tryptophan. This demonstrates that the origin of the chaetoglobosins from an 
acetate/malonate polyketide and from tryptophan with introduced methyl groups 
derived from methionine. The much lower incorporation of [1-
14
C]-propionate indicates 
that it is incorporated indirectly as acetate after several biological transformations rather 
than as a chain elongation unit via methylmalonate. 
After establishment of the basic biogenetic units, Tamm and co-workers also fed 
Chaetomium globosum with stable 
13














L-methionine were fed to Chaetomium globosum and the results demonstrated that the 
biosynthesis via a C18-polyketide, which is obtained by head-to-tail condensation of 
nine intact acetate/malonate units, and a single acetate unit which is introduced as an 
O-acetyl function, probably at a later stage of the biosynthesis, and the three intact 




The starter unit of the polyketide was also identified to be sodium acetate by 




H3] acetate. Moreover, the intact incorporation of 
L-tryptophan into chaetoglobosin A 7 and 19-O-acetylchaetoglobosin A 14 was 









N]-L-tryptophan with retention of both the ɑ-H- and the ɑ-N-atom (Scheme 
1.7). 
 
Scheme 1.7 Chaetoglobosin A 7 and 19-O-acetylchaetoglobosin A 14 isotope labelling patterns from C. globosum. 
Apart from the origins of carbon skeleton and nitrogen atom as well as hydrogen 
atoms, the sources of oxygens were still mysterious. In 1992, Ichihara and co-workers
32
 








H3] acetate and 
18
O2 gas to Chaetomium subaffine. The results demonstrated that the 
carbonyl oxygens at C-1 and C-23 originate from acetate, while the epoxide and 
carbonyl oxygens at C-20 derive from oxygen gas (Scheme 1.7). 
In conclusion, based on all these isotope labelling experiments, the biosynthesis of 
cytochalasans are clearly assembled from acetate as the starter unit and malonate as the 
elongation unit in a head to tail fashion via the polyketide pathway. Various amino acids 
are incorporated intact after assembly of the polyketide chain. Methionine is the methyl 
group donor for the alkyl branches in cytochalasans. Oxygen gas is also involved in the 
biosynthesis for the introduction of epoxide or hydroxyl moieties. 
1.3.1.4 Primary Proposal for Cytochalasan Biosynthesis 
Based on the great structural similarity of many cytochalasans and the isotope labelling 






The biosynthesis was proposed to start with the assembly of the C18-polyketide 15 
from acetyl-coenzyme A as the starter unit and eight malonates as enlongation units in a 
successive head-to-tail fashion. The C-methylation from methionine occurs before the 
stabilization of the polyketide, or before the release from the polyketide enzyme. Next, 
the amide linkage of L-tryptophan to the polyketide takes place and subsequent ring 
closure occurs to form the five-membered ring. After reductions, dehydrations and 
allylic oxidation, the tetramic acid derivative is converted to pyrrolinone 18, which can 
undergo an intramolecular Diels-Alder (IMDA) reaction to form the tricyclic core 
structure 19. After epoxidation, chaetoglobsin A is formed from chaetoglobosin J 19. 
 
Scheme 1.8 Proposed Chaetoglobosin A 7 biosynthesis by Tamm.
13
 
1.3.2 Molecular Basis of Cytochalasan Biosynthesis 
According to the isotope labelling studies, the cytochalasans are composed of one 
molecule of an amino acid and a polyketide chain with different chain lengths. Since the 
amino acid is incorporated intact, the only conceivable scenario is through the 
polyketide synthase (PKS)-nonribosomal peptide synthetase (NRPS) hybrid.
19
 The 
bacterial PKS-NRPS have been well studied for the biosynthesis of various of bacterial 
metabolites, such as bleomycin.
33
 However, because of the lack of molecular tools for 
fungi, the fungal PKS-NRPS were unknown until the first PKS-NRPS discovery for 
fusarin C in 2004 by the Cox group.
34
 Up to now, only a few cytochalasan biosynthetic 
gene clusters have been reported, including those for chaetoglobosin A 7, cytochalasin 
E 5, pyrichalasin H 20
35
 and two cryptic cytochalasan metabolites from Pyricularia 
oryzae Guy11,
36




Figure 1.3 Cytochalasans with known gene clusters. 
1.3.2.1 Chaetoglobosin A Biosynthesis 
The first discovery of a cytochalasan biosynthesis gene cluster was reported from the 
chaetoglobosin producer Penicillium expansum in 2007 by Hertweck and co-workers.
37
 
RNA silencing was applied to investigate a PKS-NRPS gene (cheA) which abolished 
the formation of chaetoglobosin A 7 and determined cheA was responsible for the 
biosynthesis of chaetoglobosin A 7. However, their attempts to perform targeted gene 
knockout in P. expansum and heterologous expression of the entire or partial che cluster 
in Aspergillus were unsuccessful.
37
 In 2015, the full genome sequences of three 
Penicillium expansum strains were reported but the che gene cluster was not 
identified.
38
 There is no direct evidence that the che cluster is actually responsible for 
chaetoglobosin A biosynthesis and possibly it is only one similar PKS-NRPS gene.
39
 
In 2013, Watanabe and co-workers
40
 reported the correct gene cluster for 
chaetoglobosin A 7 biosynthesis from Chaetomium globosum using genome mining to 
identify the PKS-NRPS protein encoded by CHGG_01239 (Scheme 1.9A). The cluster 
was confirmed by targeted gene deletion of CHGG_01239 and the adjacent trans-ER 
gene (CHGG_01240), which abolished the production of chaetoglobosin A 7. 
CHGG_01239 encodes a PKS-NRPS hybrid synthetase. CHGG_01240 encodes a 
trans-acting enoyl-reductase. The CHGG biosynthetic gene cluster also encodes two 
P450 oxygenases (CHGG_01242-1 and CHGG_01243), an FAD-dependent 
monooxygenase (CHGG_1242-2) and a transcription factor (CHGG_01237). Two 
additional genes, CHGG_01241 and CHGG_01244 were also identified. The first 
unknown protein encoded by CHGG_01241 has no significant similarity to 
characterized proteins, nor does it contain any conserved domains. While the second 






Moreover, Watanabe and co-workers fully characterized the late tailoring steps in 
chaetoglobosin A 7 biosynthesis. The pathway from prochaetoglobosin I 22 to 
chaetoglobosin A 7 was elucidated by targeted gene deletion including CHGG_01242-1, 
CHGG_01242-2, CHGG_01243, which all encode redox enzymes for tailoring steps. 
Firstly, deteletion of all three genes resulted in the loss of chaetoglobosin A 7 and the 
accumulation of prochaetoglososin I 22, which clarified that the oxygen at C-19 
originated from molecular oxygen rather than part of the polyketide chain as previously 
proposed.
32,37,40
 Next, to understand the function of single genes, a double mutant strain 
was created. To investigate the putative P450 function of CHGG_01242-1, disruption of 
CHGG_01242-2 and CHGG_01243 resulted in accumulation of 23 and a decrease of 22. 
However, deletion of two P450s CHGG_01242-1 and CHGG_01243 showed no 
conversion of 22, indicating that 22 is not the substrate for CHGG_01242-2. Disruption 
of CHGG_01242-1 and CHGG_01242-2 showed accumulation of 25 and a loss of 22, 
suggesting CHGG_01243 is responsible for the conversion of 22 to 25 (Scheme 1.9B). 
 
Scheme 1.9 A, revised chaetoglobosin A 7 CHGG biosynthetic gene clusters in C. globosum; B, the tailoring steps after 
assembly of chaetoglobosin A 7 backbone. 
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At last, to elucidate the whole biosynthetic pathway, a single mutant strain was 
created. Deletion of CHGG_01242-1 showed accumulation of 25 and 19, and loss of 22, 
indicating 25 and 19 are substrates for CHGG_01242-1, which catalyses the 
epoxidation at C-6/C-7. Analysis of the CHGG_01242-2 strain showed that it 
accumulated 24 in exchange for the loss of 22, demonstrating 24 is the substrate of the 
predicted FMO CHGG_01242-2, which catalyses the oxidation of the C-20 hydroxyl 
group into a ketone. Disruption of CHGG_01243 accumulated 23 with a reduction of 22, 
identifying that CHGG_01243 also accepts 23 as its substrate to perform 
dihydroxylation at C-19 and C-20. 
Combining all of the results obtained from the mutant studies, the complete 
oxidative tailoring pathway was elucidated for the transformation of prochaetoglobosin 
I 22 to chaetoglobosin A 7 (Scheme 1.9B). The results reveal that the three redox 
enzymes possess a considerable substrate tolerance that leads to the formation of 
various intermediates and the post-PKS/NRPS modifications are not linear.
40
 
1.3.2.2 Cytochalasin E Biosynthesis 
Cytochalasin E 5, a potent anti-angiogenic agent, is the first member of the cyclic 
carbonate group of cytochalasans. In 2011, Tang and co-workers
41
 published the 
sequence of the gene cluster (ccs) responsible for the biosynthesis of cytochalasin E 5 in 
Aspergillus clavatus through genome mining
 
(Scheme 1.10A). They deleted the central 
PKS-NRPS gene, ccsA, which abolished the production of cytochalasins E 5 and K 35, 
confirming the association between the natural products and the gene cluster. Different 
from chaetoglobosin A 7, cytochalasin E 5 has a unique vinyl carbonate moiety which is 
suggested to be introduced through the action of a Baeyer-Villiger monooxygenase 
(BVMO, CcsB). In addition, there is a typical trans-ER (CcsC), two P450 
monooxygenases (CcsD and CcsG), a transcriptional regulator (CcsR) as well as two 
proteins with unknown functions (CcsE and CcsF). CcsE shows sequence similarity to 
an α, β-hydrolase and has 54% identity with CHGG_01244, while CcsF bears 51% 
sequence identity with the protein of unknown function CHGG_01241 from C. 
globosum. CcsF has been previously suggested to be involved in the IMDA 
cycloaddtion reaction,
41
 although no evidence has been given. 
With the gene cluster elucidated, Tang and co-workers also proposed the 





 (Scheme 1.10B). Their proposal started with an ACP tethered 
highly reduced polyketide chain 26, produced by the iterative incorporation of eight 
acetate moieties by CcsA, a PKS-NRPS hybrid enzyme. A phenylalanine residue is 
proposed to extend the acyl-bound chain to form the amide 27. This amide was 
hypothesized to be reductively released by the terminal R-domain in an NAD(P)H 
dependent reaction to give aldehyde 28. After reductive chain release, the β-keto amide 
is thought to react in a Knoevenagel condensation to produce pyrrolinone 29, which is a 
dienophile for an IMDA reaction to give 30. Then cytochalasin E 5 was proposed to be 
produced after some tailoring steps including double Baeyer-Villiger oxidation. 
 
Scheme 1.10 A, cytochalasin E 5 biosynthetic gene clusters in A. clavatus; B, proposed biosynthesis for cytochalasin E 
5 by the Tang group. 
Introduction 
16 
However, in 2013, heterologous co-expression of the cytochalasin E 5 PKS-NRPS 
ccsA and trans-ER ccsC from A. clavatus in A. oryzae by Oikawa and co-workers
42
 
produced metabolite 36, an octaketide alcohol intermediate possessing the cytochalasin 
backbone, rather than the aldehyde or pyrrolinone or even DA adduct as proposed by 
Tang. Another unexpected feature was the loss of the olefin at C-4/C-5, which should 
be an alkene in cytochalasin E 5, indicating possibly that a host enzyme in A. oryzae 
reduced the proposed cytochalasan aldehyde intermediate (Scheme 1.11A).
43
 Apart 
from 36, further investigation found a similar compound which was characterized to be 
37, a hydroxylated derivative of 36, suggesting an oxidative enzyme within A. oryzae 
had also oxidised the backbone at C-16. But they suggested that the primary alcohol can 
be oxidized to an aldehyde for subsequent Knoevenagel condensation, which opens a 
door for the investigation of the IMDA reaction. 
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
 
Scheme 1.11 A, heterologous co-expression of ccsA and ccsC in A. oryzae; B, heterologous co-expression of ccsA and 
ccsC in A. nidulans or A. niger. 
In 2016, Larsen and co-workers
44
 reported co-expression of ccsA and ccsC in the 
different expression hosts A. nidulans and A. niger. They found the ccsC trans-ER was 
necessary for the co-expression system, otherwise no secondary metabolites were 
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detectable. But the major metabolite produced in both A. nidulans and A. niger was 
niduclavin 39 with a decalin ring, which is a presumably spontaneous DA reaction 
product of 38 between olefin at C-4 / C-5 (Scheme 1.11B). Another unexpected feature 
is the olefin at C-2’ / C-3’ of the phenylalanine, which was speculated to be introduced 
from the native host oxidative enzyme. However, knockout of the possible gene 
responsible for formation of this olefin in the host did not affect the production of 
niduclavin 39. These results show the potential problem with heterologous expression 
systems: the non-native host may not produce the identical metabolites as the native 
organism. 
For the tailoring steps in the cytochalasin E 5 biosynthesis, the formation of the 
carbonate would be the most interesting as cytochalasin E 5 was a new group of cyclic 
carbonate cytochalasin and supposed to be introduced by double Baeyer-Villiger 
oxidation. In 2014, Tang and co-workers
26
 reported their discovery about the 
carbonate-forming Baeyer-Villiger monooxygenase (BVMO) during cytochalasin E 5 
biosynthesis (Scheme 1.12). Firstly the biosynthetic origin of the oxygen atoms in 




O2] acetate or 
18
O2. 
Results showed that the carbonyl oxygen at C-21 of cytochalasin E 5 is derived from 
acetate during polyketide assembly, while both carbonate oxygen atoms attached to 
C-21 are derived from molecular oxygen, thereby pointing to an insertion pathway 
catalyzed by an oxygenase. Inactivation of the only possible BVMO, ccsB, abolished 
the production of cytochalasin E 5, and accumulated ketocytochalasin 42, revealing that 
CcsB participates earlier in the tailoring steps than previously proposed.
41
 The function 
of CcsB was confirmed by in vitro assays with 42 in the presence of NADPH, FAD and 
an FMN reductase, showing that CcsB catalyses the conversion of 42 into 44 and 46 via 
two consecutive oxygen insertions. However, formation of 46 was beyond expectation 
and it was believed to be shunt product from the spontaneous isomerization. Feeding of 
46 to A. clavatus ccsB deletion strain led to the restored production of 47, along with a 




Although CcsB was proved to be responsible for the proposed Baeyer-Villiger 
oxidations to form carbonate 44, the epoxidation of the C-6/C-7 olefin and the oxidative 
modifications at C-17 and C-18, as well as the conversion of cytochalasin E 5 to 




Scheme 1.12 Investigations of tailoring steps in cytochalasin E 5 biosynthesis by Tang and co-workers. 
1.3.2.3 ACE1 Metabolite Introduction and Biosynthesis 
The rice blast fungus Pyricularia oryzae can cause significant reductions in rice yields 
which could annually feed 60 million people by estimate.
46 
Researchers found that 
resistant rice strains carrying the Pi33 gene are resistant to avirulent P. oryzae strains 
carrying the ACE1 gene.
47
 While all the other combinations of the pathogen and rice 















Scheme 1.13 Interactions between different pathogens and rice cultivars. 
Molecular studies of avirulent P. oryzae strains showed that the ACE1 biosynthetic 
gene cluster (BGC) encodes a biosynthetic enzyme (avirulence conferring enzyme 1), 
which is responsible for the production of a low molecular weight compound (Scheme 
1.14). This ACE1 metabolite is the likely effector that can be recognized by the Pi33 
plants to produce an effective defence response, killing or containing the fungus within 
the infected cells, preventing the infection to other cells and thereby conferring 
resistance to the plant. However the structure of the ACE1 metabolite is still unknown. 
 
Scheme 1.14 Responce between ACE1 biosynthetic genes and functions. 
In order to identify the ACE1 metabolite that might be quite useful in crop 
protection, the ACE1 BGC was investigated. In 2007, Fudal and Lebrun et al. reported 
that the ACE1 BGC is an infection specific secondary metabolite gene cluster which is 
exclusively expressed during appressorium-mediated penetration, but not at any other 
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stages of the P. oryzae life cycle.
48
 Analysis of the P. oryzae genome revealed that the 
ACE1 BGC is a cluster of 15 genes (Figure 1.4).
49 
 This 15-gene cluster encodes two 
PKS-NRPS (ACE1 and SYN2), ten enzymes involved in polyketide tailoring 
modifications such as two enoyl reductases (RAP1 and RAP2), a protein with unknown 
function (ORF3), an α,β-hydrolase (ORFZ), an MFS transporter (MFS1) and a putative 
transcription factor (BC2). Gene inactivation of SYN2 and RAP2 showed that they are 
not necessary for the production of the avirulence signalling compound.
49
 ACE1 itself is 
a 12.4 kb gene encoding an enzyme consisting of a fungal highly-reducing polyketide 
synthase (HR-PKS)
50 
fused to a single module of a non-ribosomal peptide synthetase 
(NRPS) with a C-terminal R domain.
51 
Among the encoded tailoring enzymes, the α,β-hydrolase (ORFZ) has a 57% and 68% 
sequence identity to CcsE and CHGG_01244 respectively and the unknown protein 
(ORF3) has 44% and 64% sequence identity to the unknown proteins CHGG_01241 
and CcsF respectively.
39
 As CcsF is speculated to be DAase, ORF3 may be involved in 
the DA reaction. It has not yet been possible to identify or purify the avirulence 
compound from culture studies because ACE1 is under very tight temporal and cell type 
specific control in P. oryzae.
47
 Overall, cluster A of the ACE1 BGC shows high 
similarity to the known cytochalasan BGC. 
 
Figure 1.4 ACE1 gene cluster from P. oryzae. 
In 2015, the Cox group
47
 reported the heterologous expression of the avirulence 
gene ACE1 from P. oryzae in A. oryzae and P. oryzae itself using the multi-gene 
co-expression system devised and exploited by Cox group and co-workers. Expression 
of the ACE1 gene alone produced a polyenyl pyrone, which was then regioselectively 
epoxidised and hydrolysed to give two different diols (compounds 49 and 50) in the two 
host organisms (Scheme 1.15A). In contrast, co-expression of ACE1 and RAP1 in A. 
oryzae produced an amide 51 in low yield that is a nonaketide fused to tyrosine, similar 
to the PKS-NRPS derived backbone of the cytochalasans (Scheme 1.15B). But this 
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amide 51 is at the alcohol oxidation state, strikingly similar to the cytochalasin E 5 
backbone 36 produced by co-expression of ccsA and ccsC in A. oryzae by Oikawa,
42
 
which cannot form the pyrrolinone by Knoevenagel condensation (scheme 1.11). But 
from the backbone we can speculate that the ACE1 metabolite should be a member of 
cytochalasan family. Moreover, the biological tests showed that all of these three 
compounds had no bioactivities against rice blast disease. So these three compounds 
may be only intermediates or shunts from the real pathway which were probably 
reduced to an alcohol by an unknown enzyme in the host organism. 
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
 
Scheme 1.15 A, expression of ACE1 gene alone in A. oryzae or P. oryzae; B, heterologous co-expression of ACE1 and 
RAP1 in A. oryzae; C, O-methyl tyrosine was incorporated into ACE1 shunt metabolite by feeding experiment in A. 
oryzae;  D, heterologous co-expression of SYN2 and RAP2 in A. nidulans. 
Later in 2016, Larsen and co-workers
44
 co-expressed the cryptic genes SYN2 and 
RAP2 present in the ACE1 gene cluster from P. oryzae in A. nidulans, where SYN2 
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shares higher similarity with the ccs gene cluster than ACE1.
52
 Again, co-expression of 
both SYN2 and the trans-ER encoded by RAP2 is necessary for the formation of 
detectable product. The produced metabolite was shown to be niduporthin 53, with high 
similarity to niduclavin 39, which is the product of ccsA gene expression (scheme 
1.15D). Niduporthin 53 is also an octaketide with a decalin ring and pyrrole unit. But 
different from niduclavin 39, niduporthin 53 incorporated tryptophan rather than 
phenylalanine, and introduced only a single methyl group. 
In 2019, the Cox group reported that O-methyl tyrosine is the correct amino acid 
moiety incorporated into ACE1 metabolite.
36
 They found that pyrichalasin H 20 BGC in 
M. grisea NI980 shares high sequence similarities with the ACE1 BGC in P. oryzae. 
Therefore the biosynthetic pathway of pyrichalasin H 20 is highly similar to the ACE1 
metabolite biosynthesis. By gene deletion of pyiF (putative Diels-Alderase) in M. grisea 
NI980, early biosynthetic intermediates were isolated which contained O-methyl 
tyrosine, suggesting that the methyl group is transferred to tyrosine at a very early stage. 
Disruption of pyiA (O-methyl transferase) abolished production of pyrichalasin H 20, 
indicating O-methyl transferase is necessary for the production of cytochalasins. As an 
O-methyl transferase (56% amino acid identity to PyiA, encoded by OMET) is also 
present in the ACE1 BGC, it is probable that OMET is important for efficient production 
of the ACE1 metabolite. Feeding experiments with O-methyl tyrosine into A. oryzae 
expressing with ACE1, RAP1, ORF3 and ORFZ produced O-methyl tyrosine nonaketide 
52 in higher titer (scheme 1.15C) and abolished the production of 51, suggesting 
O-methyl tyrosine is the correct amino acid moiety incorporated into the ACE1 
metabolite. 
Based on the current knowledge about cytochalasan biosynthesis and the primary 
results, the Cox group proposed the biosynthetic pathway of the ACE1 metabolite 
(Scheme 1.16). Similar to the proposals for chaetoglobosin A 7 and cytochalasin E 5 
biosynthesis, ACE1 and RAP1 work together to catalyse the stepwise assembly of a 
nonaketide 54 from an acetyl-CoA starter unit and eight malonyl-CoA extenders to 
yield an enzyme-bound amide 55 (scheme 1.16). The co-expression of ccsA and ccsC, 
ACE1 and RAP1 produce the shunt metabolite 36 and 52 respectively in alcohol state 
rather than tetramic acid, suggesting the polyketide and amino acid hybrid was 
reductively released by the R domain to give an aldehyde.
42,47
 However, the aldehyde 
56 released from the R domain was reduced further to the observed hydroxyl group, 
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because of either the over-reduction by the R domain itself, or an unknown reductive 
enzyme in A. oryzae. 
 
Scheme 1.16 Proposed biosynthetic pathway for ACE1 metabolite by the Cox group. 
Until now, there is no direct evidence to show how the formation of the shunt 
metabolite 52 is catalysed. If the aldehyde 56 was not over-reduced, it could undergo a 
Knoevenagel condensation to form pyrrolinone 57 catalysed by an enzyme or 
spontaneously. It is speculated that the commonly found α,β-hydrolase (ORFZ in the 
ACE1 cluster, CcsE in the cytochalasin E 5 cluster) may be involved in the formation of 
pyrrolinone, but no evidence has so far been shown. Similarly, the function of proteins 
encoded by ORF3 in the ACE1 cluster and ccsF in cytochalasin E 5 as well as the 
CHGG_01241 in chaetoglobosin A 7 are still unknown. These proteins are speculated to 
be the DAase for the ring formation. After the cytochalasan backbone 58 is formed, the 
tailoring steps that may occur include: epoxidations, hydroxylations and hydroxyl 
oxidations catalysed by various oxidative tailoring enzymes found in all clusters. 
In conclusion, after the first discovery of cytochalasin 50 years ago, the 
biosynthesis of the cytochalasans is still not fully elucidated. Cytochalasin E 5, 
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chaetoglobosin A 7 and ACE1 gene clusters are reported and all cytochalasan 
biosynthetic gene clusters contain genes encoding a polyketide synthase/nonribosomal 
peptide synthetase (PKS-NRPS), a trans-enoyl reductase (ER), an α,β-hydrolase (HYD), 
and a putative Diels-Alderase (pDA). A trans-ER is required for the co-expression to 
form detectable product even though heterologous expression in other organisms proved 
to be problematic. But the shunt metabolites at the alcohol oxidation state suggests the 
aldehyde 56 is reductively released as opposed to tetramic acid formation by a 
Dieckman cyclization. The α,β-hydrolase is supposed to catalyze the Knoevenagel 
condensation, though it needs to be proven. The DA reaction is the most intriguing step 
in the biosynthesis and has been speculated to be catalyzed by DAase for a long time. 




Scheme 1.17 Fungal DA reaction in the biosynthesis of myceliothermophin E 60 (A) and equisetin 63 (B). 
In recent years, several fungal DAases have been characterized which catalyse 
trans-decalin ring formation, e.g. myceliothermophin 60,
38
 and equisetin 63
53
 (Scheme 
1.17). Structural studies suggest that DAases show little homology to known proteins or 
functional motifs and there are also no conserved cofactor-binding domains. Like these 
characterized DAases, ORF3, CcsF, CHGG_01241 also have no significant similarity to 
characterized proteins, nor do they contain any conserved cofactor-binding domains.
39
 
The tailoring steps in chaetoglobosin A 7 biosynthesis have already been fully 
elucidated by gene knock-out experiments.
40
 CcsB was proved to be the Baeyer-Villiger 
monooxygenase for the conversion of ketone to carbonate directly in the biosynthesis of 
cytochalasin E 5.
26
 However, the construction of the cytochalasan skeleton including 
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Knoevenagel condensation and DA reaction is of key importance and much more 
challenging than anticipated. 
1.4 Cytochalasan Total Synthesis 
As was mentioned above, cytochalasans display a wide range of biological properties, 
such as cytotoxic, antimicrobial, antiviral and phytotoxic activities.
19
 Structurally 
cytochalasans are characterized by the presence of a highly substituted bicyclic 
octahydro isoindolone unit fused to a macrocyclic ring. The structural diversity and high 
biological activities of this family of secondary metabolites has attracted great interests 
for organic chemists in total synthesis. Among all the total syntheses of the isoindolone 
core, DA reaction is the most popular method. Since some cytochalasans are 
commercially available for biological test, relatively few members of the cytochalasans 
have been the targets for total synthesis.
19
 
1.4.1 Total Synthesis of Cytochalasin B 
In 1978, Stork and co-workers
54
 reported the first total synthesis of cytochalasin B 2 in 
which an early intermolecular DA reaction was the key step (Scheme 1.18). The 
synthesis started with (+)-citrollenol acetate 68 and the acetate of the 1-ethyl ester of 
(+)-malic acid 70 in 8 steps including Kolbe coupling to synthesize intermediate 71. 
The other component 67, was derived from glycidaldehyde 66 after Wittig reaction, 
hydrolysis, protection, oxidation and reduction etc. The triene 72 was afforded by 
coupling of compound 67 and 71 through Horner-Wadsworth-Emmons reaction. The 
dienophile 65 for the [4+2] cycloaddition was prepared in 3 steps from methyl 
L-3-aminophenylbutyrate 64. The intermolecular DA cyclization between 65 and 72 
required harsh conditions (170 
°
C, 4 d) and provided the isoindole compound 73 in 
moderate yields (40%, endo/exo 4 : 1). Various subsequent steps were needed to 
complete the total synthesis including the esterification in last step to form the 
macrocycle.
55
 The formation of the isoindolone is biomimetic as the DA reaction reacts 




Scheme 1.18 Total synthesis of cytochalasin B 2 by Stork and co-workers by intermolecular DA reaction. Reagents and 
conditions: a, NaH, benzene, 0.25 equi. MeOH, 2 h, 55 °C, then 71, 55 °C, overnight, 50%; b, xylene, 170 °C, 4 d, 40%, 
endo/exo ≥ 4; c, 3:1:1 AcOH-H2O-THF, RT, overnight, then acetone-p-TsOH, 1.5 h, RT, 67%; d, tert-butyl hydroperoxide, 
Mo(CO)6, 1.5 h reflux, benzene, 95%; e, carbon tetrabromide, triphenylphosphine, 4 h, RT; f, zinc dust/ NaI, acetone, 4 h 
reflux; g, aqueous AcOH-THF, 4 h, RT; h, tert-butyl dimethylsilyl ether, 74%; i, dihydropyran, 63%; j, TBAF; k, Collins 
oxidation; l, methyltriphenylphosphoranylidene acetate, 1.5 h, benzene, reflux, 68% from 75; m, 1 N ethanolic NaOH, 
60 °C, 1 h; n, diethyl phosphorochloridate, then thallium benzenethiolate; o, aqueous AcOH, then acetylation; p, 
Na2HPO4, AgCF3CO2, benzene, reflux, 2 h, argon atomosphere, 36%. 
Later in 1983, Stork and co-workers
56
 improved the total synthesis of cytochalasin 
B 2 through the simultaneous formation of the isoindolone core and the macrocyclic 
fused ring in a late-stage IMDA reaction (Scheme 1.19). After preparation of 
N-acetylhydroxypyrrolone 78 and triene 77 derived from (+)-citrollenol, different from 
their previous work, they firstly performed the esterification between 77 and 78 using 
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Mukaiyama’s method to afford compound 79. The conditions for the IMDA cyclization 
were also harsh (180-190 
°
C, 6 d) and the yield for macrocycle 80 was only moderate 
(30%, endo/exo 4:1). The harsh conditions required for synthetic DA reactions suggest 
that this reaction in biological systems probably needs enzyme catalysis. After 
subsequent steps for functional group conversions, cytochalasin B 2 was prepared in a 
simpler route. This route is also biomimetic and gives the required stereoisomer. 
 
Scheme 1.19 Total synthesis of cytochalasin B 2 by Stork and co-workers. Reagents and conditions: a, 2-chloropyridine 
methiodide, 20 mol% DMAP, NEt3, RT, CH2Cl2, 69%; b, 180-190 
°
C, 6 d, 30%; c, 3 equiv. LDA, -78 
°
C, THF; d, 3 equiv. 
PhSeCl, H2O2, pyridine, CH2Cl2, 76% trans-selective; e, Ac2O, DMAP, NEt3 88%; f, 1 equiv. t-BuOOH, 2.5 mol% Mo(CO)6, 
0.7 M in benzene, 75 
°
C, 1.5 h, 89%; g, Al(OiPr)3, D, xylene, 8 h, 74%; h, K2CO3, MeOH, 86%; i, Bu4NF, THF 75%. 
Interestingly, in 2004, Haidle and Meyers
20
 established a generally applicable 
synthetic platform for the preparation of cytochalasans with varying ring sizes and 
substitutions by using a common precursor 88, derived from N,N-dibenzyl phenylalanal 
82 in 9 steps (Scheme 1.20). Similar to other synthetic routes, they firstly prepared the 




Scheme 1.20 Cytochalasan common precursor 88 synthesis (Meyers and Haidle). Reagents and conditions: a, Diethyl 
3-oxo-2-butylphosphonate, Ba(OH)2, THF-H2O, RT, 87%; b, 2, 3-dichloro-5, 6-dicyanobenzoquinone, CH2Cl2, RT, 86%; 
c, tert-butyldimethylsilyl trifluoromethanesulfonate, 2, 6-lutidine, CH2Cl2, -78 
°
C / RT, 99%; d, MeOH, RT, 98%; e, 
m-xylene, 150 
°
C, 77%; f, H2, 10% Pd/C, Boc2O, Et3N, EtOH, RT, 96%; g, TBAF, AcOH, THF, 0 
°
C; h, 1) KHMDS, THF, 
-78 
°
C; 2) 2-[N, N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine, 93% over 2 steps; i, Me2CuLi, THF, -78 
°




To test their strategy, 14-membered cytochalasin B 2 and the 11-membered 
cytochalasin L-696,474 were prepared from the common precursor 88. For cytochalasin 
B 2 (scheme 1.21), after deformylation of the lactone ring and subsequent oxidation of 
the hydroxyl group, a complex aldehyde building block 89 was obtained from 88. A 
fragment of the macrocyclic part of cytochalasin B 2, derived from (1R, 
2R)-pseudoephedrine, was coupled with 90 by means of Kocienski-Julia reaction to 
afford 91, which was acylated with diethyl-phosphonoacetic acid in the next step. Ring 
closure was performed by an intramolecular Horner-Wadsworth-Emmons reaction to 
form 92. Mild Mg(II)-induced rearrangement of the epoxide to the allylic alcohol 
completed the synthesis. As was mentioned above, this strategy was also applied to 
synthesize the 11-membered macrocarbocyclic cytochalasin L-696,474, and the authors 
proposed that this modular route is generally applicable to generate a large number of 




Scheme 1.21 Cytochalasin B 2 total synthesis from common precursor 88. Reagents and conditions: j, 
Dimethyldioxirane, acetone, 23 
°
C, 100%; k, TFA, CH2Cl2, 0 
°
C; l, [Bis(trifluoroacetoxy)iodo]-benzene, 4 Å MS, CH2Cl2, 
23 
°
C, 92% (two steps); m, Ethylenediamine, tert-amyl alcohol, 23 
°
C, 96%; n, DMP, NaHCO3, CH2Cl2, RT; o, sulfone 90, 
KHMDS, THF, -78 °C; aldehyde 89, -100 
°
C / -40 
°
C, 60% over 2 steps; p, 1. lithium bis(trimethylsilyl)amide, THF, -78 
°
C; 
2. Boc2O, -78 
°
C / -40 
°
C, 80%; q, KHMDS, THF, -78 
°
C, trans-2-(phenylsulfonyl)-3-phenyloxaziridine, -100 
°
C to -78 
°
C, 
85%; r, diethylphosphonoacetic acid, DCC, CH2Cl2, RT, 81%; s, HF-pyridine, THF, -20 
°
C, 69%; t, DMP, NaHCO3, 
CH2Cl2, RT; u, NaOCH2CF3, CF3CH2OH, DME, RT, 65% over 2 steps; v, Mg(OMe)2, MeOH, RT, 95%; w, TBAF, THF, RT, 
96%; x, MgSO4, benzene, 70 
°
C, 66%. 
1.4.2 Total synthesis of cytochalasin D 
Cytochalasin D 4 was first isolated from the microorganism Metarrhizum anisopliae, 
and its first total synthesis was published by Vedejs and Reid in 1984.
57
 Before their 
total synthesis, they investigated the N-acylpyrrolinones for DA reactions in the 
cytochalasin area (Scheme 1.22).
58
 According to the previous reports
59–61
 and their own 
research,
58
 the dienophile 94a is not suitable for DA reaction because of the instability 




Scheme 1.22 N-acylpyrrolinones for intermolecular DA reactions and tautomerisation. 
It is believed that hydroxypyrrole tautomer 96 is the crucial intermediate involved in 
the transformation.
58
 To avoid formation of non-reactive tautomers from pyrrolinone 
dienophiles, it is desirable to introduce an electron-withdrawing N substituent, e.g. 
carbonyl group. Because the electron lone pair can be delocalized on the exocyclic 
carbonyl group (structure 98), it is not favored to form hydroxypyrrole 99 which in fact is 
a 4-п-electron system and destabilizes the aromatic hydroxypyrrole intermediate.
62
 Then 
the subsequent tautomerisation to 100 can be also blocked. So they found that 
N-chloroacetyl derivative 94b was ideal for the purpose (Scheme 1.23). 
 
Scheme 1.23 The stabilizing effect of an electron withdrawing group on the pyrrolinone. 
In 1990, the Thomas group
63
 reported an another synthetic route to cytochalasin D 
4 by an IMDA reaction using N-acylpyrrolinone. The simultaneous formation of the 
isoindolone core and the macrocyclic ring is shown in scheme 1.24. They started 
synthesis with methacrolein 101 and (E)-but-2-enyldiisopinocampheylborane 102 and 
the triene compound 108 was prepared after 7 steps. N-benzoylpyrrolidinone 109 was 
then introduced and the double bond was prepared by phenylselenenylation followed by 
oxidative elimination, which is a popular strategy for the synthesis of cytochalasans. 
The unstable compound 112 underwent an IMDA reaction to form the isoindolone core 
and macrocycle simultaneously in toluene at 80 
°




Scheme 1.24 Total synthesis of cytochalasin D 4 by the Thomas group. Reagents and conditions: i, -78 
°
C, 3 h, then 
H2O2; ii, MeC(OEt)3, propanoic acid, 140-170 
°
C (48% from 101); iii, 9-BBN then H2O2 (77%); iv, (COCl)2, DMSO (77%); 
v, n-BuLi, 107, THF, hexamethylphosphoramide (85%); vi, NaOH, EtOH; vii, CO(imidazole)2, THF; viii, LiN(SiMe3)2, 109 
(92% from 108); ix, LiN(SiMe3)2, PhSeCl (100%); x, m-CPBA, H2O2, -50 
°
C to 0 
°
C; xi, toluene, 80 
°
C (25-30% from 111). 
1.5 Project Aims and Model Design 
Since the first discovery of cytochalasans over 50 years ago, until now, the full 
biosynthesis of cytochalasans especially the formation of isoindolone core and the 
macrocyclic ring are still mysterious. It is speculated that the PKS-NRPS hybrid derived 
chain 55 is released reductively by the C-terminal NRPS R domain to give an aldehyde 
56, which could undergo an intramolecular Knoevenagel condensation to form 
pyrrolinone 57. Afterwards, pyrrolinone 57 reacts with the diene through the putative 
DA reaction to afford the isoindolone core 58 (Scheme 1.25). However, the results from 
the literature synthetic studies suggest this is not a competent substrate for a DA 




Scheme 1.25 Proposed ACE1 metabolite biosynthesis. 
However, heterologous expression of the cytochalasan gene clusters in A. oryzae 
(including ACE1 and RAP1, ccsC and ccsA respectively) gave the alcohol state 
metabolites 36 and 52 rather than the corresponding aldehyde, which cannot undergo 
the Knovenagel condensation (Scheme 1.26). The product from ACE1 and RAP1 
expression has no avirulence effect, suggesting that it should only be the intermediate or 
shunt rather than the final ACE1 metabolite. Are they the shunt products of the 
cytochalasans precursors by over-reduction of the R domain or by unknown reductive 
enzyme in A. oryzae? This is the first question to investigate. 
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
 
Scheme 1.26 Possible shunt metabolites from heterologous expressions in A. oryzae. 
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If the aldehyde rather than the alcohol is released, it could undergo an 
intramolecular Knoevenagel condensation to form pyrrolinone as proposed. According 
to Baldwin's rules, this reaction is 5-exo-trig, which is favored. So it is questionable 
whether this intramolecular Knoevanagel condensation is a spontaneous reaction or it 
needs enzyme catalysis. In fact, this reaction includes two steps: nucleophilic attack 
followed by elimination of water. If these are enzyme-catalysed steps, then which 
enzyme and which step is the enzyme involved in? This is the second question to 
answer. We also want to know which tautomer is formed. 
After formation of the pyrrolinone, a putative DA reaction will occur according to 
the biosynthetic hypothesis. From the total synthesis we know, chemically, DA reaction 
needs harsh reaction conditions like high temperature and long reaction time. Moreover, 
the proposed pyrrolinone intermediate undergoes a rapid tautomerisation to a form 
unreactive for the DA reaction. Therefore it is likely that this DA reaction is an enzyme 
catalyzed reaction. But we need to provide sufficient evidence. 
To answer these questions, in vitro assays can be performed to investigate. Instead 
of using the real intermediate, which is labor and time consuming to produce enough for 
in vitro assays, several tyrosine related model compounds are needed. For the first 
question, one possibility is that A. oryzae itself harbors a reductive enzyme and reduces 
the aldehyde before the formation of pyrrolinone. In this case, the reductive enzyme in 
A. oryzae may have low substrate selectivity. So a simple tyrosine related aldehyde with 
a biologically benign acetyl group (model A 114) can be designed to perform in vitro 
assays with A. oryzae cell free extract (Figure 1.5). 
In order to test the Knoevenagel condensation, a β-keto amide group is necessary. 
So model B 115 with the shortest possible chain length was designed (Figure 1.5). Since 
the model compound is not the real enzyme substrate, possibly there will be substrate 
selectivity. But at least we can know more information about the substrate properties e.g. 
stability, reactivity as well as the properties of the corresponding product pyrrolinone. 
 
Figure 1.5 Structures of model compounds. 
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As for the putative DA reaction, a more complex model C 116 mimicking the shunt 
metabolite was designed (Figure 1.5). Model C 116 keeps not only the β-keto amide 
group, but also introduced the same alkyl chain length as the shunt metabolite with a 
triene at the end. The methyl groups on the shunt metabolite chain may be important for 
the DA reaction configuration, but for a primary test, model C 116 would be sufficient 
and relatively simple to make. 
After all these primary assays, the results will be further tested with more realistic 
intermediates extracted from fungal fermentations. The shunt metabolite 52 is at the 
alcohol state, which has to be oxidized to an aldehyde by chemical methods. Another 
aim is therefore to find suitable oxidizing conditions to convert similar alcohols to 
aldehydes. All these aldehydes will be tested in vitro with corresponding enzymes 
including ORFZ and ORF3 or cell free extracts from A. oryzae provided by Verena 
Hantke. The process will be monitored by LCMS or NMR. 
If possible, we can also feed the cytochalasan backbone to fungi to complete the 
biosynthesis of tailoring steps. After tailoring steps, hopefully we can discover the exact 





UV spectra, HRMS, and other necessary spectra. New compounds will be tested for 
avirulence properties by existing collaborators in France. In future, such compounds 
could be used in agriculture to switch on a plant’s native resistance against fungal 
disease for protecting crops which is a new environmentally friendly strategy in crop 
protection.
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2. Cytochalasan Shunt Metabolite Research, an 
Over-Reduction by Aspergillus oryzae. 
2.1 Introduction 
Heterologous expression is a common method in fungal secondary metabolite studies. 
The levels of expression of many genes in fungal hosts are often very low or even 
undetectable under typical cultivation conditions.
64
 Among the heterologous hosts, the 
well-known fungus Aspergillus oryzae has proved to be an amenable host and has been 














 among many others (Figure 2.1). 
 
Figure 2.1 Examples of successful heterologous expression in A. oryzae. 
However, heterologous co-expression of cytochalasin E 5 gene clusters (ccsA and 
ccsC) and ACE1 gene clusters (ace1 and rap1) in A. oryzae has been problematic. The 
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ccsA R domain harbors an intact conserved NADPH binding motif GXSXXG and the 
catalytic triad Ser-Tyr-Lys shared among the short chain dehydrogenase reductase SDR 
superfamily proteins, so it is expected that the R domain should release aldehyde 
suitable for Knoevenagel condensation. 
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
 
Scheme 2.1 Heterologous expressions in different fungal hosts. 
But Alcohols 36 and 51 with linear PKS-NRPS backbones were produced after 
heterologous expression in A. oryzae (section 1.3.2.3). The observation of linear 
compounds suggests that the cytochalasan backbone is released in a reductive way to 
give an aldehyde. However, the aldehyde was then over-reduced to the alcohol in 
A.oryzae and no longer useful for Knoevenagel condensation. The alcohol could be 
formed in two possible ways: either over-reduction by the R domain; or correct 
reduction by the R domain to aldehyde followed by A. oryzae shunt reduction. 
Moreover, heterologous co-expressions of the cytochalasin E 5 gene clusters (ccsC and 
ccsA) and PKS-NRPS SYN2 and RAP2 in the alternative fungal host Aspergillus 
nidulans produced niduclavin 39 and niduporthin 53 which are not over-reduced.
44
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These observations suggest that A. oryzae may contain a shunt reductase which is not 
present in A. nidulans (scheme 2.1). 
2.2 Aims 
Heterologous expression in A. oryzae has been developed as a toolkit for fungal 
secondary metabolite pathway investigation.
71
 But the potential problem caused by the 
possible presence of shunt enzymes in A. oryzae has not been well studied 
systematically, even though the unexpected over-reductions of aldehydes to alcohols 
have been observed and reported.
42,47,72
 This project was designed to find out whether 
the shunt enzymes in A. oryzae have a strong influence in aldehyde reduction. If 
aldehydes are reduced to alcohols by an endogenous enzyme in A. oryzae, it is also 
necessary to find out the corresponding genes responsible for the reductase. Since 
possible over-reduced cytochalasin E and ACE1 metabolite precursors are not native in 
A. oryzae, the unknown enzyme in A. oryzae probably does not have strict substrate 
selectivity. In order to investigate this, model A 114 which is an O-methyl tyrosine 
derived aldehyde was designed and synthesized. Afterwards, the A. oryzae cell free 
extract will be tested for its ability to reduce model A 114 in in vitro assays. If reduction 
activity can be observed, then the enzyme could be purified and sequenced. In the 
longer term, we could knockout the gene and thereby engineer an A. oryzae expression 
host which cannot reduce the ACE1 metabolite precursor and potentially allow 
heterologous ACE1 metabolite production. 
2.3 Results and Discussion 
Work in this section was performed in collaboration with master student Franck Siakeu 
and with fellow Ph.D. student Verena Hantke. I was responsible for the synthetic and in 
vitro analytical work while Verena helped with the preparation of A. oryzae cell free 
extracts. 
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2.3.1 Model A Retrosynthetic Analysis 
Model A 114 can be prepared from the oxidation of corresponding alcohol 128 which is 
an N-acetylated derivative of amino alcohol 127. Compound 127 is a known compound 
derived from L-tyrosine 123 in 4 steps involving nucleophilic substitution, methylation, 




Scheme 2.2 Model A 114 retrysynthetic analysis. 
2.3.2 Model A Synthesis 
The synthesis of model A 114 started with amine protection of L-tyrosine 123 (scheme 
2.3). Tyrosine has limited solubility in either organic solvent or water, so a mixture of 
THF and H2O (1:1) were used to increase the solubility. After protection of the amino 
group, double methylation of both phenol and carboxylic acid was achieved by methyl 
iodide under basic conditions in good yield. Reduction of methyl ester 125 by LiAlH4 
afforded alcohol 126, which was further deprotected with potassium hydroxide to free 
the amino group 127. 
After formation of the common intermediate 127, we can choose to selectively 
acetylate the amino group, but there was always minor double acetylation product 128 
formed. We therefore chose to acetylate both hydroxyl and amino groups with excess 
acetyl chloride in quantitive yield without purification and then hydrolyse the ester in 
MeOH with K2CO3 to afford compound 129. A modified Moffat oxidation of the 
hydroxyl group was then applied to give model A 114. The aldehyde is not very stable 
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over flash chromatography, but only milligram amounts of compound were needed for 
the bioassay, so preparative LCMS was used for the purification of model A 114. 
 
Scheme 2.3 Synthetic route to model A 114. 
The LCMS data of model A 114 is shown in Figure 2.2. The retention time is 
around 3.3 min tailing to 4.5 min because aldehydes are in equilibrium with its hydrate 
in the presence of water (scheme 2.3). The aldehyde hydrate 114b is much more polar 
than aldehyde 114, therefore it elutes earlier at 3.3 min. The aldehyde 114 which is the 
minor component of the equilibrium elutes at 4.5 min. The UV spectrum clearly shows 




 (220.1) also 
fit the molecular weight (221.1). ES
-
 (266.1) is the molecule plus formic acid (46.0). 
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Figure 2.2 LCMS data of model A 114. 
The 
1
H NMR of model A 114 in CDCl3 clearly shows the characteristic protons 
including the aldehyde proton chemical shift at 9.67 ppm, ɑ-proton at 4.72 ppm, two 
diastereotopic β-protons at 3.11 ppm. The aromatic protons and two methyl groups as 
well as the NH can be also found (Figure 2.3). 





H NMR of model A 114 in CDCl3. 
2.3.3 Model A Bioassays 
2.3.3.1 Preparation of Cell Free Extract from A. oryzae 
A. oryzae NSAR1 cells expressing ACE1 and RAP1 (2.0 g) were frozen in liquid 
nitrogen in a mortar and ground to a fine powder. Then 2 mL potassium phosphate 
buffer (pH 7.0, 50 mM) was added and mixed with the cell powder. After collection by 
centrifugation at 16000 × g for 30 min at 4 °C, the supernatant was collected and stored 
at -20 °C for further tests. 
2.3.3.2 Model A Bioassays with Cell Free Extract 
A suitable buffer system was developed for the in vitro assay. Since model A 114 is an 
aldehyde, any buffer containing an amino group, such as Tris, is not suitable because of 
likely imine formation. Therefore the common buffer potassium phosphate was first 
considered for the bioassay. To make sure potassium phosphate buffer has no influence 
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on model A 114, the stabilities of model A 114 in H2O and potassium phosphate buffer 
(pH 7.0, 50 mM) were tested at 28 °C over time. 
Figure 2.4 shows the results of model A 114 in H2O at 28 °C after 0 h, 1 h, 3 h and 
overnight. It clearly shows that model A 114 is stable in H2O even after overnight 
incubation and there was no alcohol 129 formed. 
 
Figure 2.4 Model A 114 in H2O over time at 28 °C. 
Figure 2.5 shows the results of model A 114 in potassium phosphate buffer (pH 7.0, 
50 mM) at 28 °C after 0 h, 1 h, 3 h and overnight. It shows that model A 114 is also 
stable in buffer over time and there was also tiny amount of alcohol 129 at 3.7 min, but 
this was from the incomplete oxidation of alcohol during the synthesis of the aldehyde. 
Therefore potassium phosphate buffer can be used for the bioassay with the CFE. 
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Figure 2.5 Model A 114 in potassium phosphate buffer (pH 7.0, 50 mM) over time (from bottom to top: alcohol 129, 0 min, 
60 min, 180 min and overnight) at 28 °C. 
 
Figure 2.6 Model A 114 in potassium phosphate buffer (pH 7.0, 50 mM) with CFE over time (from bottom to top: 0 min, 
15 min, 30 min, 45 min, 60 min and 180 min). 
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The model A 114 bioassay was performed with A. oryzae cell free extract (CFE) in 
potassium phosphate buffer (pH 7.0, 50 mM) with addition of NADPH at 28 °C over 
time and the sample without cell free extract was observed as a negative control. The 
result of the negative control is the same with the tests shown above in figure 2.5. While 
the CFE sample showed that after 15 min, some alcohol 129 was formed. After 1 h, 
almost all model A 114 was converted to alcohol 129 (Figure 2.6). Compared with the 
negative control, it is obvious that the aldehyde 114 was reduced to the corresponding 
alcohol 129 by an unknown protein in the CFE. 
Moreover, the N-protected aldehyde 130, prepared from oxidation of intermediate 
126, was also applied for the A. oryzae CFE assay and the aldehyde 130 was reduced to 
alcohol 126 as well in the presence of A. oryzae CFE. This further confirmed the 
exisistence of possible broadly selective aldehyde reductase in the A. oryzae CFE and 
indicated it has no strict substrate selectivity. Therefore it could also reduce the ACE1 
metabolite precursor 56 to shunt alcohol 52, even though it is not native metabolite in A. 
oryzae. 
 
Scheme 2.4 Preparation of aldehyde 130 for the assay. 
2.3.3.3 Protein Purification and Identification by ESI Q TOF 
To find out the enzyme responsible for the reduction, proteins in the A. oryzae CFE 
were separated by size exclusion chromatography and the activities of different 
fractions were tested with model A 114 by Verena Hantke. The cofactor NADH or 
NADPH for the enzyme activity was tested by in vitro assays with the most effective 
fraction possessing enzyme activity. It showed that the enzyme of interest is 
NADPH-dependent. 
Three fractions with enzyme activities were combined and the proteins inside were 
further separated by a strong anion exchange column. After further enzyme assays of 
different fractions, it turned out that the protein of interest was neutral or positively 
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charged at pH 7.0. Further protein sequence analysis by ESI Q TOF (Dr. Jennifer 
Senkler work group Prof. Braun, Institute of Plant Genetics, Leibniz University of 
Hannover) showed that the enzyme responsible for the reduction belongs to the family 
of NAD(P)H-dependent oxidoreductases. Malate dehydrogenase and alcohol 
dehydrogenase are two NADPH-dependent enzymes potentially involved in the 
reduction. 
2.4 Conclusion and Outlook 
Heterologous expression is a powerful tool in natural product biosynthesis investigation. 
However, heterologous expression of ACE1 gene cluster in A. oryzae was only partially 
successful. A native enzyme in A. oryzae was proposed to reduce the ACE1 metabolite 
precursor 56 to shunt alcohol 52 during the early biosynthetic step, thereby the full 
biosynthesis of ACE1 metabolite was not completed. The hypothesis was confirmed by 
in vitro assays with A. oryzae NSAR1 CFE. A synthetic model A 114 was reduced its 
corresponding alcohol 129 in the presence of CFE of A. oryzae. It proved the hypothesis 
that the ACE1 alcohol 52 is an over-reduction shunt metabolite, produced by a native 
enzyme in A. oryzae. 
Further protein purification and sequence analysis showed that malate 
dehydrogenase and alcohol dehydrogenase in A. oryzae are two NADPH-dependent 
enzymes potentially involved in the reduction. Malate dehydrogenase is an enzyme in 
the citric acid cycle that catalyzes the reversible conversion of malate 131a into 
oxaloacetate 131b using the reduction of NAD
+
 to NADH (scheme 2.5). As part of 
primary metabolism, it has specific and essential role. Therefore it might be not 
involved in the reduction of ACE1 metabolite precursor 56. 
 
Scheme 2.5 Catalysed reaction by malate dehydrogenase. 
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Alcohol dehydrogenases exsist in many organisms and facilitate the interconversion 
between alcohols and aldehydes or ketones with the reduction of (NAD
+
) to NADH 
(scheme 2.6). It is more likely that alcohol dehydrogenase is involved in the reduction 
of ACE1 aldehyde 56. 
 
Scheme 2.6 Catalysed reaction by malate dehydrogenase. 
Afterwards, the gene responsible for the alcohol dehydrogenase could be knocked 
out and A. oryzae after deletion of the reductase could be used for expression of 
cytochalasan BGC as well as some other secondary metabolites BGC where aldehydes 
are intermediates. Eventually it could be used for the investigation of ɑ,β-hydrolase 
function and putative Diels-Alderase. It might also be possible to complete the full 
biosynthesis of ACE1 metabolite. 
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3. Investigation of Knoevenagel Reaction by In Vitro 
Assays with Model Compounds. 
3.1 Introduction 
3.1.1 Brief Introduction to the Knoevenagel Condensation 
The Knoevenagel condensation is a modification of the aldol reaction named after Emil 
Knoevenagel (1865-1921).
74
 It is a nucleophilic addition of an active hydrogen 
compound to a carbonyl group (usually an aldehyde) followed by a dehydration reaction 
to yield an α,β-unsaturated ketone, catalysed either by acid or by base. 
Under basic conditions the dicarbonyl compound is deprotoned to form an enolate, 
which is ready to attack the aldehyde to form a new C-C bond. After protonation and 
elimination of H2O through an E1cb mechanism, an α,β-unsaturated ketone is formed 
(scheme 3.1A). Under acidic conditions, an enol is formed which is nucleophilic and 
can attack the activated aldehyde to from a new C-C bond. Further elimination of H2O 
under acidic condition then affords the α,β-unsaturated ketone (scheme 3.1B). 
 
Scheme 3.1 Example of Knoevenagel condensation. A, mechanism catalyzed by base; B, mechanism catalyzed by acid. 
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 The Knoevenagel condensation is a very useful reaction in organic synthesis. For 
example, in the synthesis of coumarin derivatives, which are natural products found in 
many plants with various bioactivities, the construction of the coumarin core can be 
achieved using a Knovenagel condensation in an efficient and environmentally friendly 
strategy.
75
 An example is shown in scheme 3.2 for the synthesis of 
3-acetyl-8-ethoxycoumarin 134.
76
 Here the initial Knoevenagel reaction is followed by 
an intramolecular transesterification to give the benzopyrone 134. 
 
Scheme 3.2 Synthesis of 3-acetyl-8-ethoxycoumarin 134. 
3.1.2 Knovenagel Condensations Involved in Natural Product Biosynthesis 
Knoevenagel condensations are hypothesized to be involved in many fungal natural 
product biosynthetic pathways, such as those for sorbicillin 137,
77





 and UCS1025A 150
79
 among many others (scheme 3.3). The common 
feature for these proposed reactions in biosynthesis is that polyketide aldehydes are 
released by a reductive release (R) domain, followed by intramolecular Knoevenagel 
condensation, either spontaneously or catalyzed by as-yet uncharacterized enzymes to 
give a pyrrolinone. 
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Scheme 3.3 Examples of fungal natural products biosynthesis potentially involving Knoevenagel condensations. 
However, there is currently very little experimental support for the existence of 
Knoevenagel enzymes. One of the few examples is the biosynthesis of azaphilones. 
These are fungal pigments which exhibit a wide range of significant biological 
activities.
80
 Targeted inactivation of the mpp7 gene in Monascus pilosus resulted in the 
abolition of the main pigment components 152 and accumulation of 155. Both 152 and 
155 were Knoevenagel condensation products, but the regioselectivities were different. 
Therefore it was proposed that Mpp7 assists in regioselective Knoevenagel aldol 
condensation during pigment biosynthesis (scheme 3.4).
81
 
But there is very little in vitro evidence for possible Knoevenagel enzymes, 
possibly because of competing facile chemical catalysis. This is especially likely to be 
possible in the cases of intramolecular Knoevenagel reactions. 
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Scheme 3.4 Knock-out experiment of mpp7 suggested its regioselective role in Knoevenagel condensation during 
azaphilone pigment biosynthetic pathway. 
The skeleton of the cytochalasans has been also proposed to be formed via 
Knoevenagel condensation and subsequent Diels-Alder reaction for many years. For 
example, during cytochalasin E 5 biosynthesis, the PKS-NRPS backbone 27 is believed 
to be reductively released to an aldehyde 28 by the R domain (scheme 3.5). Aldehyde 
28 could undergo a Knovenagel condensation to give pyrrolinone 29, which could serve 
as a dienophile for a subsequent Diels-Alder reaction. However, it is still mysterious if 
this reaction is spontaneous or enzyme catalyzed. If enzyme catalysed, an ɑ,β-hydrolase 
might be involved in this reaction. All known cytochalasan BGCs include an 
ɑ,β-hydrolase encoding gene. But the precise role of this family of hydrolases is still 
unknown. 
 
Scheme 3.5 Knoevenagel condensation is proposed to be involved in cytochalasin E 5 biosynthesis. 
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3.1.3 Synthesis of β-keto Amide Compounds 
As shown in scheme 3.3, many natural products that are supposed to derive from a 
Knoevenagel condensation contain a β-keto amide or ester moiety. In fact, β-keto 














 Therefore, a variety of methods have been 
developed for the preparation of β-keto amides. 
The most traditional methods for the introduction of β-keto amides involve 













 or acylated 
Meldrum’s acids (Figure 3.1).93 Among these methods, the straightforward coupling 
of amines and β-keto acids or aminolysis of β-keto esters are limited due to the 
instability of the keto-acid intermediates
93 and competing formation of enamines of 
the ketones. β-keto thiolester 158 and N-hydroxysuccinimidylacetoacetate 159 are 
effective reagents for introducing β-keto amides,90 though they are restricted to 
certain structures. Diketene 160 is not stable and also limited to specific 
structural types. 
 
Figure 3.1 Reagents used for introducing β-keto amides. 
Dioxinone 161 is also known as diketene acetone adduct, and is stable at room 
temperature. However, 161 releases acetylketene 163 when heated above 100 °C 
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(Scheme 3.6). Acetylketene 163 can efficiently acetoacetylate nucleophiles, e.g. 




Scheme 3.6 Mechanism of dioxinone 161 theromolysis. 
Dioxinones 161 can not only introduce β-keto amides, but also diverse 
functionalization of it is well studied. As shown in scheme 3.7, the dioxinone methyl 




 which are 
ready for a variety of chemical reactions, such as Wittig reaction, HWE reaction etc. 
 
Scheme 3.7 Functionalization of the dioxinone 161. 
Dioxinone phosphonate 167 is widely used in natural product synthesis, especially 
for those compounds containing tetramic acids or pyrrolinones. Ikarugamycin 177 is an 
unusual pentacyclic tetramic acid antibiotic produced by Streptomyces sp.
96
 The total 
synthesis of Ikarugamycin 177 was achieved by Napier and co-workers using dioxinone 
phosphonate 167 as an efficient way to construct the tetramic acid moiety (scheme 3.8).
97
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Scheme 3.8 (+)-Ikarugamycin 177 synthesis by Napier and co-workers. Reagents and conditions: a, PhI(OAc)2 (1.2 eq.), 
KOH (2 eq.), MeOH, 25 °C, 8 h then Amberlyst-15, THF-H2O (95:5 (v/v)), 25 °C, 24 h, 68%; b, Pb(OAc)4 (1.05 eq.), 
MeOH-THF (1:1 (v/v)), 0 °C, 0.5 h then Amberlyst-15, 3Å molecular sieves, MeOH, 25 °C, 16 h, 62%; c, DiBAL-H (2 eq.), 
THF, 0 °C, 2 h; d, PDC (2 eq.), 3Å molecular sieves, CH2Cl2, 25 °C, 0.5 h, then DBU (cat.), CH2Cl2, 0 °C, 72-120 h; e, 
dioxinone phosphonate 167 (1.2 eq.), KHMDS (1.2 eq.), THF, 0 °C-25 °C, 4 h, 65%; f, Amberlyst-15, CH3CN-H2O (9:1 
(v/v)), 25 °C, 12 h; g, 178 (1 eq.), K2CO3 (6 eq.), 18-C-6 (10 eq.), toluene, -20 °C-0 °C, 4 h; h, NH4OAc (4 eq.), Pd(PPh3)4 
(cat.), dioxane, 25 °C, 24 h, 78%; i, mesitylene sulfonyl chloride (1 eq.), Et3N (1 eq.), THF, 25 °C, 10 min then 179 (2-3 
eq.), DMAP (3-4 eq.), THF, 25 °C, 4 h, 60%-80%; j, HOAc, Pd(PPh3)4 (cat.), THF, 25 °C, 12 h, 96%; k, toluene, 105 °C, 
8-10 h, 77%; l, t-BuOK (2 eq.), t-BuOH, 0 °C, 15 min, 75%; m, anhydrous TFA (0.01 M in substrate), 72 °C, 5 min, 55%. 
The synthesis started from a previously reported intermediate 168, which was 
constructed by an intramolecular Diels-Alder reaction.
98
 Oxidation of 168 with 
PhI(OAc)2 afforded a mixture of alcohol 169. Subsequent oxidative cleavage of alcohol 
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169 with Pb(OAc)4 and immediate protection of the resulting aldehyde provided acetal 
170a. After conversion of ester to aldehyde utilizing standard chemistry and 
epimerization of cis-aldehyde 170b to a more stable trans-aldehyde 170c in the presence 
of DBU, dioxinone phosphonate 167 was introduced by HWE reaction to give an 
exclusively E isomer 171. After acetal deprotection, the required Z olefinic side chain was 
then elaborated via a cis selective Horner-Emmons reaction
99
 with allyl 
bis-trifluoroethylphosphonoacetate 178, providing the Z allyl ester 172a. Deprotection of 
allyl ester 172a afforded carboxylic acid 172b, which was coupled with 178 to give 
amide 173. Deblocking of 173 to secondary amine 174 and thermolysis of dioxinone 
moiety at 105 °C in a diluted solution yielded macrocyclic bis-amide 175 via an 
intramolecular trapping of the resulting highly electronphilic acyl ketene. The subsequent 
Dieckmann-type cyclization of the highly constrained bis-amide 176 was carried out to 
give the tetramic acid moiety, which was further deprotected to afford Ikarugamycin 177. 
Interestingly, dioxinone phosphonate 167 was also exploited for the construction of 
the isoindolinone core of muironolide A 194, which is a tetrachlorinated marine 
metabolite isolated in minute quantities from a specimen of Phorbas.
100
 Dioxinone 182 
was affored in 3 steps including reduction of the ester 180 with i-Bu2AlH, Swern 
oxidation and olefination with dioxinone phosphonate 167. Amine 187 was prepared in 
three steps from propargyl alcohol 183.
101
 Copper-catalyzed methylmagnesation of 
propargyl alcohol 183 followed by the iodine quench afforded 184. The synthesis was 
completed by the Kumada coupling with vinylmagnesiumbromide and a one-pot 
elaboration of the hydroxy group to PMB-protected amine 187. Thermolysis of dioxinone 
182 in the presence of amine 187 provided amide 188, followed by site-selective 
cross-metathesis with methyl acrylate 189 to afford 190. Heating of compound 190 in 
toluene at reflux resulted in intramolecular cycloaddition to isoindolinone core with 
correct stereochemistry. Triethylamine had no effect on the rate of the reaction, indicating 
that it cyclized through a pericyclic process rather than a stepwise anionic double Michael 
addition pathway. 
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Scheme 3.9 Synthesis of muironolide A 194 isoindolinone core using dioxinone phosphonate 167. Reagents and 
conditions: a, i-Bu2AlH, CH2Cl2, then Swern oxidation, 40%; b, dioxinone phosphonate 167, NaH, THF, 58%; c, MeMgBr, 
CuI (cat.), I2; d, 5 mol% Pd(PPh3)4, CH2=CHMgBr, toluene, 23 °C, 75%; e, NBS, PPh3, THF, then p-methoxybenzylamine, 
43%; f, PPTS, toluene, 110 °C, 3 h, 95%; g, 10 mol%, HGII catalyst, 81%; h, toluene, 110 °C, 60%, dr > 30:1; i, NaBH4, 
CeCl3, MeOH, CH3SO2Cl, Et3N, CH2Cl2, 23 °C, DBU, toluene, 85 °C, 6 h, 64%. 
Other approaches for introduction of β-keto amides have also been reported, e.g. 





condensation of amide enolates with acyl chlorides (scheme 3.10).
104
 Enzymatic 
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Scheme 3.10 Other approaches for introduction of β-keto amides. 
3.2 Aims 
Cytochalasans have been known for several decades and the late-stage tailoring steps 
including several oxidative reactions and Baeyer-Villiger rearrangements have been 
elucidated.
40,41
 However, cytochalasan skeleton formation is still mysterious partially 
because of the lack of substrates for use in in vitro assays. It is proposed that 
Knoevenagel condensation and subsequent Diels-Alder reaction are likely to be 
responsible for the isoindolone core formation. In this project, we aim to investigate the 
proposed Knoevenagel reaction by in vitro assays. 
For the cytochalasan substrate, we designed and synthesized model B 115 instead 
of the more complex and unavailable ACE1 nonaketide backbone for initial 
experiments. Model B 115 bears an aldehyde and a β-keto amide, which can be 
introduced by dioxinone 161. For the enzyme, Verena Hantke expressed and partially 
purified ORFZ. Model B 115 will be firstly tested in H2O and buffer to understand its 
properties. If it could form the corresponding pyrrolinone 204a spontaneously, ORFZ 
would be tested to check if it can accelerate this reaction. If it is not spontaneous, in 
vitro assays would be performed with ORFZ to study its function in the proposed 
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Knoevenagel condensation (scheme 3.11). In addition the chemical stability of the 
proposed pyrrolinone product 204a will also be investigated as this forms the required 
dienophile for the proposed later DA reaction. In addition, we wish to observe possible 
tautomer formation under biological reaction conditions. 
 
Scheme 3.11 Proposed in vitro assays with model B 115. 
3.3 Results and Discussion 
3.3.1 Model B Retrosynthetic Analysis 
Model B 115 is a new compound, but its phenylalanine analog 207 was reported by 
Tamm and Snider respectively using two different strategies.
106,107
 Both of their β-keto 
amides were introduced using diketene 160 as shown in scheme 3.12. But the aldehyde 
group were preprared in two different ways: hydrolysis of a diethyl acetal 206 or 
oxidation of a primary alcohol 209. Hydrolysis of diethyl acetal 206 with HCl in 
aqueous THF gave relatively pure aldehyde without further purification. But it needed 
more steps to prepare the somewhat inaccessible diethyl acetal 206. Compound 209 was 
easily synthesized by acetoacetylation of the commercial available amino alcohol 208 
using diketene 160, even though some bis-ester amide also formed. But the unstable 
aldehyde had to be purified after oxidation of the primary alcohol. 
 
Scheme 3.12 Two methods reported for the synthesis of 207 by Tamm (A) and Snider (B).
106,107
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Model B 115 synthesis could be also achieved by the same strategies, e.g. oxidation 
of alcohol 210 or hydrolysis of diethyl acetal 213 (scheme 3.13). Alcohol 210 could be 
obtained by acetoacetylation of amino alcohol 127, which was prepared previously in 
chapter 2. Diethyl acetal 213 could be derived from acetoacetylation of 212. Since the 
dioxinone 161 is commercially available, we prefer to introduce β-keto amide by 
thermolysis of 161 instead of diketene 160. This offers other advantages later since 
functionalization of 161 is also well-known. 
 
Scheme 3.13 Retrosynthetic analysis of model B 115. 
The intermediate 212 can be prepared from N-protected amino alcohol 126 via 
oxidation of hydroxyl group, protection of aldehyde and hydrolysis of carbamate 
(Scheme 3.13). The preparation of 126 was previously described in chapter 2. 
3.3.2 Model B Synthesis 
The model B 115 synthesis is shown in scheme 3.14. Amino alcohol 127 was prepared 
over 4 steps from L-tyrosine 123 as described in chapter 2. We introduced the 
dicarbonyl group with dioxinone 161 through thermolysis above 100 °C in toluene. 
When the ratio of the reagents is 1:1, there was some bis-ester amide formed. Use of 
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less dioxinone 161 resulted in relatively pure product and the excess amino alcohol 127 
was recycled. 
After synthesis of compound 210, modified Moffat oxidation was applied to make 
model B 115. Since 115 was not stable and underwent rapid degradation, 115 could not 
be purified by flash chromatography. But 115 was relatively stable in acetonitrile and 
water, so preparative LCMS was successfully applied for the milligram scale 
purification of model B 115. In the presence of water, model B 115 is also in 
equilibrium with its hydrated form 115b. 
 
Scheme 3.14 Model B 115 synthesis via oxidation. 
Model B 115 was also prepared via hydrolysis of diethyl acetal 213 (scheme 3.15). 
N-protected amino alcohol 126 was firstly oxidized to the aldehyde without purification, 
and then protected with triethyl orthoformate with a catalytic amount of p-TsOH at 
50 °C overnight. The diethyl acetal group was stable in basic conditions, so the 
carbamate was hydrolysed with KOH in a mixture of H2O and MeOH overnight at 
50 °C to afford compound 212. Reaction between compound 212 and dioxinone 161 in 
toluene above 100 °C for 2 h provided compound 213 in good yield, which was 
hydrolysed to give model B 115 in aqueous THF with HCl at 0 °C in 2 h. The reaction 
was monitored by LCMS over time to avoid formation of pyrrolinone 204a after 
prolonged acidic conditions. After complete reaction, the mixture was neutralized with 
1 M NaOH solution to pH 6 to reduce the solubility of aldehyde in acidic aqueous 
solution. This synthetic route provided relatively pure model B 115. 
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Scheme 3.15 Model B 115 synthesis via hydrolysis of diethyl acetal 213. 
 
Figure 3.2 LCMS data of model B 115. 
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The LCMS data of model B 115 after purification by preparative LCMS is shown 
in figure 3.2. It is tailing in the LCMS from 3.7 min to 4.8 min because aldehydes are in 
equilibrium with aldehyde hydrate in the presence of water. Hydrate 115b elutes earlier 
at 3.7 min because it is much more polar. Aldehyde is minor in this equilibrium at 4.8 
min. The UV spectrum clearly shows the aromatic ring absorbance at 223 nm and 274 
nm. The mass spectra also fit the molecular weight (263.1). 
1
H NMR data for model B 115 was not very clean, since after purification and 
lyophilisation model B 115 had already slightly degraded. But the characteristic 
chemical shifts can be found including the aldehyde proton (9.56 ppm), ɑ-proton (4.47 




H NMR of model B 115 in CD3CN. 
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3.3.3 Tautomerism Investigations 
3.3.3.1 Synthesis of Model B Pyrrolinone 
Before we performed bioassays, we should firstly synthesize the pyrrolinone 204a 
chemically to understand its properties. Model B 115 was treated with 1 M NaOH 
solution at 0 °C for 5 min, and extracted with EtOAc to afford pyrrolinone 204a. By 
detection with LCMS, the clear conversion of model B 115 to the corresponding 
pyrrolinone can be observed (Figure 3.4). Different from model B 115, the UV 
spectrum not only has the aromatic ring absorbance, but also has absorbance at 328 nm, 
which is the absorbance from the pyrrolinone ring. The molecular mass (245.1) also fit 








Figure 3.4 Conversion of model B 115 to pyrrolinone 204b and its UV, mass spectra. 
As mentioned in the cytochalasan total synthesis, pyrrolinone 204a probably also 
undergoes a tautomerism to 204b. To further confirm this, the pyrrolinone 204a was 
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attempted to be characterized by NMR. However, O-methyl tyrosine pyrrolinone 204b 
proved to be rather unstable and it was difficult to get good NMR data. Crude 
pyrrolinone 204b from simple workup degrades even before the NMR measurement is 
finished. Purification by preparative LCMS following by evaporation at 35 °C afforded 
a different compound, rather than the O-methyl tyrosine pyrrolinone 204b (Figure 3.5). 
The retention time of the new compound is around 4.4 min, which elutes earlier than 
pyrrolinone 204b at 6.8 min, suggesting it is more polar. Moreover, UV absorbance 





, we can deduce that water was added to the pyrrolinone ring. 
 




 comparison of O-methyl tyrosine pyrrolinone 204b and diastereomers 
216/217 after purification. A, ELSD signal of pyrrolinone 204b; B, ELSD signal of diasteromers after purification; C, UV 
absorption of pyrrolinone 204b; D, UV absorption of diastereomers 216/217 after purifition; E, ES
+
 of pyrrolinone 204b; F, 
ES
+
 of diastereomers 216/217 after purifition; G, ES
-
 of pyrrolinone 204b; F, ES
-
 of diastereomers 216/217 after purifition. 
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Originally, we proposed that water was added to the pyrrolinone through Michael 
addition to form compound 219 (scheme 3.16). However, purification by preparative 
LCMS and characterization by NMR showed a different compound and a more complex 
reaction pathway. 
 
Scheme 3.16 Original proposal for the hydration of pyrrolionone 204a through Michael addition. 
The full NMR data of 216/217 is shown in figure 3.5. The 
1
H NMR and 
13
C NMR 
suggest it is a mixture of two diastereomers. The existance of more than two CH2 
groups in the HSQC spectrum ruled out the possibility of the original proposal that 219 
is the compound. 
 




Figure 3.5 NMR data of diastereomers 216/217 in CD3CN. 
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Table 3.1 NMR data of compounds 216/217. Not all 
1
H signals could be integrated due to overlap. Solvent: CD3CN. (Two 







(J / Hz) 
COSY HMBC HSQC Structure 
2 170.6 -- -- -- -- -- 
 




3 2, 3, 5, 6, 12 CH2 
4b 2.12 m 
5 87.1 -- -- -- -- -- 
6 44.9 2.94 m -- 4, 5, 7, 8 CH2 
7 128.3 -- -- -- -- -- 
8 131.6 7.24 d (8.6) 9 9, 10 CH 
9 113.5 6.90 d (8.6) 8 7, 10 CH 
10 158.6 -- -- -- -- -- 
11 54.8 3.79 s -- -- CH3 
12 206.1 -- -- -- -- -- 







(J / Hz) 
COSY HMBC HSQC Structure 
2 171.9 -- -- -- -- -- 
 
3 54.2 3.77 m 4 2, 4, 12 CH 
4a 
34.9 
2.59 dd (8.6, 13.6) 
3 2, 3, 5, 6, 12 CH2 
4b 1.89 dd (8.6, 13.6) 
5 86.6 -- -- -- -- -- 
6 44.6 2.96 m -- 4, 5, 7, 8 CH2 
7 128.1 -- -- -- -- -- 
8 131.6 7.24 d (8.6) 9 9, 10 CH 
9 113.5 6.90 d (8.6) 8 7, 10 CH 
10 158.6 -- -- -- -- -- 
11 54.8 3.79 s -- -- CH3 
12 203.4 -- -- -- -- -- 
13 29.1 2.23 s -- 3, 12 CH3 
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After analysis of full NMR, the new compounds were found to be a mixture of 
diastereomers 216/217. The structures and possible mechanism of formation are shown 
in scheme 3.17. 
 
Scheme 3.17 Structures of new compounds and possible mechanism. 
3.3.3.2 Synthesis of Phenylalanine Pyrrolinone 
Since O-methyl tyrosine pyrrolinone 204b is rather unstable to get NMR data, we 
decided to synthesize its analog phenylalanine pyrrolinone 222b to investigate its 
properties. 222b is reported to be relatively stable (scheme 3.18).
107
 Theromolysis of 
dieketene acetone adduct 161 with commercially available phenylalanine derived amino 
alcohol 208 in toluene at 103 °C afforded 209. Alcohol 209 was oxidized by Moffat 
oxidation to aldehyde 207, following by cyclization with 1 M NaOH for 5 min. 222 was 
purified by prep-LCMS. 
1
H NMR showed that it tautomerized to 222b. 
 
Scheme 3.18 Synthesis of known phenylalanine pyrrolinone 222b. 
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The LCMS data of compound 222b is shown in figure 3.6. From the UV we can see 
clearly the absorbance at 328 nm, arising from the unsaturated ring. This absorption was 




 also fit 
the molecular weight (215.1). 
 
Figure 3.6 LCMS data of compound 222b. 
From the 
1
H NMR (Figure 3.7), the chemical shift for proton 4 is a singlet at 5.56 
ppm. This is consistent with the 6π aromatic structure of the ring, the downfield shift 
resulting from the aromatic ring current. The protons 6 now are no longer diastereotopic 
due to the loss of the stereocenter at the C-5. The optical rotations for compound 209 
and 222b were also measured. An optical rotation ɑ of -20.6 was measured at 23 °C at 
589 nm for compound 209, while compound 222b showed no rotation, consistent with 
the planar structure. The 
1
H δH value for H-12 is consistent with C-11 being an enol 
rather than a ketone. Likewise the δC shift of C-11 at 172 ppm is also consistent with an 
enol rather than a ketone.  





H NMR of compound 222b in CDCl3. 







(J / Hz) 
COSY HMBC HSQC Structure 
2 170.5 -- -- -- -- -- 
 
3 106.9 -- -- -- -- -- 
4 98.9 5.54 s 6 2, 3, 5 CH 
5 131.7 -- -- -- -- -- 
6 34.7 3.70 s 4, 8, 12 4, 5, 7, 8 CH2 
7 136.8 -- -- -- -- -- 
8 128.7 7.21 m 6, 9 6, 9, 10 CH 
9 128.8 7.33 m 8, 10 7, 8 CH 
10 127.0 7.28 m 9 8 CH 
11 172.3 -- -- -- -- -- 
12 19.3 2.15 s 6 3, 11 CH3 
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3.3.3.3 Retrosynthesis and Synthesis of ɑ-methyl Pyrrolinone 
Even though the pyrrolinone tautomerism was well studied from NMR, IR and theoretic 
calculations,
106,108
 we still wanted to make a further investigation about tautomerism in 
a more straightforward way because it is of key importance for the following DA 
reaction. So we propose to block the tautomerism by introducing a methyl group at the 
alpha position to make a comparison between tautomerized pyrrolinone and 
non-tautomerized pyrrolinone. 
The synthesis of ɑ-methyl pyrrolinone 231 could mimic the model B 115 synthesis 
via dioxinone 161 theromolysis with amino alcohol 228 and oxidation of alcohol 226 
following with cyclization. The synthesis of the key intermediate 228 was described by 
Heinrich et al
109
 through a radical carbodiazenylation derived from p-anisidine 224 
(Scheme 3.19). 
 
Scheme 3.19 Retrosynthetic analysis of ɑ-methyl pyrrolinone 231. 
The synthesis of the ɑ-methyl pyrrolinone started with the diazotization, by 
treatment of p-anisidine 224 with sodium nitrite and excess HBF4 below 5 °C (scheme 
3.20). The subsequent carbodiazenylation reaction was carried out at room temperature 
in a previously degassed mixture of DMSO and H2O under an inert atmosphere, 
between diazonium salt 225 and methallyl alcohol 226 with iron(II)sulfate heptahydrate 
as reductant to afford compound 227 as a yellow oil.
109
 After reduction of the diazo 
group with Zn/HCl, ɑ-methyl amino alcohol 228 was obtained in high yield and reacted 
with dioxinone 161 at 103 °C for 2 h in toluene to afford compound 229, which was 
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then oxidized by Moffat oxidation overnight to aldehyde 230. Treatment of aldehyde 
230 with 1 M NaOH solution at 0 °C for 5 min afforded ɑ-methylated pyrrolinone 231. 
 
Scheme 3.20 Synthesis of ɑ-methyl pyrrolinone 231. 
In contrast to the non-methylated pyrrolinones 204b and 222b, ɑ-methyl 
pyrrolinone 231 has no UV absorbance beyond 300 nm, consistent with formation of a 
different tautomer as compared to the non-methylated pyrrolinones (Figure 3.8). The 
molecular weight (259.1) is also found in the ES
+
 plus proton and sodium as well as the 
aromatic carbon cation (121.0). However, in contrast to pyrrolinone 222b with a 
hydroxyl group which can form an anion, ɑ-methyl pyrrolinone 231 cannot form anion 
well and only fragmentions are observed in the ES
-
 mass spectra. 
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Figure 3.8 LCMS data of ɑ-methyl pyrrolinone 231. 
From the 
1
H NMR (Figure 3.9), benzylic proton 6 shows two doublets at 2.84 ppm, 
because the two protons are diastereotopic and split each other. The chemical shift for 
proton 4 is at 7.72 ppm because it is deshielded by eletron withdrawing groups. This 
compares to 5.7 ppm in compound 222b which has a more aromatic character. Proton 
13 resonates at 2.51 ppm, consistent with an acetyl group rather than the 1-hydroxy 
ethylidene observed in 222b (2.2 ppm). Finally the δC value of 194 ppm for C-12 is 
consistent with it being a ketone. 





H NMR of ɑ-methyl pyrrolinone 231 in CDCl3.  
Table 3.3 NMR data of ɑ-methyl pyrrolinone 231. Solvent: CDCl3. 
Atom δC (ppm) δH (ppm) Multiplicity (J / Hz) COSY HMBC HSQC Structure 
1 -- 6.26 s 4 -- -- 
 
2 168.6 -- -- -- -- -- 
3 135.2 -- -- -- -- -- 
4 160.6 7.72 d (2.1) 1 2, 5, 12 CH 
5 61.7 -- -- -- -- -- 
6a 
44.1 
2.87 d (2J 13.6) 6b 
4, 5, 7, 8, 14 CH2 
6b 2.81 d (2J 13.6) 6a 
7 126.9 -- -- -- -- -- 
8 131.1 7.05 d (8.6) 9 6, 9, 10 CH 
9 114.0 6.84 d (8.6) 8 7, 10 CH 
10 158.9 -- -- -- -- -- 
11 55.3 3.79 s -- 10 CH3 
12 194.3 -- -- -- -- -- 
13 29.2 2.51 s -- 3, 12 CH3 
14 23.0 1.35 s -- 4, 5, 6 CH3 
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From table 3.4, we can make a clear comparison about NMR chemical shifts 
between the tautomerised pyrrolinone 222b and non-tautomerised pyrrolinone 231. 
Tautomerism strongly influenced the carbon chemical shifts on the pyrrolinone rings as 
well as the proton chemical shift beyond the ring. 
Table 3.4 NMR data comparison of phenylalanine pyrrolinone 222b and ɑ-methyl pyrrolinone 231. 
  
Atom δH / ppm J / Hz δC / ppm Atom δH / ppm J / Hz δC / ppm 
2 -- -- 170.5 2 -- -- 168.6 
3 -- -- 106.9 3 -- -- 135.2 
4 5.54 -- 98.9 4 7.72, d 2.1 160.6 
5 -- -- 136.8 5 -- -- 61.7 
6 3.70, s -- 34.7 
6a 2.87, d 13.6 44.1 
6b 2.81, d 13.6 44.1 
11 -- -- 172.3 12 -- -- 194.3 
12 2.15 -- 19.3 13 2.51, s -- 29.2 
In compound 231, H-4 is a normal alkene proton conjugated with 
eletron-withdrawing carbonyl group and amide group. Therefore the chemical shift is in 
lower field because of the lower electron density. C-12 is a normal carbonyl group with 
chemical shift at 194.3 ppm. H-6 are diastereotopic and hence two doublets are 
observed. However, in compound 222b, H-4 is in an aromatic environment and shielded 
by the aromatic ring current, i.e. lone pair donation from nitrogen atom. Therefore the 
chemical shift of H-4 is in higher field. H-6 are no longer diastereotopic because of 
tautomerism and a singlet is observed, consistent with the planar structure. The carbon 
and proton chemical shifts at 12 shifted to high field significantly, suggesting the 
tautomerism occurred on the carbonyl group rather than on the amide to form an 
aromatic ring. This can be further confirmed by the fact that C-11 chemical shift goes to 
Investigation of Knoevenagel Reaction by In Vitro Assays with Model Compounds 
75 
higher field while C-2 chemical shift does not change so much. All these facts discussed 
above confirm the tautomerism occurs on the carbonyl rather than the amide group. 
3.3.4 Model B Bioassays 
3.3.4.1 Preparation of Proteins and Cell Free Extract 
The ORFZ and ORF3 proteins were prepared and partially purified from E. coli 
expression by Verena Hantke. In addition, cell free extract was prepared from A. oryzae 
NSAR1 cells expressing the ACE1, RAP1 and ORFZ genes from the ACE1 gene cluster. 
The cells were frozen in liquid nitrogen in mortar and ground to an even powder. Then 
2 mL potassium phosphate buffer (pH 7.0, 50 mM) was added and mixed with the cell 
powder. After collection by centrifugation at 16000 × g for 30 min at 4 °C, the 
supernatant was collected and stored for further tests. 
3.3.4.2 Model B Assays in Water 
Since model B 115 is not very stable, and there is a possibility that model B 115 can 
form the corresponding pyrrolinone 204b spontaneously, it was first tested in water or 
buffers before enzyme assays to investigate the effects of the solvents. 
Model B 115 was synthesized via oxidation of alcohol 210 or hydrolysis of diethyl 
acetal 213 and purified by prep-LCMS. After collection of model B 115 fractions, all 
the acetonitrile and most of the water were evaporated under reduced pressure to give a 
solution of model B 115 in water. The concentration was measured to be around 2 mM. 
Model B 115 solution (50 μl) was further diluted with 150 μl distilled water and 
was incubated in a water bath at 28 °C over 1 h, 3 h and 17 h. After this time any 
reaction was observed by direct LCMS analysis of the aqueous solution. Figure 3.10 
shows the results of model B 115 in H2O at 28 °C over time. It is relatively stable in 
water after 3 h and only tiny amount of diastereotopic alcohols (216/217 at 4.4 min) 
were formed after 17 h. The UV and mass spectra of the compound at 4.4 min is 
consistent with alcohols 216/217 (Figure 3.11). The peak at 4.0 min is the unoxidised 
alcohol 210 which is always present as a minor component of the aldehyde. 
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Figure 3.10 Model B 115 in H2O at 28 °C over time. 
 
Figure 3.11 UV and Mass spectra of compound 216/217 at 4.4 min. 
3.3.4.3 Model B Pyrrolinone Assays in Buffers 
Since the pyrrolinone 204b is not stable, it is necessary to understand its properties in 
buffers before further model B 115 assays. Therefore it was prepared and tested in 
phosphate buffer. The crude pyrrolinone 204b was used directly for tests after workup 
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because of its instability. Pyrrolinone 204b in potassium phosphate buffer (75 mM, pH 
6.0, 7.0, 8.0) was incubated at 28 °C over time. 
The results showed that after 2 hours, pyrrolinone 204b was completely converted 
to a new peak at 5.7 min (Figure 3.12). The UV absorption at 273 nm and 224 nm 
indicates it contains tyrosine moiety, but the loss of the absorpotion around 328 nm 
means the the conversion occurred on the pyrrolinone ring. From mass spectral analysis, 
it is deduced to be a dimer 232 (Figure 3.13). The HRMS confirmed this since its 
calculated molecular fomular is C28H30N2O8. 
 
Figure 3.12 Pyrrolinone 204b in potassium phosphate buffer (75 mM, pH 6.0, 7.0, 8.0) at 28 °C after 2 h. 
 
Figure 3.13 UV absorption and mass spectra of dimer 232 at 5.7 min. 
Investigation of Knoevenagel Reaction by In Vitro Assays with Model Compounds 
78 
Next, the new compound was prepared in large scale and purified by prep-LCMS. 
It was stable enough to get NMR data. From the 
1
H NMR and 
13
C NMR spectra, it is 
obvious this new compound is a dimer. Further analysis with 2D NMR shows its 




H NMR of dimer 232 in CD3CN. 






C NMR and HMBC of dimer 232 in CD3CN. 
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The mechanism of the dimer 232 formation is not very clear. It seems like model B 
115 firstly forms pyrrolinone spontaneously, and then is converted to alcohols 216/217. 
Alcohols 216/217 can react with pyrrolinone 204b followed with oxidation to form the 
dimer 232. 







(J / Hz) 
COSY HMBC HSQC Structure 
2 169.3 -- -- -- -- -- 
 
3 57.1 4.20 overlap 4 2, 4, 12 CH 
4 47.4 3.31 d (7.4) 3 2, 3, 5, 6, 12, 17, 18, 19, CH 
5 87.9 - -- -- -- -- 
6 46.3 3.21 m -- 4, 5, 7, 8 CH2 
7 127.4 -- -- -- -- -- 
8 132.4 7.30 d (8.6) 9 6, 9, 10 CH 
9 113.9 6.91 d (8.6) 8 7, 10 CH 
10 158.9 -- -- -- -- -- 
11 55.0 3.79 s -- 10 CH3 
12 203.0 -- -- -- -- -- 
13 29.2 2.22 s -- 3, 12 CH3 
15 167.6 -- -- -- -- -- 
16 61.1 -- -- -- -- -- 
17 66.4 4.20 overlap -- 18 CH 
18 60.6 -- -- -- -- -- 
19 40.4 3.13 m -- 17, 18, 20, 21 CH2 
20 126.4 -- -- -- -- -- 
21 132.1 7.13 d (8.6) 22 19, 22, 23 CH 
22 113.7 6.86 d (8.6) 21 20, 23 CH 
23 158.8 -- -- -- -- -- 
24 54.9 3.76 s -- 23 CH3 
25 197.2 -- -- -- -- -- 
26 26.8 1.59 s -- 16, 25 CH3 
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3.3.4.4 Model B Assays in Buffers without N2 Protection 
As model B 115 is an aldehyde, any buffer containing amino group, such as Tris, should 
be avoided. Therefore, potassium phosphate buffer is the first buffer to be considered. 
Model B 115 in 150 μl potassium phosphate buffer (pH 6.0, 7.0, 8.0, 75 mM) was 
incubated at 28 °C over 1 h, 4 h and 23 h without nitrogen protection. 
At pH 6.0, model B 115 was relatively stable at 28 °C after 4 hours (Fig. 3.16). 
However, after 23 hours, some diastereotopic alcohols 216/217 formed and tiny amount 
of dimer 232 could be also observed. 
 
Figure 3.16 Model B 115 in potassium phosphate buffer (pH 6.0, 75 mM) at 28 °C without protection over time. 
At pH 7.0, model B 115 in potassium phosphate buffer (75 mM) at 28 °C could 
form alcohols 216/217 in large amount after 4 hours (Fig. 3.17). After 23 hours, model B 
115 disappeared and alcohols 216/217 and dimer 232 formed in a nearly equal amount. 
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Figure 3.17 Model B 115 in potassium phosphate buffer (pH 7.0, 75 mM) at 28 °C without protection over time. 
At pH 8.0, model B 115 in potassium phosphate buffer (75 mM) at 28 °C was stable 
in 1 hour. After 4 hours, model B 115 disappeared and only tiny amount of alcohols 
216/217 left, while dimer 232 formed in large amount (Fig. 3.18). After 23 hours, only 
dimer 232 was detectable. 
 
Figure 3.18 Model B 115 in potassium phosphate buffer (pH 8.0, 75 mM) at 28 °C without protection over time. 
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3.3.4.5 Model B Assays in Buffers with N2 Protection 
The formation of the dimer 232 is an oxidation, so it is better to perform assays 
under an inert atmosphere. Therefore model B 115 in potassium phosphate buffer (pH 
6.5, 7.0, 7.5, 8.0, 37.5 mM) were incubated in water bath at 28 °C over 2 h, 6 h and 23 h 
under nitrogen protection. 
At pH 6.5, model B 115 was relatively stable after 6 h at 28 °C (Figure 3.19). But 
after 23 h, some alcohols 216/217 were formed. The formation of 216/217 appeared 
faster in phosphate buffer (pH 6.5, 37.5 mM) than that in water. 
 
Figure 3.19 Model B 115 in potassium phosphate buffer (pH 6.5, 37.5 mM) at 28 °C. 
When the buffer pH was raised to 7.0, model B 115 was observed to be less stable. 
After 23 h at 28 °C, large amount of alcohols 216/217 were formed (Figure 3.20). 
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Figure 3.20 Model B 115 in potassium phosphate buffer (pH 7.0, 37.5 mM) at 28 °C. 
 
Figure 3.21 Model B 115 in potassium phosphate buffer (pH 7.5, 37.5 mM) at 28 °C. 
The results of model B 115 in potassium phosphate buffer pH 7.5 and pH 8.0 were 
very similar and shown in figure 3.21 and figure 3.22 respectively. They showed that 
model B 115 formed alcohols 216/217 in a much faster rate in weakly basic conditions 
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than in slightly acidic or neutral conditions. After 23 hours, model B 115 was converted 
to alcohols completely and quantitatively, with no formation of the dimer 232. 
 
Figure 3.22 Model B 115 in potassium phosphate buffer (pH 8.0, 37.5 mM) at 28 °C. 
The model B 115 in potassium phosphate buffer tests suggest that it is sensitive to 
pH values in phosphate buffer. Compared to that in water, it seems potassium phosphate 
also has influence on model B 115 stability. To further confirm this, model B 115 in 
potassium phosphate buffers (pH 8.0) with different concentrations at 28 °C over time 
were performed. 
It showed that when the concentration of the phosphate buffer was higher, the more 
alcohols 216/217 were formed (Figure 3.23). The peak at 6.1 min has no UV 
absorbance and the mass is not relevant to model B 115. Therefore it may be impurity 
inside, but it did not affect the tests. 
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Figure 3.23 Model B 115 in potassium phosphate buffer (pH 8.0) after 2 h at 28 °C. 
 
Figure 3.24 Model B 115 in potassium phosphate buffer (pH 8.0) after 8 h at 28 °C. 
After 8 hours, model B 115 was almost all converted to alcohols 216/217 when the 
buffer concentration was 100 mM (Figure 3.24). However, only a little of alcohols 
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216/217 was formed when the buffer concentration was 25 mM. It clearly shows the 
potassium phosphate strongly influenced the stability of model B 115. 
Next, model B 115 stability in HEPES buffer (pH 7.5, 50 mM) was tested at 37 °C 
over time. Compared to that in potassium phosphate buffer, model B 115 is much more 
stable in HEPES even in slightly basic condition. After 5 h, only a tiny amount of 
alcohols 216/217 were formed. So it can be used for bioassays with enzymes (Figure 
3.25). 
 
Figure 3.25 Model B 115 in HEPES buffer (pH 7.5, 50 mM) at 37 °C. 
3.3.4.6 Model B Bioassays with Enzymes 
ORFZ was expressed and partially purified from E. coli by Verena Hantke. The 
bioactivity was tested with model B 115 in water firstly to see if it was active in water. 
Model B 115 in H2O and with boiled enzyme are two negative controls. ORFZ and 
ORF3 together were also tested to see if ORF3 was needed. The bioassays were 
performed in 200 μl scale at 30 °C over time. 
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After 30 min and 90 min, the reaction mixtures were monitored by LCMS 
respectively (figure 3.26 and figure 3.27). Apparently there are no significant 
differences between enzyme and negative controls even after 90 min. Model B 115 was 
stable in this condition and the enzyme did not appear to catalyze Knoevenagel 
condensation possibly because the enzyme was not active in H2O. 
 
Figure 3.26 Model B 115 in H2O with enzymes after 30 min at 30 °C. 
 
Figure 3.27 Model B 115 in H2O with enzymes after 90 min at 30 °C. 
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Next, ORFZ activity was tested in HEPES buffer (pH 7.5, 50 mM) with model B 
115 at 35 °C over time. As usual, model B 115 in HEPES and with boiled enzyme were 
two negative controls. After 30 min, the reaction mixtures were analyzed by LCMS 
(Figure 3.28). Compared with negative controls, no obvious conversion was observed 
after 30 min. 
 
Figure 3.28 Model B 115 in HEPES (pH 7.5) with enzymes after 30 min at 35 °C. 
 
Figure 3.29 Model B 115 in HEPES (pH 7.5) with enzymes after 90 min at 35 °C. 
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After 90 min, some alcohols 216/217 were formed in all negative and positive 
controls possibly because of the HEPES buffer rather than the enzyme activity (Figure 
3.29). 
3.4 Discussion and Conclusion 
3.4.1 Pyrrolinone Tautomerism 
In this project, three pyrrolinones were prepared (Fig. 3.30). Compared with α-methyl 
pyrrolinone 231, both O-methyl pyrrolinone 204b and phenylalanine pyrrolinone 222b 
tautomerize and have a characteristic UV absorbance at 328 nm indicative of the 
aromatic tautomers. The stabilities between O-methyl pyrrolinone 204b and 
phenylalanine pyrrolinone 222b are very different. Phenylalanine pyrrolinone 222b can 
be purified by prep-LCMS and characterized by NMR. However, O-methyl pyrrolinone 
204b is much less stable and converted to alcohols 216/217 after prep-LCMS 
purification. Oxygen atom can make the aromatic ring more electron rich and influence 
the stability, but the detailed mechanism is still uncertain because the aromatic ring is 
isolated from the pyrrolinone. 
 
Figure 3.30 Pyrrolinones prepared. 
As discussed in cytochalasan total synthesis (section 1.4), synthetic chemists have 
proved that tautomerised pyrrolinones are not suitable for DA reaction. However, if an 
acyl group is introduced on the nitrogen atom, the pyrrolinone will not tautomerise and 
hence can be applied for DA reaction (scheme 3.21).
110
 When the dienophile 235 is 
doubly activated, the DA reactions tend to be highly selective and efficient. Moreover, 
unsymmetrical 1,3,5-trienes react preferentially at the most substituted 1,3-diene unit 
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Scheme 3.21 Failed attempt of DA reaction and successful DA reaction with N-acyl pyrrolinone. 
However, in nature, cytochalasan precursors do not contain an 
electron-withdrawing group on the nitrogen atom of the pyrrolinone ring. Therefore the 
pyrrolinones during cytochalasan biosynthesis are not competent for the following DA 
reaction. The putative DA reaction in cytochalasan biosynthesis is thus not spontaneous 
and needs a DAase. The enzyme can affect the reaction possibly in two ways, either by 
catalysis of the reaction in a much faster rate before pyrrolinone tautomerism, or 
speeding up the equilibrium between the tautomerised and non-tautomerised 
pyrrolinone. 
3.4.2 Pyrrolinone Conversion 
O-Methyl pyrrolinone 204b is converted spontaneously to alcohols 216/217. This 





 and hirsutellones 242 (Fig. 3.31).
113
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Figure 3.31 Fungal natural products containing alcohols 216/217 framework. 
However, pyrrolinone 243 was also proposed to be oxidized either spontaneously or 





Scheme 3.22 Proposed hydroxylation biosynthesis pathway. 







 and pyrrocidines 




Figure 3.32 Fungal natural products containing similar hydroxylation pattern. 
3.4.3 Enzyme Assays 
After performing bioassays in different buffers with different pH values, no enzyme 
activity was observed. There are so many possibilities accounting for this. Firstly, the 
ɑ,β-hydrolase (ORFZ) may have strict substrate selectivity since the model compound is 
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not the real cytochalasin precursor. Moreover, the pyrrolinone might be converted too 
fast to be monitored. 
However, there is high probability that Knoevenagel condensation is spontaneous. 
Firstly, model B 115 can form alcohols 216/217 in different buffers spontaneously after 
several hours. While model B pyrrolinone 204b can be also converted to alcohols 
216/217 in less than 30 min. From model B 115 to 216/217, a five-membered ring was 
formed probably by Knoevenagel condensation. If Knoevenagel condensation is the 
rate-determining step, so pyrrolinone 204b cannot be observed in the assays (Scheme 
3.23). 
 
Scheme 3.23 Formation of alcohols 216/217 probably via Knovenagel condensation. 
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
 
Scheme 3.24 Heterologous expression of cytochalasin E 5 genes (ccsC and ccsA) and PKS-NRPS genes (SYN2 and 
RAP2) in A. nidulans. 
Moreover, heterologous expression of cytochalasin E genes (ccsC and ccsA) and 
PKS-NRPS genes (SYN2 and RAP2) in A. nidulans produced niduclavin 39 and 
niduporthin 53 respectively. In this heterologous expression, Knoevenagel condensation 
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must be spontaneous because ccsF or orfz were not expressed. The olefin at 2‘ and 
3‘ was possibly introduced by a shunt oxidation in A. nidulans, or by an air oxidation 
reported by Tang group (Scheme 3.24).
108
 
The proposal for the biosynthesis of niduporthin 53 is shown in scheme 3.25. 
Polyketide aldehyde 249 is reductively released from the PKS-NRPS by its R domain, 
which undergoes spontaneous Knoevenagel condensation to form pyrrolinone 250. 
Pyrrolinone 250 tautomerises to 251, that is not suitable for both two possible DA 
reactions any more, e.g. isoindolone core formation and decalin ring formation.
108
 The 
tautomerised pyrrolinone 251 cannot undergo DA reaction to form decalin possibly 
because the hydroxyl group cannot make dienophile as electron poor as a carbonyl 
group. But tautomerised pyrrolinone 251 can be oxidized in air automatically to 
compound 252,
108
 which is ready for DA reaction. But this air oxidation was not 
observed during model B 115 assays. The decalin formation is possibly spontaneous 
through a [4+2] DA reaction between the terminal diene and the dienophile present 
within the polyketide chain. 
KS  AT  DH  CMeT ER0 KR  ACP  C  A  T  R  ER
 
Scheme 3.25 Proposal for niduporthin 53 biosynthesis in A. nidulans. 
From the observations discussed above, Knoevenagel condensation is deduced to 
be probably spontaneous. However, fast tautomerization produces an aromatic 
intermediate which is not competent for the expected subsequent DA reaction. 
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4. Investigation of Diels-Alder Reaction by In Vitro 
Assays with Model Compounds. 
4.1 Introduction 
4.1.1 General Description of the Diels-Alder Reaction. 
The Diels-Alder reaction is named after Professor Otto Diels and his student Kurt Alder, 
who were awarded the Nobel Prize for the discovery of this reaction.
116
 Diels-Alder 
reactions are [4+2] cycloadditions between a conjugated diene and an alkene (usually 
called the dienophile) to afford a six-membered ring with up to four contiguous 
stereocenters in a stereospecific and highly stereoselective manner. In a Diels-Alder 
reaction, the conjugated diene can be linear or cyclic with different substituents, but it 
has to be in the s-cis conformation. Diels-Alder Reactions can be further divided into 
normal electron demand and inverse electron demand Diels-Alder reactions based on the 
conjugated substituents. 
4.1.1.1 Normal Electron Demand and Inverse Electron Demand Diels-Alder 
Reactions. 
When the diene is electron-rich and dienophile is electron-deficient, two new bonds are 
formed between the highest occupied molecular orbitals (HOMO) of the diene and 
lowest unoccupied molecular orbital (LUMO) of dienophile (scheme 4.1A). 
Electron-donating group raises the HOMO of the diene and electron-withdrawing group 
lowers the LUMO of the dienophile, thus the Diel-Alder reaction occurs smoothly. This 
is the most common type of Diels-Alder reaction, which is also called normal electron 
demand Diels-Alder reaction. 
Investigation of Diels-Alder Reaction by In Vitro Assays with Model Compounds 
96 
 
Scheme 4.1 A, Normal electron demand Diels-Alder reaction; B, Inverse electron-demand Diels-Alder reaction. 
However, in contrast to a normal electron demand Diels-Alder reaction, when the 
diene is electron-deficient and dienophile is electron-rich, the LUMO of diene and 
HOMO of dienophile are close in energy, thus they interact strongly and result in bond 
formation. This is called inverse electron-demand Diels-Alder reaction (iEDDA) which 
was discovered by Bachmann and Deno in 1949.117 Since inverse electron demand 
Diels-Alder reactions often involve hetero atoms, it is particularly useful in the synthesis 
of compounds containing heterocycles. 
Scheme 4.2A shows a general inverse electron demand Diels-Alder reaction between 
tetrazines 259 and olefins 260. This reaction proceeds rapidly in aqueous media in high 
yield without need for catalysis and tolerates a broad range of functionality. It has already 
been developed to be a potential click reaction by both the Fox and Hilderbrand 
groups.
118,119
 Now it is widely used in bioorthogonal chemistry for labeling of 
proteins,120 cell surface,121 nucleic acids,122 and cancer cells.123 
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Scheme 4.2 A, general scheme of inverse electron demand Diels-Alder reaction between tetrazines 259 and olefins 260; 
B, Testing the reaction as a bioorthogonal biolabelling method with a functionalized thioredoxin by Fox and 
co-workers.
119
 Trx = thioredoxin. 
4.1.1.2 Stereospecificity and Stereoselectivity 
The Diels-Alder reaction is a syn addition with respect to both the dienophile and the 
diene, thus it is stereospecific. When the substituents are on the same side of the 
dienophile, they will be cis on the newly formed ring, and vice versa (scheme 4.3). 
 
Scheme 4.3 The Diels-Alder reaction via syn addition. 
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The substituents on the diene can be cis,cis, cis,trans and trans,trans. Both cis,cis- 
and trans,trans-disubstitued dienes give rise to cis product whereas 
cis,trans-disubstituted dienes give trans product (scheme 4.4). 
 
Scheme 4.4 The Diels-Alder reaction via syn addition. 
The Diels-Alder reaction is stereoselective and follows endo rule when it is 
irreversible and the dienophile has a π bond in its electron-withdrawing group. Though 
the endo product is more sterically hindered, it is kinetically favorable because in the 
endo transition state, p orbitals of the electron-withdrawing group on the dienophile 
with the p orbitals of the diene overlap to stabilize the transition state, even though no 
bonds are formed (scheme 4.5). 
 
Scheme 4.5 Endo product formation due to secondary orbital overlap. 
However, secondary orbital effects are not strong bonding interactions. When 
dienes are highly substituted and dienophiles are bulky, or it is a reversible reaction, the 
secondary orbital effect only plays a minor role and the exo isomer will be favored due 
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to steric effects. In an intramolecular Diels-Alder reaction (IMDA), dienophile and 
diene are held together, thus bonding interactions across space are also not so important 
and the exo product is also often preferred. 
4.1.2 Diels-Alder Reactions in Total Synthesis 
The Diels-Alder reaction is one of the most powerful tools in synthetic organic 
chemistry, especially in complex natural product synthesis, such as for terpenes, 
sesquiterpenes, and even alkaloids. Indeed, it has been applied to the synthesis of 
complex pharmaceutical and biologically active compounds,
124







 and diaporthichalasin 290 (Scheme 4.6).
128,129
 
Equisetin 63 and betaenone C 282 are two decalin-containing natural products with 
biological activities.
126,130
 Both of their decalin formations were achieved using the 
intramolecular Diels-Alder reaction where new stereocenters were formed 
stereoselectively (Scheme 4.6A and 4.6B). Reserpine 286 is an indole alkaloid isolated 
in 1952 with remarkable physiological properties.
131
 The first total synthesis of 
reserpine 286 was carries out by Woodward using an intermolecular Diels-Alder 




Diaporthichalasin 290 is an isoindolone and decalin-containing secondary 
metabolite isolated from the filamentous fungus Diaporthe sp. Bkk3.
132
 It is suspected 
to be biosynthesized in a cytochalasin-type pathway.
129
 The total synthesis of 
diaporthichalasin 290 was accomplished using two intramolecular Diels-Alder reactions 
to give decalin ring and isoindolone core (scheme 4.6D). It is notable that the hydroxyl 
group on the pyrrolinone ring blocks the tautomerism, thus making pyrrolinone possible 
for the following Diels-Alder reaction. The dehydrated compound 291 was also 
produced, either before or after the Diels-Alder reaction. 
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Scheme 4.6 Diels-Alder steps in natural product total synthesis. 
The DA reaction has been also applied to the synthesis of cytochalasans. The 
simultaneous formation of the isoindolone core and macrocyclic ring using IMDA 
reaction is an efficient stragety for the construction of cytochalasan skeleton. In chapter 
one, we have already described the total synthesis of cytochalasin B 2 and cytochalasin 
D 4 in detail via DA reactions. Another good example of cytochalasin H 303 total 
synthesis is shown in scheme 4.7 using this strategy.
133
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Scheme 4.7 Syntheis of cytochalasin H 303 via IMDA reaction. Reagents and conditions: a, imidazole, TBDMSCl, DMF, 
RT, 12 h, 98%; b, DIBAL-H, toluene, -78 °C, 2 h, RT, 2 h, 87.5%; c, DMSO, oxalyl chloride, CH2Cl2, -60 °C, NEt3, 95%; d, 
Ph3P=CHCO2Et, bezene, 70 °C, 5 h, 71%; e, LiAlH4, ether, 0 °C, 2 h, 88%; f, m-CPBA, CHCl3, -20 °C, 2 h, 96%; g, LiAlH4, 
THF, 0 °C, 2 h, 69%; h, Dimethyl sulphide, N-chlorosuccinimide, toluene, -20 °C, 30 min, then 2 h, triethylamine, 75%; i, 
Ph3P=CHCO2Me, bezene, 80 °C, 6 h, 63%; j, Dowex 50W-X8, MeOH, RT, 3 h, 98%; k, Diisopropylamine, 
ClCH2OCH2CH2SiMe3, reflux, 2 h, 86%; l, Dowex 50W-X8, MeOH, RT, 3 h, 70%; m, Pd-C, H2, 4 h, 95%; n, DMSO, oxalyl 
chloride, CH2Cl2, -60 °C, NEt3, 95%; o, n-BuLi, methyl triphenylphosphonium bromide, THF, 0 °C, 3 h; p, 
9-Bicycloboranonane, THF, reflux, 4 h, 0 °C, NaOH, H2O2, 30 min, 78%; q, DMSO, oxalyl chloride, CH2Cl2, -60 °C, NEt3, 
85%; r, n-BuLi, dienylphosphonate, THF, -78 °C, 2 h, 87%; s, NaOH, MeOH, H2O, RT, 3 h, 98%; t, 
1,l'-Carbonyldi-imidazol, THF, 12 h, 95%; u, LiHMDS, THF-hexane, 1-benzoylpyrrolidinone, -78 °C, 7 h, 87%; v, LiHMDS, 
THF-hexane, PhSeCl, -78 °C, 2 h, 95%; w, m-CPBA, CHCl3, -50 °C, then H2O2; x, toluene, 100 °C, 5 h, 37%; y, NaOH, 
MeOH, H2O, 0 °C, 2 h, 98%; z, LDA,TMSCl, THF, -78 °C, 1 h, 98%; ii, PhSeCl, THF, TBAF, 0 °C, 2 h, 78%; iii, pyridine, 
H2O2, RT, 12 h, 68%; iv, NaBH4, EtOH, 0 °C, 72%; vi, pyridine, 4-DMAP, Ac2O, RT, 2 h, 94%; vii, m-CPBA, CH2Cl2, 
-20 °C, 1 h, 65%; viii, Aluminium isopropoxide, o-xylene, 125 °C, 8 h, 51%; ix, HF, ACN, RT, 3 h, 40%. 
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The synthesis started with chiral hydroxyl ester 292 and introduced another chiral 
center at C-18 by stereoselective peracid epoxidation, followed by reduction of the 
epoxide 294 using lithium aluminum hydride to give diol 295. The diol 295 was further 
converted to the long-chain aldehyde ester 296 using conventional chemistry including 
alcohol protection, deprotection, oxidation and Wittig reaction etc. The conjugated 
triene 297 was constructed by Horner-Wadsworth-Emmons reaction to afford mainly 
the EEE-isomer. The introduction of N-benzoyl pyrrolinone moiety to 298 was achieved 
by substitution and phenylselenation-oxidation elimination. The benzoyl group 
delocalizes the electron lone pair on the nitrogen to increase the antiaromatic character 
of the pyrrolinone to keep it reactive for DA reaction. Intramolecular Diels-Alder 
reaction was performed in toluene at 100 °C for 5 h to give desired exo adduct 299 with 
high stereoselectivity. After construction of the cytochalasan skeleton, modifications 
were carried out on the tricyclic core including hydrolysis, phenylselenation-oxidation 
elimination, reduction, epoxidation and rearrangement etc to provide cytochalasin H 
303. 
4.1.3 Diels-Alderase during Natural Product Biosynthesis 
The importance of the Diels-Alder reaction also gained intense interests among 
biochemists. Frequent occurrence of apparent [4+2] cycloaddition adducts in secondary 
metabolites such as lovastatin 304,
134





spirotetronates (e.g. Maklamicin 306)
136
 among others, and the feasibility of biomimetic 
total synthesis of complex natural products using Diels-Alder reactions as the key steps 
suggest that nature may also make use of this valuable reaction (Figure 4.1).
124
 
Extensive survey of these possible [4+2] adducts demonstrated more than 400 natural 




Figure 4.1 Examples of natural products containing apparent [4+2] cycloaddition adducts. 
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However, even though many proposals for the involvement of Diels-Alderase in 
natural products biosynthesis and numerous efforts have been made, relatively few 
Diels-Alderases were reported during late 1990s to early 2000s. These include 
solanapyrone synthase (Sol5)
135
 and lovastatin nonaketide synthase (LovB).
134
 
Solanapyrone 305 is a decalin-containing phytotoxin produced by the pathogenic 
fungus, Alternaria solani. After the first suggestion of a biological Diels-Alder reaction 
by labelling experiments,
138
 enzyme activity was confirmed by in vitro assays with 
crude enzyme from A. solani (scheme 4.8). Incubation of prosolanapyrone III 308 with 
denatured enzyme for 10 min at 30 °C resulted in 10% conversion of the substrate to 
give the decalin product 309 and 310 in an exo:endo ratio of 3:97, consistent with the 
endo rule. Incubation with crude enzyme increased the conversion of the substrate to 25% 
and the exo/endo ratio to 53:47. These results show that the net enzymatic consumption 
of the substrate is 15% and exo/endo ratio for the enzymatic reaction is 87:13. Moreover, 
the enzyme is also responsible for the oxidation of alcohol 307 to aldehyde 308. 
 
Scheme 4.8 In vitro assays of solanapyrone 305 Diels-Alderase (Sol5). 
Lovastatin 304 is a decalin-containing cholesterol-lowering drug isolated from 
Aspergillus terreus. Its biosynthesis has been long proposed to require a Diels-Alder 
reaction. Its biosynthesis has been extensively investigated by Vederas and 
co-workers.
139
 The exsistence of Diels-Alder catalysis during lovastatin biosynthesis 
was confirmed by in vitro assays in 2000.
134
 Because the dienophile moiety in lovastatin 
304 does not contain an electron-withdrawing group, the Diels-Alder reaction is 
proposed to occur at the hexaketide stage before the termination of chain extension. 
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Hexaketide 313 can undergo a spontaneous Diels-Alder reaction with denatured 
lovastatin nonaketide synthase (LNKS) to give a 1:1 ratio of the decalins 314b and 314c. 
However, incubation with active LNKS without co-factor afforded three products 314a, 
314b and 314c in a ratio of 1:15:15, in which 314a has the same configuration with 
lovastatin 304. Compared with the negative control, LNKS catalyzed Diels-Alder 
reaction to form the lovastatin decalin ring (scheme 4.9). 
 
Scheme 4.9 In vitro assays of lovastatin nonaketide synthase (LNKS). 
As the whole-genome sequencing and searching tools of biosynthetic gene clusters 
of the secondary metabolites develop, the identification and characterization of 
plausible Diels-Alderases become more convenient and faster. In recent years, 
investigation of Diels-Alder reaction involved in natural product biosynthesis has 
become a hot topic and more than ten Diels-Alderases have been identified during the 







 varicidin A 320
141
 and pyrroindomycin A 324
142
 (scheme 4.10). 
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Scheme 4.10 Diels-Alderases identified in recent years involved in the biosynthesis of decalins and cyclohexenes. 
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4.1.4 Putative Diels-Alderase Involved in Cytochalasan Skeleton Biosynthesis 
Many of the known Diels-Alderases which have been identified catalyze decalin 
formation. The biogenetic formation of the octahydro-isoindolone core of the 
cytochalasan skeleton has not been reported yet since the first cytochalasan discovery 
50 years ago. 
4.1.4.1 Indirect Evidences of Involvement of a Diels-Alder Reaction 
The involvement of a Diels-Alder reaction during cytochalasan biosynthesis was 
implied by the occurance of proxiphomin 325
143
 and P450 inhibition experiments.
144
 
Proxiphomin 325 was isolated from Phoma sp. S298 culture (Figure 4.2). It possesses 
the same stereochemistry as cytochalasin B 2. It is believed to be an adduct of the 
intramolecular [4+2] cyclization, a biogenetic precursor of cytochalasin B 2. Treatment 
of Chaetomium subaffine with cytochrome P-450 inhibitors caused accumulation of 
various less-oxidized intermediates, including prochaetoglobosin I 22, which is 
suggested to be the chaetoglobosin A 7 intermediate directly after the IMDA reaction. 
The great structure similarity of potential cytochalasin precursors after putative IMDA 





Figure 4.2 Strucures of potential cytochalsan precursors after IMDA reaction. 
4.1.4.2 Indirect Chemical Evidences of a Putative Diels-Alderase 
It has been long speculated that a putative Diels-Alderase is involved during the 
isoindolone formation,
13
 which is supported indirectly by several observations. 
Chemically, low stereoselectivity (endo : exo = 52 : 48) was observed during 
biomimetic synthesis of proxiphomin 325 via IMDA reaction (scheme 4.11A),
146
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indicating that a DAase is needed to control the steroselectivity. Moreover, the harsh 
chemical conditions (high temperature and long reaction time) required for the IMDA 
reactions to construct the isoindolone core during cytochalasan total synthesis also 
suggest the involvement of an enzyme in vivo (scheme 4.11). 
 
Scheme 4.11 IMDA reaction steps involved in the synthesis of proxiphomin 325 and cytochalasin B 2. 
In addition, as discussed in section 1.4.2, the pyrrolinones used as dienophile for 
DA reactions have been widely investigated. The parent compound 329 is thermally 
unstable.
147
 Compound 330 tautomerises to its enol form irreversibly,
106
 and compound 
332 isomerizes to its 5-benzylidene isomer 333 (scheme 4.12A).
148
 Thus these 
pyrrolinones are no longer directly competent for the DA cyclization in organic 
synthesis.
149
 It has been found that an electron-withdrawing substituent, e.g. an acyl 
group on nitrogen, is particularly important to keep pyrrolinones active for the IMDA 
reactions (scheme 4.11). Introduction of the N-acyl group on the pyrrolinone can 
decrease the aromatic character of the heterocycle and prevent tautomerism (scheme 
4.12B). An example is the synthesis of cytochalasin H 303 using N-benzoyl pyrrolinone 
298 to construct the isoindolone core via IMDA reaction (scheme 4.12C).
133
 But, in 
nature, the proposed pyrrolinone intermediate on the cytochalasin pathway does not 
bear an electron-withdrawing substituent, thus an enzyme must be needed. 
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Scheme 4.12 A, Pyrrolinones are not suitable dienophiles; B, Introduction of acyl group decreases aromaticity; C, 
N-benzoyl pyrrolinone 298 used for synthesis of cytochalasin H 303.
133
 
However, a retro-Diels-Alder reaction of prochaetoglobosin I 22 produced equal 
amounts of prochaetoglobosin I 22 and its exo diastereomer 338 rather than the 
expected triene precursor 337 (scheme 4.13).
32
 This demonstrates that the DA reaction 
actually occurs via pyrrolinone 337 to afford cyclization adducts without 
stereoselectivity although the N-acyl is absent. This provides indirect evidence for the 
involvement of DA reaction during the isoindolone core formation and also suggests a 
Diels-Alderase should be involved to favor the endo-transition state during biosynthesis 
at room temperature. 
 
Scheme 4.13 Retro Diels-Alder reaction of the chaetoglobosin precursor 22. 
4.1.4.3 Indirect Biological Evidences of a Putative Diels-Alderase 
Biologically, the heterologous expression of the cytochalasin E 5 gene cluster (ccsC and 
ccsA) from A. clavatus and PKS-NRPS gene cluster (RAP2 and SYN2) from P. oryzae 
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in the host A. nidulans produced two decalin compounds niduclavin 39 and niduporthin 
53 respectively.
44
 The failure to observe the expected DA reaction adduct, e.g. the 
isoindolone core, demonstrates that the putative DAase is required to control the IMDA 
reaction regioselectively, otherwise the decalin will be formed possibly in a 
spontaneous way. 
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Sceheme 4.14 Heterologous expression of PKS-NRPS gene clusters in A. nidulans. 
Recently, Chooi and co-workers reported the heterologous expression of the 
PKS-NRPS gene (phmA) and trans-ER (phmE) from Parastogonospora nodorum in A. 
nidulans (Scheme 4.14C).
150
 Instead of the decalin compounds 39 and 53 (scheme 4.14), 
the Knoevenagel condensation product 2-pyrrolinone 339 was isolated and 
characterized. However, heterologous expression of the whole gene cluster in A. 
nidulans including the putative Diels-Alderase (phmD) still produced 2-pyrrolinone 339 
rather than the expected isoindolone core, suggesting that the tautomeric pyrrolinone 
prephomacin 339 is not competent as a dienophile for the Diels-Alder reaction. This 
observation is consistent with what was observed during myceliothermophin E 60 
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Based on these indirect chemical and biological evidences, an IMDA reaction is 
speculated to be involved in the biosynthesis of the cytochalasan isoindolone core and a 
putative DAase must be needed to control the region- and stereo-selectivity. However, 
the DAase responsible for the isoindolone formation has not been identified yet. 
4.2 Aims 
From the first cytochalasan discovery in 1966, there have been approximately 400 
cytochalasans reported.
151
 However, the biosynthesis of this kind of bioactive and useful 
compound is still mysterious especially the formation of the isoindolone framework. 
The Diels-Alder reaction is proposed to occur to form the cytochalasan isoindolone core. 
But it is still not clear whether the Diels-Alder reaction is a spontaneous or an enzyme 
catalysed reaction. It is challenging to prove a putative Diels-Alderase partially because 
the natural [4+2] cyclization substrate is frequently complex and time-consuming to 
prepare for the testing of activity and mechanistic study of the candidate enzymes.
152
 
In this section, we aim to verify the proposals of cytochalasan biosynthesis, 
especially Diels-Alder reaction through in vitro assays. The cryptic ACE1 metabolite is 
believed to be a member of the cytochalasan family even though the structure has not 
been elucidated yet.
47
 As the ACE1 metabolite shows its potential application as an 
agrochemical for crop protection,
47
 we expect to investigate cytochalasan biosynthesis 
with its DA precursor and find out its structure as well. 
For the best case scenario, the substrate for the in vitro assays is the aldehyde 56b 
after chain reductive release, which possesses the same backbone with ACE1 shunt 
product 52. Considering that cytochalasin E 5 has the olefin at C-4/C-5, while the 
cytochalasin E 5 shunt metabolite C-4/C-5 is saturated during heterologous expression 
in A. oryzae, it is possible that the olefin at C-4/C-5 is reduced by an unknown enzyme 
in A. oryzae to saturated carbons (scheme 4.15A). Therefore, there is also a possible 
olefin at C-4/C-5 in the ACE1 shunt metabolite 52, thus we would like to introduce the 
possible olefin at C-4/C-5 for the substrate. As the methyl groups on the alkyl chain 
may be not crucial for the enzyme activity, a model compound 116 is designed 
mimicking the ACE1 precursor 56b for an initial attempt. As it is found out that 
O-methyl tyrosine is incorporated into the ACE1 metabolite backbone,
36
 model C 116 is 
also designed with an O-methyl tyrosine (scheme 4.15B). 
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Scheme 4.15 A, possible reduction of cytochalasin E 5 backbone double bond at C-4/C-5 during heterologous 
expression in A. oryzae; B, design of model C 116 mimicking ACE1 shunt product 52. 
Model C 116 can be applied to both in vivo and in vitro assays. For in vivo assays, 
Model C 116 can be fed into P. oryzae cultures to study if it can be incorporated and 
modified to a new cytochalasan. For in vitro assays, firstly it will be used for 
Knoevenagel condensation tests to confirm if it is spontaneous. Afterwards, in vitro 
assays of Diels-Alder reaction would be performed using Knovenagel condensation 
product pyrrolinone as the substrate. The enzymes ORFZ and ORF3 would be 
expressed and purified from E. coli by Verena Hantke. 
4.3 Results and Discussion 
4.3.1 Model C Retrosynthetic Analysis 
Model C 116 was designed to mimick the ACE1 shunt 52 for both Knovenagel 
condensation and Diels-Alder reaction tests. Therefore both β-keto amide and triene 
moieties have to be included in the model. We initially planned to make the aldehyde by 
deprotection of the corresponding cyclic acetal. At the start of this study, tyrosine, rather 
than O-methyl tyrosine, was believed to be the amino acid incorporated. We assumed 
that the methyl groups on the alkyl chain may be unimportant for the Knoevenagel and 
Diels-Alder reactions. This would greatly simplify the required synthesis. Therefore we 
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first planned to synthesize the model without the side-chain methyl groups (scheme 
2.14). 
The retrosynthetic analysis is shown in scheme 4.16. The amide bond is 
disconnected to fragment A 342 and fragment B 343. The β-keto amide can be 
introduced through the thermolysis of dioxinone. Originally, fragment A 342 was a 
tyrosine derived cyclic acetal, while fragment B 343 can be further disconnected to 
fragment C 167 and fragment D 345 which can be assembled by a 
Horner-Wadsworth-Emmons reaction. Fragment C 167 is a known compound which 
was first prepared by Boeckman et al.
153
 for the synthesis of tetramic acids, permitting 
Wadsworth-Emmons olefination under mild conditions. Fragment D 345 is long chain 
aldehyde with triene at the end of the chain. 
 
Scheme 4.16 Model design and retrosynthetic analysis. 
Fragment A 342 is a known compound derived from methyl L-tyrosine 346 in 5 
steps (Scheme 4.17).
154
 Nakamura and co-workers protected the amino group with Cbz 
of L-tyrosine methyl ester 346. The aldehyde 349 was prepared by oxidation of alcohol 
348 following protection with ethylene glycol to afford the cyclic acetal 350. 
Investigation of Diels-Alder Reaction by In Vitro Assays with Model Compounds 
113 
 
Scheme 4.17 Nakamura's synthetic route to fragment A 342. 
We chose a different synthetic route to provide fragment A 342 in 4 steps. Since 
different amino protected L-tyrosines are commercially available, we planned to start 
with Fmoc protected L-tyrosine because Fmoc is resistant to acid condition during 
cyclic acetal formation. However, Fmoc-tyrosine is very expensive as starting material 
(1 g, 75 €, Iris Biotech GmbH) while bis-protected compound 351 is much cheaper (25 
g, 50 €, Iris Biotech GmbH) and the tert-Butyl group can be deprotected simultaneously 
during acetal formation under acid conditions. The aldehyde could be prepared by a 
reduction of ester, or Weinreb amide (scheme 4.18). Here we chose the latter method 
which is a reliable way to provide aldehydes in high yield. The aldehyde could be 
protected by ethylene glycol in the presence of acid. Organic base can be used to 
deprotect Fmoc easily to free amino group. 
 
Scheme 4.18 Fragment A 342 retrosynthetic analysis. 
Fragment D 345 is a new compound, but an analog 362 was prepared by Millar and 
co-workers in an efficient way (scheme 4.19).
155
 In their synthesis, Wittig reaction was 
applied for the construction of the triene and the ZEE isomer was converted to EEE by 
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iodine under light. After release of alcohol and Swern oxidation, compound 362 was 
prepared in a short and effictive way. 
 
Scheme 4.19 Millar’s strategy to prepare compound 362. 
Here we adopted their synthetic strategy to prepare fragment D 345. Wittig reaction 
was applied to build the triene moiety between a diene 356 and aldehyde 365. The diene 
compound 356 was known to be derived from commercially available dienol 355.
155
 
The other reagent for the Wittig reaction is aldehyde 365 which could be prepared from 
mono protection of diol 363 and oxidation (Scheme 4.20). 
 
Scheme 4.20 Retrosynthetic analysis of fragment D 345. 
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4.3.2 Model C Synthesis 
4.3.2.1 Synthesis of Fragment A 
The approach to the construction of modified tyrosine 342 began with commercially 
available Fmoc and t-Bu protected L-tyrosine 351，which was employed to make 
Weinreb amide 352 in high yield. Weinreb amide 352 can be stored in -20 
o
C for long 
time until needed. Next, Weinreb amide 352 was selectively reduced with LiAlH4 to 
aldehyde 353 at 0 °C for 1 h. The resulting aldehyde 353 was protected with ethylene 
glycol, catalysed by p-TsOH, in high yield. During the protection of the aldehyde 353, 
the tert-butyl group on the phenol was simultaneously deprotected. Finally, 
diethylamine was used to remove the Fmoc group to afford fragment A 342 in good 
yield. All the compounds were prepared without optimisation (scheme 4.21). 
 
Scheme 4.21 Synthesis of fragment A 342. 
4.3.2.2 Synthesis of Fragment C 
Fragment C 167 was prepared by lithiation of freshly distilled acetone diketene adduct 
161 in THF at -50 °C, followed by quenching the resultant yellow precipitate with an 
excess of hexachloroethane (scheme 4.22).
153
 The resultant chlorinated acetone diketene 
adduct 166 was treated with potassium diethylphosphite 367 in DMF to afford fragment 
C 167 via a nucleophilic substitution. 
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Scheme 4.22 Synthesis of Fragment C 167. 
4.3.2.3 Synthesis of Fragment D 
The synthesis of fragment D 345 started from the preparation of Wittig reagent 356 and 
aldehyde 365. Mono protection of octane-1,8-diol 363 with benzoyl chloride following 
by Swern oxidation afforded aldehyde 365. Wittig reagent 356 was prepared by 
bromination of (2E,4E)-hexa-2,4-dien-1-ol 355 with phosphorus tribromide at -10 °C 
and treating with triphenylphosphine in toluene at room temperature for 3 d. Wittig 
reaction between 356 and aldehyde 365 with n-BuLi gave triene mixture 369 in 
moderate yield (EEE:EEZ = 64:36 from NMR). The mixture of E and Z isomers cannot 
be separated by flash chromatography, but the mixture was directly used for the 
hydrolysis of acetate 369 with anhydrous K2CO3 in MeOH. After hydrolysis, the 
EEE-isomer 370 can be obtained from recrystallization with n-hexane in 50% yield 
while the EEZ-isomer in mother liquor can be isomerized to the EEE-isomer 370 using 
a catalytic amount of iodine exposed to light for 10 min. After a second recrystallization, 
a further 15% EEE-isomer 370 was obtained and the combined trienol 370 was oxidized 
by Swern oxidation to give fragment D 345 (scheme 4.23). Fragment D 345 underwent 
rapid degradation during flash chromatography. Therefore it was used directly in the 
next step after drying, without further purification. Compounds containing the triene 
moiety are sensitive to light and undergo polymerization, so they should be kept in the 
dark. 
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Scheme 4.23 Synthesis of Fragment D 345. 
4.3.2.4 Coupling of Fragment A, Fragment C and Fragment D 
The coupling strategy is shown in scheme 4.24. Synthesis of fragment B 343 was 
achieved by a Horner-Wadsworth-Emmons (HWE) reaction between fragment C 167 
and fragment D 345 with n-BuLi at -78 °C in low yield, possibly because of the triene 
degradation on the silica gel. After purification by flash chromatography, fragment B 
343 underwent thermal decomposition above 100 °C in toluene in the presence of 
fragment A 342 to afford the corresponding β-keto amide 371. But the deprotection of 
the cyclic acetal 371 proved to be more difficult than anticipated. Several attempts 
including HCl, AcOH, TFA, p-TsOH and several Lewis acids such as 
bis(acetonitrile)dichloropalladium(II), FeCl3, InCl3, LiBF4, Ph3BF4, as well as netural 
catalysts pyridinium p-toluenesulfonate (PPTS) were made at room temperature 
overnight. All these attempts failed to deprotect 371 because either the triene degraded 
under the acidic conditions, or the cyclic acetal was resistant to the reaction conditions. 
 
Scheme 4.24 Coupling of fragment A 342, fragment C 167, fragment D 345 and deprotection. 
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Finally, the deprotection was achieved using HCl in aqueous THF at 60 °C for 3 h. 
With lower concentration of acid and shorter reaction time, the triene can be kept intact. 
But the corresponding Knoevenagel condensation product pyrrolinone 372 was formed 
spontaneously under these conditions. As previously observed (chapter 3.3.3), the 
pyrrolinone 372 tautomerised to enol form 372b (scheme 4.25). 
 
Scheme 4.25 Deprotection of 371 and tautomerism. 
The LCMS data of pyrrolinone 372b shows its UV absorbance at 398 nm, which is 
characteristic of pyrrolinone tautomerism absorbance and even longer because of the 
additional double bond conjugation (Figure 4.3). The characteristic trident triene UV is 
also observed around 266 nm. It is eluted quite late at 11.3 min in LCMS because of the 
high hydrophobicity of the molecule. The ES
+
 (420.3) and ES
-
 (418.2) also fit the 
molecular mass (419.2). However, there is no DA adduct observed in LCMS. 
Investigation of Diels-Alder Reaction by In Vitro Assays with Model Compounds 
119 
 
Figure 4.3 LCMS data of compound 372b. 
Pyrrolinone 372b is relatively stable at -20 °C for several months, but it is unstable 
at room temperature and only 
1
H NMR is available. From the 
1
H NMR data shown in 
figure 4.4, we can see benzylic protons at 3.66 ppm are singlet rather than a doublet 
doublet because compound 372 rapidly tautomerised to 372b and lost chiral center, 
which further confirms the pyrrolinone tautomerism. Also the 
1
H chemical shift of H-4 
at 5.6 ppm agrees with model B pyrrolinone 204b. 





H NMR of compound 372b in CDCl3. 
Even though pyrrolinone 372b was formed spontaneously at 60 °C under acidic 
conditions, it is hard to make a conclusion that the Knoevenagel condensation is a 
spontaneous reaction under biological conditions. 
The inability to isolate the required aldehyde 341 meant that we had to redesign the 
synthesis to use a more easily deprotected aldehyde blocking group. Here we chose to use 
the diethyl acetal group which can be hydrolysed at 0 °C. Thus the synthetic route was 
modified as shown in scheme 4.26. Protected tyrosine O-methyl ether 212 was already 
available (section 3.3.2), and this coupled smoothly with fragment B 343 under standard 
conditions. This gave 374 which was then smoothly deprotected to the required aldehyde 
116 at 0 °C in a mixture of aqueous HCl and THF. By this stage of the project we realized 
that O-methyl tyrosine was the correct substrate incorporated into ACE1 metabolite. 
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Scheme 4.26 Synthesis of model C 116 via hydrolysis. 
 
Figure 4.5 LCMS data of Model C 116. 
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The LCMS data of model C 116 shows that it is eluted between 6.8 min to 8.8 min 
because the aldehyde is in equilibrium with hydrate in the presence of water (figure 4.5). 
The trident absorbance is the characteristic UV spectrum of the triene moiety around 






4.3.2.5 Model C Pyrrolinone Synthesis 
Pyrrolinone 376b was first synthesized by chemical methods to investigate its properties 
including retention time and UV spectrum before assays. The diethyl acetal 374 was 
treated with TFA in CH2Cl2 at room temperature for 3 h to provide 376 (Scheme 4.27). 
The UV absorbance at 387 nm indicates it tautomerises to 376b (Figure 4.6). After 
tautomerism, it is no longer suitable for Diels-Alder reaction.
108
 However, it is unstable 
to complete the NMR measurement, so only the LCMS data is available for the 
moment. 
 
Scheme 4.27 Synthesis of pyrrolinone 376b. 
The LCMS data of pyrrolinone 376b is shown in figure 4.6. A clear conversion of 
diethyl acetal 374 to pyrrolinone 376b was observed after reaction and it was eluted 
quite late because of the hydrophobicity of the molecule. The UV showed the typical 
trident absorbance of the triene at 266 nm as well as the characteristic absorbance above 
300 nm from the tautomerised pyrrolinone. The mass spectra ES
+
 (434.5) and ES
-
 
(432.3) also fit the pyrrolinone molecular weight (433.3). 
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Figure 4.6 LCMS data of pyrrolinone 376b. 
4.3.3 Model C Bioassays 
4.3.3.1 Preparation of Proteins and Cell Free Extract 
The ORFZ and ORF3 proteins were prepared and partially purified from E. coli 
expression by Verena Hantke. In addition, cell free extract was prepared from A. oryzae 
NSAR1 cells expressing the ACE1, RAP1 and ORFZ genes from the ACE1 gene cluster. 
The cells were frozen in liquid nitrogen in mortar and ground to even powder. Then 2 
mL potassium phosphate buffer (pH 7.0, 50 mM) was added and mixed with the cell 
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powder. After collection by centrifugation at 16000 × g for 30 min at 4 °C, the 
supernatant was collected and stored for further tests. 
4.3.3.2 Model C Assays in Water and Buffers 
As previously discussed in chapter 2, the Knoevenagel condensation involved in 
cytochalasan biosynthesis is probably a spontaneous reaction. Since model C 116 is 
similar to cytochalasin precursor, it was firstly used to test Knoevenagel condensation in 
water and potassium phosphate buffers to investigate its properties. 
The assays were performed in 250 μl volume containing 4 mM model C 116 and 50 
μl DMSO. The solvents used for assays were H2O, 40 mM potassium phosphate buffer 
(pH 6.5, 7.0, 7.5, 8.0) and 80 mM potassium phosphate buffer (pH 8.0) respectively. 
After incubation at 30 °C over time (2 h, 4 h and 6 h), 50 μl reaction mixture was diluted 
with equal volume of acetonitrile before analysis by LCMS. 
Figure 4.7 shows that model C 116 is stable in H2O at 30 °C. After 6 h, there was 
still no pyrrolinone detected by LCMS. The peak at 10.3 min is diethyl acetal 374 due to 
the incomplete hydrolysis. 
 
 Figure 4.7 Model C 116 in H2O over time at 30 °C. 
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However, model C 116 was converted to pyrrolinone 376b at 11.8 min in 40 mM 
potassium phosphate buffer (pH 6.5) at 30 °C in 2 h (Figure 4.8). The peak at 8.7 min has 
the same molecular weight (433.3) as pyrrolinone 376b, but its UV spectrum suggests 
that it is not pyrrolinone 376b (Figure 4.9). Figure 4.10 shows the UV and mass at 7.7 min, 
which is possibly the hydrated pyrrolinone 378 based on the knowledge of model B 115 
investigation. 
 
Figure 4.8 Model C 116 in 40 mM potassium phosphate buffer pH 6.5 over time at 30 °C. 
 
Figure 4.9 UV spectrum and molecular weight at 8.7 min. 
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Figure 4.10 Possible structure, UV spectrum and molecular weight at 7.7 min. 
Model C 116 showed similar performance in 40 mM phosphate buffer when pH 
value is 7.0 or 7.5 as shown in figure 4.11 and figure 4.12. Model C 116 disappeared 
and pyrrolinone 376b was detected after 2 h at 30 °C. After 6 h, pyrrolinone 376b was 
still detectable, suggesting that it is relatively stable in these conditions. 
 
Figure 4.11 Model C 116 in 40 mM potassium phosphate buffer pH 7.0 over time at 30 °C. 
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Figure 4.12 Model C 116 in 40 mM potassium phosphate buffer pH 7.5 over time at 30 °C. 
Pyrrolinone 376b was also formed in 40 mM potassium phosphate buffer (pH 8.0) 
after 2 h. However, it was converted after 4 h, indicating that pyrrolinone 376b is less 
stable when the condition is more basic (Figure 4.13). 
 
 Figure 4.13 Model C 116 in 40 mM potassium phosphate buffer pH 8.0 over time at 30 °C. 
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When the concentration of phosphate buffer (pH 8.0) was 80 mM, there was no 
pyrrolinone 376b detected after 2 h, possibly because it degraded in 2 h. Therefore it 
suggests phosphate ion has influence on the stability of pyrrolinone 376b (Figure 4.14). 
 
Figure 4.14 Model C 116 in 80 mM potassium phosphate buffer pH 8.0 over time at 30 °C. 
4.4 Discussion and Future Work 
4.4.1 Knoevenagel Condensation Tests 
In this section, model C 116 mimicking shunt metabolite 52 was designed and prepared 
in a short and effective way. It was firstly used to test Knoevenagel condensation by in 
vitro assays. The assay results showed that Knoevenagel condensation was spontaneous 
in potassium phosphate buffer to give pyrrolinone 376b, which was consistent with the 
assays with model B 115. The recently reported cytochalasin heterologous expression in 
A. nidulans produced pyrrolinone 339, which also suggests Knoevenagel condensation 
is spontaneous in vivo (scheme 4.28). Therefore we can make a conclusion that 
Knoevenagel condensation is a spontaneous reaction. 
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Scheme 4.28 Heterologous expression of cytochalasin genes in A. nidulans by Chooi and co-workers.
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But there is still minor possibility that ɑ,β-hydrolase can accelerate pyrrolinone 
formation, even though the acceleration was not observed by in vitro assays with model 
B 115. The enzyme activity has not been tested systematically with model C 116. 
4.4.2 Diels-Alder Reaction Investigations 
The model C pyrrolinone 376b was prepared under acidic condition which tautomerised 
to its enol form. There have been not much done with model C pyrrolinone 376b, 
partially because all the chemical and biological evidences point to the fact that the enol 
form pyrrolinone cannot serve as dienophile for the Diels-Alder reaction. 
Chemically, from the cytochalasan total synthesis (chapter one), it is known that 
tautomerised pyrrolinone is not suitable for Diels-Alder reaction any more in chemical 
conditions and an electron-withdrawing group has to be introduced to the pyrrolinone 
N-atom prior to Diels-Alder reaction. 
Biologically, there has been no Diels-Alderase report regarding the isoindolone 
formation. However, the decalin ring formation catalyzed by Diels-Alderase MycB was 
reported by Tang group.
108
 The non-tautomerised pyrrolinone 59 can form a decalin in 
the presence of MycB. But MycB cannot catalyse the decalin formation with 
tautomerised pyrrolinone 379 (scheme 4.29). This suggests that tautomerism of 
pyrrolinone can strongly influence the results of the in vitro assays even though the 
position of the dienophile did not change. Therefore it would be predictable the 
tautomerised pyrrolinone cannot form the isoindolone core of cytochalasan in biological 
condition since the position of the olefin in the dienophile shifts. 
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Scheme 4.29 Diels-Alderase cannot catalyze tautomerised pyrrolinone in the decalin formation. 
Another biological evidence is heterologous expression of the full cytochalasin 
gene cluster including the gene encoding the putative Diels-Alderase in A. nidulans by 
Chooi and co-workers as shown in scheme 4.28.
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 However, instead of Diels-Alder 
adduct, pyrrolinone 339 was produced, suggesting the putative Diels-Alderase cannot 
catalyse the tautomerised pyrrolinone 339. 
4.4.3 Future Work 
P. oryzae, which is the fungus for ACE1 metabolite production, can incorporate a variety 
of tyrosine derivatives to produce cytochalasan analogs. Therefore model C 116 feeding 
experiments in P. oryzae is ongoing to see if it can be incorporated and modified in 
vivo. 
Besides, in vitro assays will be performed to investigate the ORFZ activity with 
model C 116 for catalysis of Knovenagel condensation. Moreover, model C pyrrolinone 
376b will be used for assays for Diels-Alder reaction. Though pyrrolinone tautomerism 
occurs, it might be still possible that Diels-Alderase can catalyse this reaction. 
If ORF3 cannot catalyse the Diels-Alder cyclization of tautomerised pyrrolinone 
376b, it is worthwhile to have another try with non-tautomerised pyrrolinone, whose 
tautomerism is blocked by introducing a ɑ-methyl group. Although the synthesis of 
compound 385 is not undertaken due to time constraints, a reasonable synthetic plan is 
drafted as shown in scheme 4.30. As ɑ-methyl amino alcohol 228 and diketene 
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derivative 343 have already been prepared, so the synthesis can be achieved in 6 steps 
including protection of amino group, oxidation of alcohol, acetal formation, 
deprotection of carbamate, theromolysis and cyclization. 
 
Scheme 4.30 Proposed synthetic plan for the compound 385
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5. ACE1 Metabolite Precursor Investigations 
5.1 Introduction 
All the compounds investigated in chapters 2-4 are only models mimicking the ACE1 
shunt metabolite 52. Since in some cases enzymes have strict substrate selectivity and the 
methyl groups on the polyketide chain might be necessary for the stereoselectivity of the 
Diels-Alder reaction, the correct ACE1 metabolite precursor 56 has to be synthesized and 
used for the in vitro assays. Heterologous expression and chemical synthesis are two 
applicable methods to produce the ACE1 metabolite precursor 56. 
Compared with chemical synthesis, heterologous expression is often more 
cost-effective in milligram scale synthesis. However, at the early stage, the fact that 
OMET is crucial for the correct biosynthesis of ACE1 metabolite had not been realized 
(section 1.3.2.3). Therefore only a minor alcohol compound 51 was produced by 
heterologous co-expression of ACE1 and RAP1 in A. oryzae. The alcohol compound 51 
was not available in high enough titer to be extensively oxidized and studied for in vitro 
assays. 
 
Figure 5.1 Structures of shunts 51 and 52 from heterologous expressions and proposed ACE1 metabolite precursor 56.  
In the middle of this project, it was found that OMET is involved in the early steps 
during pyrichalasin H 20 biosynthesis. Since pyrichalasin H 20 BGC shares high 
sequence similarities with ACE1 BGC and ACE1 BGC also contains OMET gene, it 
was deduced that OMET is also involved in ACE1 metabolite biosynthesis (section 




 Feeding experiment with O-methyl tyrosine into A. oryzae expressing ACE1, 
RAP1, ORF3 and ORFZ produced O-methyl tyrosine nonaketide 52 in much higher titer 
(2 mg/L) and abolished the production of 51, suggesting O-methyl tyrosine is the 
correct amino acid moiety incorporated into ACE1 metabolite. Thus it makes 
heterologous expression possible and efficient for the production of ACE1 shunt 
metabolite 52, which could be further oxidized by one step oxidation to provide ACE1 
metabolite precursor 56, if we think the double bond next to ketone is not crucial for the 
Diels-Alder reaction. 
5.2 Aims 
In this section, we aim to prepare the ACE1 metabolite precursor 56 for in vitro enzyme 
assays. Heterologous expression followed by oxidation will be the first priority for the 
preparation of 56 (scheme 5.1A). If possible, 56 will also be used for Knoevenagel 
condensation and Diels-Alder reaction tests. The loss of the olefin next to ketone should 
not have strong influence on Diels-Alder reaction. 
 
Scheme 5.1 A, proposed oxidation of alcohol 52 to 56; B, synthesis of compound 387 for oxidation investigation. 
Even though ACE1 shunt metabolite 52 can be extracted from fungi extracts in 
milligram scale, it is still too precious to investigate oxidation methods. Therefore we 
plan to make the alcohol 387 for the primary oxidation studies, which could be easily 
prepared from one step thermolysis of dioxinone 343 (scheme 5.1B). If succeeded, the 
method will be applied for the oxidation of 52. 
Chemical synthesis is an alternative way to provide ACE1 metabolite precursor 56 
if the oxidation of alcohol 52 in the presence of triene is problematic. 
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5.3 Results and Discussion 
5.3.1 Oxidation Attempts of Alcohol to Aldehyde 
Compound 387 was easily prepared through thermolysis of fragment B 343 in the 
presence of amino alcohol 124 in toluene for 3 hours (scheme 5.2). 
 
Scheme 5.2 Synthesis of compound 387 and failed attempts towards oxidation of 387. 
However, the oxidation of the primary alcohol 387 in the presence of the triene 
proved to be problematic because the conjugated trienes were sensitive to acid, heat, 
and electrophilic attack,
155
 as well as the steric hindrance and possible hydrogen bond 
between the hydroxyl group and carbonyl group. 
The first attempt to oxidize 387 was by Moffat oxidation because it worked very 
well for preparation of model B 115 (section 3.3.2). However, standard reaction 
conditions cannot oxidize compound 387 after overnight even with excess amount of 
oxidizing reagents. Detection by LCMS clearly showed no conversion of alcohol 387 to 
model C 116 even after 3 days. Moffat oxidation is not applicable to oxidation of 
compound 387. The same story happened with Swern oxidation. 
The third attempt was Dess-Martin periodinane in dichloromethane at room 
temperature without weak base. After reaction for 3 h, the reaction mixture was checked 
by LCMS and compound 387 had disappeared. But the new compounds were not 
aldehydes and the UV showed no triene absorbance any more. So DMP appeared to 
destroy the triene and it was not applicable for compound 387 oxidation. 
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A similar situation happened with PCC and PDC oxidation, which are stronger 
oxidizing reagents than DMP. The reactions were performed in CH2Cl2 at r.t. and 
compound 387 was totally degraded after 2 h. No further attempts were made towards 
this oxidation. 
5.3.2 ACE1 Metabolite Precursor Retrosynthetic Analysis 
Since the oxidation of alcohol in the presence of triene proved to be more difficult than 
anticipated, the organic synthesis of aldehyde via hydrolysis of diethyl acetal is more 
important. 
ACE1 metabolite precursor 56 can be disconnected through the amide bond to two 
fragments: the amino acid fragment 212 and long alkyl chain fragment 388 (scheme 5.3). 
Compound 212 was prepared before for the synthesis of model B 115 and diethyl acetal 
can be hydrolysed with HCl in aqueous THF in the presence of triene. Compound 388 is 
supposed to be synthesized by the acylation of Meldrum's acid under basic condition. 
Construction of alkyl chain 390 is the major task including the conjugated triene and 
three methyl groups that will be discussed in scheme 5.4. 
 
Scheme 5.3 Retrosynthetic analysis of cytochalasan precursor 56. 
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Scheme 5.4 Retrosynthetic analysis of compound 390. 
The triene can be constructed through Wittig reaction or 
Horner-Wadsworth-Emmons reaction. Here we can choose HWE reaction because 
phosphonate 392 is a known compound derived from tiglic aldehyde 397 through four 
steps.
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 Compound 391 can be further disconnected to compound 393 and 394, which 
could link by a Suzuki reaction. Compound 393 and 394 are known and can be 
synthesized from commercially available compound 395 and TBS protected alcohol 396 
respectively. Actually compound 392, 393, 394 have already been synthesized, but the 
Suzuki reaction did not work for the moment. The synthetic work paused because the 
shunt metabolite 5 can be obtained from fungal fermentation with milligram scale. 
5.4 Discussion and Conclusion 
In this section, attempts of alcohol oxidation towards aldehyde in the presence of triene 
have been made but all failed. The reasons behind was not investigated in detail. From 
the known knowledge, the conjugated trienes were sensitive to acid, heat, and 
electrophilic attack.
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 However, compound 361 can be oxidized by Swern oxidation 
efficiently (scheme 5.5). If it is because of the formation of possible hydrogen bond 
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between hydroxyl group and carbonyl group, Moffat oxidation can oxidize 210 to 
prepare model B 115. Therefore it is hard to oxidize 387 possibly because of 
combination of several factors. 
 
Scheme 5.5 Successful oxidation of alcohols. 
In 2013, a PhD thesis towards total synthesis of cytochalasan (Hugh Allen Hoather, 
University of Manchester) reported a similar compound oxidation containing a 
tetraene.
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 Seven oxidizing reagents and different conditions were tried and failed to 
oxidize the secondary alcohol 398 to corresponding ketone 399 (scheme 5.6). 
 
Scheme 5.6 Failed attempts of similar compound oxidation. 
Since it is difficult to oxidize ACE1 metabolite 52, it is meaningful to restart the 
synthesis of ACE1 metabolite precursor from hydrolysis of diethyl acetal. However, due 
to the problems met during model compounds studies and time constraints, this part of 
work has not been completed.
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6. Conclusion and Outlook 
The overall aim of the project was to investigate the biosynthesis of the cytochalasan 
backbone including reductive release, putative Knoevenagel condensation and 
Diels-Alder reactions. In order to achieve this, three model compounds were designed, 
prepared and applied for in vitro assays. The current findings include that:  
A) A. oryzae is not a proper host for cytochalasin heterologous expression since the 
native alcohol dehydrogenase in A. oryzae can reduce aldehyde to alcohol shunt 
metabolite. 
Model A 114 was designed and synthesized for over-reduction investigation. In vitro 
assays in phosphate buffer confirmed that model A 114 can be reduced to alcohol by 
alcohol hydrogenase in A. oryzae. This indicates that compound 52 is a shunt metabolite 
and A. oryzae is not a proper host for cytochalasan genes expression. However, if the 
genes responsible for the reductase could be knocked out, A. oryzae after deletion of 
reductase can be used for expression of cytochalasan BGC. 
B) Pyrrolinones tautomerise to their enol form, which is no longer competent for the 
following Diels-Alder reaction. This has been already confirmed by both chemical and 
biological evidences. 
Five pyrrolinones were prepared and the tautomerism was further confirmed by UV and 
NMR comparison of different pyrrolinones (Figure 6.1). After tautomerism, 
pyrrolinones have a characteristic UV absorbance above 300 nm and are no longer 
suitable for Diels-Alder reaction because the double bond shifts. 






































ZH181 8197 (6.711) 3: Diode Array 
1.772226.57
328.57
ZH320 8178 (6.695) 3: Diode Array 
1.466210.57
328.57
ZH305 5587 (4.535) 3: Diode Array 
1.377223.57
 
Figure 6.1 Comparison of UV spectra from different pyrrolinones. 
C) The Knoevenagel condensation is a spontaneous reaction in potassium phosphate 
buffer, which is also proved by Chooi and co-workers by heterologous expression. But 
it is still mysterious if ɑ,β-hydrolase could accelerate this reaction. 
In vitro assays with model B 115 and model C 116 were performed. The results showed 
that Knoevenagel condensation is a spontaneous reaction in potassium phosphate buffer, 
which is consistent with the recent report by heterologous expression.
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 Though no 
enzyme activity was observed by in vitro assays with model B 115, the possibility that 
ORFZ can accelerate the Knoevenagel condensation cannot be ruled out. There are 
several possible reasons accounting for this. Firstly and importantly, ORFZ is only a 
possible enzyme responsible for Knoevenagel condensation. Gene knock-out 
experiment performed by Verena Hantke showed that deletion of orfz abolished 
production of cytochalasin intermediate, suggesting that ORFZ must be involved in an 
early cytochalasin backbone assembly step, but lack of any intermediates precluded 
hard conclusions. Other possibilities include that the enzyme is inactive after E.coli 
expression or it has strict substrate selectivity. 
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Currently, model C 116 is applied for in vivo and in vitro assays. In vivo assays 
with model C 116 are ongoing by feeding experiments into Pyricularia oryzae to 
investigate if it can be incorporated and exploited as cytochalasin precursor. Moreover, 
in vitro assays with model C 116 will also be carried out to test ORFZ and ORF3 
activities.  
In future, if ORF3 cannot catalyse the Diels-Alder cyclization of tauromerised 





7.1 General Experimental Details 
All reactions in anhydrous solvents were conducted under an atmosphere of dry 
nitrogen in glassware that was flame-dried. All commercially available reagents and dry 
solvents were used directly without further purification unless otherwise stated. 
In vitro assays: Assay of ORFZ was performed in 200 μL volume containing 50 mM 
HEPES (pH 7.5), 0.5 mM model B 115, 10 μL DMSO, and ORFZ. The reaction was 
incubated at 35 °C over time and monitored by LCMS. Before detection, reaction was 
quenched with the same amount of acetonitrile and protein was removed by 
centrifugation. The supernatant was analyzed directly by LCMS.  
NMR analysis: 
1
H-NMR data are reported in the following format: chemical shift 
(multiplicity, coupling constants, integration and assignment). Chemical shifts are 
reported in ppm with the residual solvent resonance as internal standard (CDCl3: 7.26 
ppm; CD3CN: 1.94 ppm). Multiplicity is abbreviated as follows: s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, br = broad. 
13
C NMR spectra were recorded at 100 
or 125 MHz, with Bruker Avance 400, DPX 400, or DRX 500 instruments. Chemical 
shifts are reported in ppm with the solvent resonance as internal standard (CDCl3: 77.2 
ppm; CD3CN: 116.0, 0.2 ppm). Some proton and carbon assignments were made with 












C HMBC experiments. All δ values are 
in ppm. All J values are in Hz. 
Column Chromatography: For column chromatography silica 60 Å (particle size 
35-70 micron, Sigma-Aldrich or 40-63 micron, Macherey-Nagel) was used. Columns 
were packed under N2 pressure. Products were eluted with the indicated solvent 
mixtures. Purified fractions were analysed by TLC and combined if same Rf was 
observed. Final products were evaporated under vacuum.  
TLC: TLC analysis was performed on TLC plates with a polyester backed 0.2 mm 
silica gel phase from Macherey and Nagel using the indicated solvent systems. Analysis 
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of the plates were performed by ultraviolet light (254 nm) or with potassium 
permanganate or 2,4-DNP solution. 
Analytical LCMS: Analytical LC-MS data were obtained with a Waters LCMS 
system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a 
Phenomenex Kinetex column (2.6 μ, C18, 100 Å, 4.6 × 100 mm) equipped with a 
Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted at 1 mL/min. Detection 
was by Waters 2998 Diode Array detector between 200 and 600 nm; Waters 2424 





between 100 m/z and 1000 m/z. Solvents were: A, HPLC grade H2O containing 0.05% 
formic acid; B, HPLC grade MeOH containing 0.045% formic acid; and C, HPLC 
grade CH3CN containing 0.045% formic acid. Gradients were as follows. Method 1. 
Kinetex/CH3CN: 0 min, 10% C; 10 min, 90% C; 12 min, 90% C; 13 min, 10% C; 15 
min, 10% C. 
Preparative LCMS: Purification of compounds was generally achieved using a 
Waters mass-directed autopurification system comprising of a Waters 2767 autosampler, 
Waters 2545 pump system, a Phenomenex Kinetex Axia column (5 μ, C18, 100 Å, 21.2 
× 250 mm) equipped with a Phenomenex Security Guard precolumn (Luna C5 300 Å) 
eluted at 20 mL/min at ambient temperature. Solvent A, HPLC grade H2O + 0.05% 
formic acid; Solvent B, HPLC grade CH3CN + 0.045% formic acid. The postcolumn 
flow was split (100:1) and the minority flow was made up with HPLC grade CH3CN + 
0.045% formic acid to 1 mL·min
-1
 for simultaneous analysis by diode array (Waters 
2998), evaporative light scattering (Waters 2424) and ESI mass spectrometry in positive 
and negative modes (Waters SQD-2). Detected peaks were collected into glass test 
tubes. Acetonitrile in combined tubes were evaporated under vacuum, then water was 
evaporated using freeze dryer. 
IR analysis: IR analysis was performed with the Fourier transform 
spectrophotometer IR Affinity-1S from the company Shimadzu. 
HRMS: High-resolution mass spectra data were obtained on an electrospray 
ionization LC/MS equipped with a time-of-flight mass analyzer. 
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Optical rotation: Optical rotations were measured on a Perkin-Elmer polarimeter 
type 341 in a quartz glass cuvette (10 cm) with a Na lamp and are reported as: [α]D
T(°C ) 
= XX (c (g / 100 mL), solvent). 




Methyl chloroformate (Sigma-Aldrich, 3.57 mL, 46.1 mmol) 
was added to a solution of L-tyrosine (8.30 g, 46.1 mmol) and 
NaHCO3 (11.62 g, 138.3 mmol) in a mixture of H2O/THF 
(200 mL/200 mL). After stirring at room temperature 
overnight, the mixture was diluted with H2O (200 mL) and washed with Et2O (200 mL). 
The aqueous layer was acidified and extracted with EtOAc (3 × 60 mL). The combined 
organic extracts were washed with H2O, dried over MgSO4 and concentrated under 




 = +19.2 (c = 0.25, MeOH) (lit. +21.5, c = 2.375, MeOH); 
1
H NMR (CD3OD, 400 
MHz): δ 7.03 (d, 2H, J = 8.4, 5-ArH), 6.68 (d, 2H, J = 8.4, 6-ArH), 4.30 (dd, 1H, J = 5.0, 
8.7, 2-CH), 3.58 (s, 3H, 9-CH3), 3.06 (dd, 1H, J = 5.0, 13.9, 3-CH2), 2.82 (dd, 1H, J = 8.7, 
13.9, 3-CH2); IR (KBr) νmax 3334, 2958, 2484, 1685, 1612, 1512, 1643, 1373, 1244, 1055 
cm
-1
; ES-MS: m/z (%): 194.1 [M-CO2H] (100), 240.2 [M]H
+






To a stirred solution of N-(methoxycarbonyl)-L-tyrosine 124 
(8.8 g, 36.8 mmol) in DMF (90 mL) was added K2CO3 (18.9 
g, 137 mmol) and iodimethane (7.4 mL, 115 mmol) at 0 °C. 
The solution was allowed to warm to room temperature. 
After overnight, the solution was filtrated and the filtrate was 
acidified with diluted aqeous HCl and extracted with EtOAc (3 × 50 mL). The extract was 
washed with sat. aqueous NaHCO3 and NaCl, dried over MgSO4, filtered and 





 = +9.8 (c = 1.0, MeOH) (lit. +14.4, c = 1.11, EtOH); 
1
H NMR (CDCl3, 400 MHz): 
δ 6.96 (d, 2H, J = 8.5, 5-ArH), 6.72 (d, 2H, J = 8.5, 6-ArH), 5.53 (d, 1H, J = 8.2, CONH), 
4.49 (dd, 1H, J = 6.5, 14.3, 2-CH), 3.65 (s, 3H, 8-CH3), 3.60 (s, 3H, 11-CH3), 3.53 (s, 3H, 
10-CH3), 2.97 (dd, 1H, J = 5.8, 14.0, 3-CH2), 2.89 (dd, 1H, J = 6.8, 14.0, 3-CH2). IR (neat) 
νmax 2953, 2839, 1720, 1666, 1612, 1512, 1438, 1244, 1176, 1058, 1031 cm
-1
; ES-MS: 
m/z (%): 208.3 [M-C2H3O2]
+
 (74), 236.3 [M-CH3O]
+
 (40), 268.3 [M]H
+







To a stirred suspension of LiAlH4 (0.76 g, 20 mmol) in dry 
THF (20 mL) was slowly added the ester 125 (2.67 g, 10 
mmol) in THF (10 mL) at 0 °C. After being stirred at the 
same temperature for 15 min, the mixture was allowed to 
warm to room temperature for 2 h. After complete reaction dectected by TLC, the mixture 
was cooled to 0 °C and acidified with 4N HCl. The mixture was extracted with EtOAc (3 
× 30 mL), dried over MgSO4, concentrated under vacuum and purified by flash 
chromatography (petroleum ether/EtOAc = 1:1) to give 126 as a colourless oil (1.88 g, 
79%). 
Rf = 0.2 (petroleum ether/EtOAc = 1:1); [α]D
26
 = -14.9 (c = 1.0, MeOH) (lit. -23.1, c = 
1.95, EtOH); 
1
H NMR (CDCl3, 400 MHz): δ 7.10 (d, 2H, J = 8.5, 5-ArH), 6.81 (d, 2H, J 
= 8.5, 6-ArH), 5.28 (s, 1H, CONH), 4.40 (s, 1H, OH), 3.90-3.80 (m, 1H, 2-CH), 3.75 (s, 
3H, 8-CH3), 3.64-3.56 (m, 4H, 1-CH2 and 10-CH3), 3.51 (dd, 1H, J = 5.2, 11.2, 1-CH2), 
2.78-2.73 (m, 2H, 4-CH2); IR (neat) νmax 3323, 2951, 1697, 1612, 1510, 1460, 1442, 
1361, 1242, 1178, 1029 cm
-1
; ES-MS: m/z (%): 208.1 [M-H2O-CH2]
+
 (10), 222.0 
[M-H2O]
+






A solution of 126 (2.03 g, 8.5 mmol) in 25% aqueous KOH 
was stirred at 50 °C overnight. The mixture was then extracted 
with EtOAc (3 × 15 mL). The combined extracts were washed 
with H2O, sat. aqueous NaCl and then concentrated under vacuum. Recrystallization 





 = -17.3 (c = 1.0, MeOH) (lit. -21.5, c = 1.0, EtOH); m.p. 95 °C (lit. 94-96 °C); 
1
H 
NMR (CDCl3, 400 MHz): δ 7.10 (d, 2H, J = 8.6, 5-ArH), 6.85 (d, 2H, J = 8.6, 6-ArH), 
3.79 (s, 3H, 8-CH3), 3.62 (dd, 1H, J = 3.9, 10.6 Hz, 1-CH), 3.37 (dd, 1H, J = 7.2, 10.6, 
1-CH), 3.11-3.03 (m, 1H, 2-CH), 2.72 (dd, 1H, J = 5.2, 13.6, 3-CH), 2.46 (dd, 1H, J = 8.6, 
13.6, 3-CH), 1.90 (br, 2H, NH2); IR: (KBr) νmax 3338, 3273, 3170, 2839, 1598, 1510, 
1247, 1176, 1026 cm
-1
; ES-MS: m/z (%): 121.1 [C8H9O]
+
 (100), 182.2 [M]H
+
 (22). 
S-2-Acetamido-3-(4-methoxyphenyl)propyl acetate 128. 
Amino alcohol 127 (50 mg, 0.27 mmol) was dissolved in 
pyridine (10 mL) and excess acetic anhydride was added 
dropwise. After reaction at room temperature for 2 h, the 
solvent was evaporated and the residue was dissolved in 
EtOAc (20 mL). The solution was washed with H2O, sat. aqueous NaCl, dried over 
MgSO4 and evaporated under vacuum to afford 128 as a colourless oil (65 mg, 99%). 
[α]D
23
 = -4.9 (c = 0.3, MeOH); 
1
H NMR (CDCl3, 400 MHz): δ 7.09 (d, 2H, J = 8.6, 
5-ArH), 6.83 (d, 2H, J = 8.6, 6-ArH), 5.82 (s, 1H, CONH), 4.42-4.32 (m, 1H, 2-CH), 
4.10-4.00 (m, 2H, 1-CH2), 3.78 (s, 3H, 8-CH3), 2.83 (dd, 1H, J = 6.3, 13.9, 3-CH), 2.74 
(dd, 1H, J = 7.8, 13.9, 3-CH), 2.08 (s, 3H, 12-CH3), 1.96 (s, 3H, 10-CH3); 
13
C NMR 
(CDCl3, 101 MHz) δ 171.0 (11-C), 170.4 (9-C), 158.5 (7-C), 130.2 (5-C), 128.7 (4-C), 
114.1 (6-C), 64.6 (1-C), 55.2 (8-C), 50.1 (2-C), 36.4 (3-C), 23.0 (12-C), 20.9 (10-C); IR: 
(KBr) νmax 3286, 1720, 1643, 1556, 1514, 1469, 1458, 1390, 1246, 1033 cm
-1
; HRMS 
calcd for C14H19NO4 [M+Na]
+




K2CO3 (180 mg, 1.3 mmol) was added to a solution of ester 
128 in CH3OH (15 mL). After reaction at room temperature 
overnight, the solvent was evaporated under vacuum and the 
residue was dissolved in EtOAc. After washing with H2O, sat. 
aqueous NaCl and dried over MgSO4, organic solvent was 






 = -10.5 (c = 0.4, MeOH) (lit. -28.8, c = 1, MeOH); 
1
H NMR (CDCl3, 400 MHz): δ 
7.12 (d, 2H, J = 8.6, 5-ArH), 6.83 (d, 2H, J = 8.6, 6-ArH), 5.89 (d, 1H, J = 7.2, CONH), 
4.15-4.06 (m, 1H, 2-CH), 3.78 (s, 3H, 8-CH3), 3.65 (dd, 1H, J = 3.6, 11.1, 1-CH), 3.55 (dd, 
1H, J = 5.2, 11.1, 1-CH), 2.86-2.73 (m, 2H, 3-CH), 1.95 (s, 3H, 10-CH3); IR: (KBr) νmax 
3317, 2956, 2931, 1645, 1612, 1552, 1512, 1438, 1300, 1247, 1047, 1026 cm
-1
; ES-MS: 
m/z (%): 224.3 [M]H
+
 (100), 206.3 [M-H2O]H
+
 (40), 182.3 [M-43]H
+
 (16), 147.2 
[M-H2O-NH3]H
+




Modified Moffat oxidation was applied for the preparation of 
model A 114. EDC·HCl (42.8 mg, 0.22 mmol) and 
dichloroacetic acid (11.6 mg, 0.09 mmol) were added to a 
solution of alcohol 129 (10 mg, 0.045 mmol) in toluene (1 
mL) and DMSO (1 mL). The reaction was stirred at 25 °C for 16 h and then H2O was 
added. The mixture was extracted with EtOAc (3 × 2 mL), washed with sat. aqueous 
NaCl, dried over MgSO4 and evaporated under vacuum to give a crude aldehyde which 




 = -1.0 (c = 2.8, CH2Cl2); 
1
H NMR (CDCl3, 400 MHz): δ 9.63 (s, 1H, 1-CHO), 7.06 
(d, 2H, J = 8.6, 5-ArH), 6.84 (d, 2H, J = 8.6, 6-ArH), 5.96 (s, 1H, CONH), 4.71 (dd, 1H, J 
= 6.6, 12.7, 2-CH), 3.79 (s, 3H, 8-CH3), 3.16 (dd, 1H, J = 5.7, 14.3, 3-CH2), 3.08 (dd, 1H, 
J = 7.0, 14.3, 3-CH2), 2.02 (s, 3H, 10-CH3); 
13
C NMR (CD3CN, 101 MHz) δ 200.1 (1-C), 
170.3 (9-C), 158.5 (7-C), 130.3 (5-C), 129.1 (4-C), 113.8 (6-C), 60.3 (2-C), 54.8 (8-C), 
32.9 (3-C), 21.7 (10-C); IR: (KBr) νmax 3280, 1732, 1637, 1610, 1510, 1440, 1373, 1300, 
1244, 1176, 1029 cm
-1
; HRMS calcd for C12H15NO3 [M+Na]
+







To a stirred solution of amino alcohol 127 (100 mg, 0.55 
mmol) in anhydrous toluene (10 mL) was added a 
solution of dioxinone (78 mg, 0.55 mmol). The reaction 
was heated to 105 °C for 3 h. The mixture was 
concentrated under vacuum and the residue was purified by flash chromatography 
(CH2Cl2/MeOH = 20:1) to give 210 as a yellow solid (78 mg, 53%). 
Rf = 0.6 (CH2Cl2/MeOH = 40:1); [α]D
25
 = -2.7 (c = 1.0, MeOH); m.p. 62-63 °C; 
1
H NMR 
(CDCl3, 400 MHz): δ 7.24-7.18 (m, 1H, CONH), 7.12 (d, 2H, J = 8.1, 5-ArH), 6.81 (d, 
2H, J = 8.1, 6-ArH), 4.19-4.09 (m, 1H, 2-CH), 3.76 (s, 3H, 8-CH3), 3.69-3.62 (m, 1H, 
1-CH2), 3.57-3.50 (m, 1H, 1-CH2), 3.42-3.29 (m, 2H, 10-CH2), 2.85-2.71 (m, 2H, 3-CH2), 
2.19 (d, 3H, J = 2.1, 12-CH3); 
13
C NMR (CDCl3, 101 MHz) δ 204.6 (11-C), 166.3 (9-C), 
158.3 (7-C), 130.2 (5-C), 129.6 (4-C), 114.0 (6-C), 63.8 (1-C), 55.2 (8-C), 53.3 (2-C), 
49.9 (10-C), 36.1 (3-C), 30.8 (12-C); IR (KBr) νmax 3383, 3319, 2927, 2837, 1710, 1639, 
1614, 1529, 1514, 1442, 1359, 1325, 1290, 1246, 1222, 1176, 1026 cm
-1
; HRMS calcd 
for C14H19NO4 [M+Na]
+
 m/z = 288.1212, found 288.1212. 
Methyl-S-(1,1-diethoxy-3-(4-methoxyphenyl)propan-2-yl)carbamate 211. 
EDC·HCl (25 g, 130.5 mmol) and dichloroacetic acid 
(6.78 g, 52.2 mmol) were added to a solution of alcohol 
126 (6.24 g, 26.1 mmol) in toluene (30 mL) and DMSO 
(30 mL). The reaction was stirred at 25 °C for 16 h and 
then H2O was added. The aqueous layer was extracted 
with EtOAc (3 × 100 mL), washed with sat. NaCl, dried over MgSO4 and evaporated 
under vacuum to give a crude aldehyde which was used for next step without 
purification. The crude aldehyde (6.18 g, 26.1 mmol) and catalytic amount of p-TsOH 
were added to a solution of triethyl orthoformate (19.3 g, 130 mmol) in dry EtOH (50 
mL). After reaction at 50 °C overnight, EtOH was removed under reduced pressure. The 
crude oil was diluted with EtOAc and washed with H2O, sat. aqueous NaCl solution. 
After drying over MgSO4, EtOAc was removed and the crude product was purified by 
flash chromatography (petroleum ether/EtOAc = 8:1) to give 211 as an oil (6.5 g, 80%). 
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Rf = 0.3 (petroleum ether/EtOAc = 4:1); [α]D
25 
= -16.8 (c = 1.0, MeOH); 
1
H NMR 
(CDCl3, 400 MHz): δ 7.11 (d, J = 8.4, 2H, 5-ArH), 6.82 (d, 2H, J = 8.4, 6-ArH), 4.91 (d, 
J = 8.5, 1H, 12-NH), 4.30 (d, J = 3.1, 1H, 1-CH), 4.04-3.94 (m, 1H, 2-CH), 3.80-3.69 
(m, 4H, 8-CH3 and 11-CH2), 3.64-3.55 (m, 4H, 10-CH3 and 11-CH2), 3.54-3.44 (m, 2H, 
11-CH2), 2.86 (dd, 1H, J = 6.4, 14.1, 3-CH2), 2.73 (dd, 1H, J = 7.8, 14.1, 3-CH2), 
1.25-1.15 (m, 6H, 12-CH3); 
13
C NMR (CDCl3, 101 MHz) δ 158.1 (7-C), 156.8 (9-C), 
130.3 (5-C), 130.1 (4-C),113.8 (6-C), 102.2 (1-C), 63.7 (11-C), 55.2 (8-C), 54.2 (10-C), 
52.0 (2-C), 35.2 (3-C), 15.3 (12-C); IR (neat) νmax 2976, 1708, 1504, 1234, 1159, 894, 
758, 738 cm
-1
; HRMS calcd for C16H25NO5 [M+Na]
+
 m/z = 334.1630, found 334.1631. 
S-1,1-Diethoxy-3-(4-methoxyphenyl)propan-2-amine 212. 
To a solution of compound 211 (2.0 g, 6.1 mmol) in MeOH 
and H2O 60 mL (1:1) was added KOH (7.2 g, 12.2 mmol) 
and stirred at 50 °C overnight. The mixture was then 
extracted with EtOAc (3 × 15 mL). The combined extracts 
were washed with H2O, sat. aqueous NaCl and concentrated under vacuum. Purification 
by flash chromatography (CH2Cl2/MeOH = 30:1, TEA was added) afforded 212 as a 
white solid (1.3 g, 85%). 
Rf = 0.35 (CH2Cl2/MeOH = 15:1); [α]D
23
 = -13.2 (c = 0.67, MeOH); 
1
H NMR (CDCl3, 
400 MHz): δ 7.11 (d, 2H, J = 8.6, 5-ArH), 6.85 (d, 2H, J = 8.6, 6-ArH), 4.20 (d, 1H, J = 
5.6, 1-CH), 3.79-3.65 (m, 5H, 8-CH3 and 9-CH2), 3.59-3.49 (m, 2H, 9-CH2), 3.07-3.00 
(m, 1H, 2-CH), 2.90 (dd, 1H, J = 4.1, 13.6, 3-CH2), 2.44 (dd, 1H, J = 9.4, 13.6, 3-CH2), 
1.46 (br, 2H, NH2), 1.25-1.18 (m, 6H, 10-CH3); 
13
C NMR (CDCl3, 101 MHz) δ 158.1 
(7-C), 131.0 (5-C), 130.2 (4-C), 113.9 (6-C), 105.7 (1-C), 63.5 (9-C), 63.1 (9-C), 55.2 
(8-C), 54.9 (2-C), 37.7 (3-C), 15.4 (10-C), 15.4 (10-C); IR (KBr) νmax 2974, 2900, 1610, 
1583, 1510, 1442, 1300, 1244, 1176, 1107, 1056, 1033, 808 cm
-1
; HRMS calcd for 
C14H23NO3 [M+H]
+
 m/z = 254.1756, found 254.1758. 
S-N-(1,1-Diethoxy-3-(4-methoxyphenyl)propan-2-yl)-3- oxobutanamide 213. 
161 (35.0 mg, 0.25 mmol) was added to a solution of 212 
(63.0 mg, 0.25 mmol) in anhydrous toluene (10 mL). The 
solution was heated at 105 °C for 3 h. The reaction 
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mixture was concentrated under vacuum and the residue was purified by flash 
chromatography (CH2Cl2/MeOH = 100:1) to give 213 as a yellow solid (72.0 mg, 86%). 
Rf = 0.3 (CH2Cl2/MeOH = 30:1); [α]D
25 
= -16.9 (c = 0.3, MeOH); 
1
H NMR (CDCl3, 400 
MHz): δ 7.06 (d, 2H, J = 8.6, 5-ArH), 6.80 (d, 1H, J = 8.9, CONH), 6.75 (d, 2H, J = 8.6, 
6-ArH), 4.33-4.23 (m, 2H, 1-CH and 2-CH), 3.76-3.66 (m, 4H, 8-CH3 and 13-CH2), 
3.61-3.40 (m, 3H, 13-CH2), 3.25 (s, 2H, 10-CH2), 2.85 (dd, 1H, J = 6.0, 14.3, 3-CH2), 
2.68 (dd, 1H, J = 8.3, 14.3, 3-CH2), 2.11 (s, 3H, 12-CH3), 1.22-1.09 (m, 6H, 14-CH3); 
13
C 
NMR (CDCl3, 101 MHz) δ 203.8 (11-C), 165.3 (9-C), 158.1 (7-C), 130.1 (5-C), 129.9 
(4-C), 113.7 (6-C), 102.1 (1-C), 63.7 (13-C), 63.6 (13-C), 55.1 (8-C), 52.6 (2-C), 50.5 
(10-C), 34.8 (3-C), 30.5 (12-C), 15.3 (14-C), 15.2 (14-C); IR (KBr) νmax 3282, 2976, 
2931, 1716, 1641, 1610, 1583, 1550, 1510, 1415, 1244, 1060, 1031, 954 cm
-1
; HRMS 
calcd for C18H27NO5 [M+Na]
+
 m/z = 360.1787, found 360.1782. 
S-N-(1-(4-Methoxyphenyl)-3-oxopropan-2-yl)-3-oxobutanamide 115. 
Diethyl acetal 213 (30.0 mg, 89.0 mmol) was dissolved in 
THF (2 mL) mixed with H2O (0.5 mL). After cooling to 
0 °C, concentrated HCl (37%, 1.0 mL) was added and the 
reaction was stirred for 3 h. After complete reaction 
checked by LCMS, the solution was neutralized with 
NaOH solution and extracted with EtOAc (3 × 2 mL). The organic solvents were 
combined and evaporated under vacuum to afford 115 as a yellow oil (21.0 mg, 90%). 
The aldehyde is unstable because of possible polymerization and cannot be purified by 
flash chromatography. But it can be purified by preparative LCMS to afford yellow solid 
after freeze drying. 
[α]D
30 
= -12.0 (c = 0.9, CH2Cl2). 
1
H NMR (CD3CN, 400 MHz): δ 9.57 (s, 1H, 1-CHO), 
7.17 (d, 2H, J = 8.6, 5-ArH), 6.88 (d, 1H, J = 8.6, 6-ArH), 4.51-4.44 (m, 1H, 2-CH), 3.79 
(s, 3H, 8-CH3), 3.39 (s, 2H, 10-CH2), 3.15 (dd, 2H, J = 5.3, 14.3, 3-CH2), 2.91 (dd, 2H, J 
= 8.5, 14.3, 3-CH2), 2.15 (s, 3H, 12-CH3); 
13
C NMR (CD3CN, 101 MHz) δ 203.0 (11-C), 
199.7 (1-C), 166.7 (9-C), 158.5 (7-C), 130.4 (5-C), 128.8 (4-C), 113.8 (6-C), 60.3 (2-C), 
54.8 (8-C), 50.2 (10-C), 33.0 (3-C), 29.5 (12-C); IR (KBr) νmax 3250, 1647, 1610, 1510, 
1300, 1244, 1176, 1110, 1031, 819 cm
-1
; HRMS calcd for C14H17NO4 [M+Na]
+
 m/z = 






A mixture of amino alcohol 208 (Sigma-Aldrich, 200 mg, 1.32 
mmol) and dioxinone 161 (188 mg, 1.32 mmol) in anhydrous 
toluene (10 mL) was heated to 103 °C for 3 h. The reaction 
mixture was concentrated under vacuum and the residue was 
purified by flash chromatography (CH2Cl2:MeOH = 20:1) to give 209 as a white solid 
(180 mg, 58%). 
Rf = 0.3 (CH2Cl2/MeOH = 20:1); [α]D
23
 = -20.6 (c = 0.5, MeOH); 
1
H NMR (CDCl3, 400 
MHz): δ 7.33-7.21 (m, 5H, 5,6,7-ArH), 7.14-7.07 (br, 1H, CONH), 4.26-4.17 (m, 1H, 
2-CH), 3.71 (dd, 1H, J = 3.7, 11.2, 1-CH), 3.59 (dd, 1H, J = 5.4, 11.2, 1-CH), 3.37 (q, 2H, 
J = 17.3, 21.5, 9-CH2), 2.91 (dd, 1H, J = 7.1, 13.9, 3-CH), 2.84 (dd, 1H, J = 7.7, 13.7, 
3-CH), 2.21 (s, 3H, 11-CH3); IR (KBr) νmax 3292, 3084, 2924, 1712, 1641, 1543, 1357, 
1159, 1039 cm
-1




EDC·HCl (40.8 mg, 0.21 mmol) and dichloroacetic acid 
(10.9 mg, 0.08 mmol) were added to a solution of 209 (10 
mg, 0.04 mmol) in toluene (1 mL) and DMSO (1 mL). The 
reaction was stirred at 25 °C for 16 h and then H2O was 
added. The aqueous layer was extracted with EtOAc (3 × 5 mL), and the organic 
solvents combined to give a solution of aldehyde, which was treated with 1 M NaOH 
solution (10 mL) for 5 min at 0 °C. The organic phase was separated and the aqueous 
phase was extracted with EtOAc. The combined organic solvents were washed with sat. 
aqueous NaCl, dried over MgSO4 and evaporated under vacuum. Purification by 
preparative LCMS gave 222b as a white solid (5.5 mg, 60%). 
[α]D
23
 = 0 (c = 0.3, MeOH); 
1
H NMR (CDCl3, 400 MHz): δ 7.35-7.19 (m, 5H, 8, 9, 
10-ArH), 5.54 (s, 1H, 4-CH), 3.70 (s, 2H, 6-CH2), 2.15 (s, 3H, 12-CH3); IR (KBr) νmax 
3153, 3026, 1668, 1626, 1494, 1452, 1436, 1419, 1357, 1263, 1070, 966 cm
-1
; ES-MS: 








To an ice-salt-cooled solution of the 4-methoxyaniline (4.92 g, 
40.0 mmol) in HBF4 (50%, 14 mL) and H2O (15 mL) was added 
dropwise a precooled solution of NaNO2 (2.90 g, 42.0 mmol) in 
H2O (6.5 mL). During the addition, the temperature was carefully kept below 5 °C and the 
resulting mixture was left to stir at 0 °C for 30 min. The diazonium salt was collected by 
filtration, washed with Et2O, and extensively dried under vacuum to afford 225 as a 
purple solid (7.50 g, 85%). (Caution: Diazonium salts may decompose violently upon 
heating.) 
1
H NMR (d6-DMSO, 400 MHz): δ 8.59 (d, 2H, J = 9.4, 2-ArH), 7.47 (d, 2H, J = 9.4, 
3-ArH), 4.03 (s, 3H, 5-CH3); 
13
C NMR (d6-DMSO, 101 MHz) δ 169.3, 136.5, 117.7, 
103.7, 57.9; IR (KBr) νmax 3118, 2250, 1581, 1568, 1512, 1492, 1465, 1440, 1342, 1286, 
1195, 1029, 997, 839 cm
-1
; ES-MS: m/z (%): 107.1 [C7H7O]
+








To a mixture of DMSO/H2O (6 mL, 5:2, v/v, previously 
degassed with N2) were added FeSO4·7H2O (1.67 g, 6.00 
mmol) and 2-methallyl alcohol (1.0 mL, 0.87 g, 12.0 mmol) 
under an N2 atmosphere. A solution of diazonium 
tetrafluoroborate (2.0 mmol) in a mixture of DMSO/H2O (3.0 
mL, 5:2, v/v, previously degassed with N2) was added 
dropwise. The reaction mixture was stirred for an additional 
15 min, then diluted with H2O (50 mL) and extracted with diethyl ether (3 × 50 mL). The 
combined organic phases were washed with sat. aqueous NaCl (50 mL), then dried over 
Na2SO4. The solvent was evaporated under high vacuum to afford 227 as a yellow oil 
(376 mg, 60%). 
1
H NMR (CDCl3, 400 MHz): δ 7.65 (d, 2H, J = 8.9, 10-ArH), 7.10 (d, 2H, J = 8.6, 
5-ArH), 6.92 (d, 2H, J = 8.9, 11-ArH), 6.76 (d, 2H, J = 8.6, 6-ArH), 3.81 (s, 3H, 13-CH3), 
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3.73 (s, 3H, 8-CH3), 3.70 (d, 2H, J = 2.2, 1-CH2), 3.04 (d, 1H, J = 13.4, 3-CH2), 2.92 (d, 
1H, J = 13.4, 3-CH2), 1.17 (s, 3H, 14-CH3); IR (KBr) νmax 3415, 2933, 2835, 1722, 1602, 
1585, 1510, 1462, 1440, 1419, 1369, 1300, 1244, 1176, 1143, 1103, 1029, 835 cm
-1
; 
ES-MS: m/z (%): 194.0 [C11H15]H
+
 (17), 243.0 [2 × C7H7NO]H
+







Alcohol 227 (12.0 mg, 0.05 mmol) was dissolved in MeOH (2 
mL) and zinc dust (300 mg, 4.59 mmol) and HCl (6 M, 5 mL) 
were added. After reaction overnight at room temperature, the 
pH was adjusted with aqueous NaOH (20%) to pH > 12 and 
the aqueous solution extracted with EtOAc (3 × 20 mL). The combined organic phases 
were dried over Na2SO4 and the solvent was evaporated. The residue was purified by 
flash chromatography (CH2Cl2/MeOH = 20:1) to give 228 as a yellow oil (8.0 mg, 82%). 
Rf = 0.3 (CH2Cl2/MeOH = 20:1); 
1
H NMR (CDCl3, 400 MHz): δ 7.08 (d, 2H, J = 8.5, 
5-ArH), 6.80 (d, 2H, J = 8.5, 6-ArH), 3.75 (s, 3H, 8-CH3), 3.32 (dd, J = 10.7, 14.7, 2H, 
1-CH2), 2.74 (s, 3H, OH and NH2), 2.62 (s, 2H, 3-CH2), 0.98 (s, 3H, 9-CH3); 
13
C NMR 
(CDCl3, 101 MHz) δ 158.2 (7-C), 131.4 (5-C), 129.4 (4-C), 113.6 (6-C), 69.3 (1-C), 55.2 
(8-C), 53.6 (2-C), 44.5 (3-C), 24.4 (9-C); IR (KBr) νmax 3228, 2910, 2814, 2736, 1610, 
1570, 1535, 1508, 1465, 1246, 1031, 763 cm
-1






N-(1-Hydroxy-3-(4-methoxyphenyl)-2-methylpropan-2-yl)-3- oxobutanamide 229. 
A mixture of amino alcohol 228 (180 mg, 0.92 mmol) and 
dioxinone 161 (130 mg, 0.92 mmol) in anhydrous toluene 
(15 mL) was heated to 103 °C for 3 h. The reaction 
mixture was concentrated under vacuum and the residue 
was purified by flash chromatography (CH2Cl2/MeOH = 
20:1) to give 229 as a colourless oil (148 mg, 58%). 
Rf = 0.5 (CH2Cl2/MeOH = 20:1); 
1
H NMR (CDCl3, 400 MHz): δ 7.12 (d, 2H, J = 8.5, 
5-ArH), 6.93 (s, 1H, CONH), 6.83 (d, 2H, J = 8.5, 6-ArH), 3.79 (s, 3H, 8-CH3), 3.70-3.60 
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(m, 2H, 1-CH2), 3.39 (s, 2H, 10-CH2), 3.01 (d, 1H, J = 13.6, 3-CH), 2.86 (d, 1H, J = 13.6, 
3-CH), 2.26 (s, 3H, 12-CH3), 1.16 (s, 3H, 13-CH3); 
13
C NMR (CDCl3, 101 MHz) δ 204.6 
(11-C), 166.3 (9-C), 158.5 (7-C), 131.5 (5-C), 128.3 (4-C), 113.7 (6-C), 68.8 (1-C), 59.6 
(2-C), 55.2 (8-C), 49.8 (10-C), 40.7 (3-C), 31.1 (12-C), 22.6 (13-C); IR (KBr) νmax 3305, 
3078, 2933, 1712, 1647, 1610, 1550, 1463, 1244, 1161, 1031, 883 cm
-1
; HRMS calcd 
for C15H21NO4 [M+Na]
+
 m/z = 302.1368, found 302.1367. 
3-Acetyl-5-(4-methoxybenzyl)-5-methyl-1,5-dihydro-2H-pyrrol-2-one 231. 
EDC·HCl (17.2 mg, 0.09 mmol) and dichloroacetic acid 
(4.6 mg, 0.04 mmol) were added to a solution of 229 (5.0 
mg, 0.02 mmol) in toluene (0.5 mL) and DMSO (0.5 mL). 
The reaction was stirred at 25 °C for 16 h and then H2O 
was added. The aqueous layer was extracted with EtOAc (3 × 2 mL), and the organic 
solvents combined to give a solution of aldehyde, which was treated with 1 M NaOH 
solution (5 mL) for 5 min at 0 °C to afford pyrrolinone 231. The organic phase was 
separated and the aqueous phase was extracted with EtOAc. The combined organic 
solvents were washed with sat. aqueous NaCl, dried over MgSO4 and evaporated under 
vacuum. Purification by preparative LCMS gave 231 as a yellow solid (2.6 mg, 56%). 
1
H NMR (CDCl3, 400 MHz): δ 7.72 (d, 1H, J = 2.0, 4-CH), 7.05 (d, 2H, J = 8.6, 8-ArH), 
6.84 (d, 2H, J = 8.6, 9-ArH), 6.26 (s, 1H, 1-CONH), 3.79 (s, 3H, 11-CH3), 2.90 (d, 1H, J 
= 13.6, 6-CH2), 2.83 (d, 1H, J = 13.6, 6-CH2), 2.51 (s, 3H, 13-CH3), 1.35 (s, 3H, 14-CH3); 
13
C NMR (CDCl3, 101 MHz) δ 194.3 (12-C), 168.6 (2-C), 160.6 (4-C), 158.9 (10-C), 
135.2 (3-C), 131.1 (8-C), 126.9 (7-C), 114.0 (9-C), 61.7 (5-C), 55.3 (11-C), 44.1 (6-C), 
29.2 (13-C), 23.0 (14-C); IR (KBr) νmax 3261, 2920, 1697, 1512, 1246, 1031, 819 cm
-1
; 
HRMS calcd for C15H17NO3 [M+Na]
+





Fmoc-protected amino acid (Iris Biotech GmbH, 2.5 mmol, 
1.15 g) was added to a dry 100 mL round bottom flask 
equipped with a magnetic stir bar, dissolved in dry CH2Cl2 
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(10 mL) with DIEA (0.4 mL) and cooled to 0 ºC. After stirring for 10 min at 0 ºC, 
EDC·HCl (575 mg, 3.0 mmol) and HOBt (400 mg, 3.0 mmol) were added as solids. The 
mixture was stirred at 0 ºC for another 10 min, then N,O-dimethylhydroxylamine (300 mg, 
3 mmol) and DIEA (0.5 mL) were added. The mixture was allowed to stir at 0 ºC for an 
additional hour, then allowed to warm to room temperature. The mixture was stirred for 
another 16 h. The reaction mixture was transferred with CH2Cl2 rinses (50 mL) to a 
separatory funnel, then washed with aqueous HCl (2 N, 3 × 30 mL), sat. aqueous 
NaHCO3 solution (2 × 30 mL) and sat. aqueous NaCl solution (2 × 30 mL). The organic 
layer was dried over anhydrous Na2SO4, concentrated on a rotary evaporator, dried under 
vacuum and the residue was purified by flash chromatography (petroleum ether/EtOAc = 
2:1) to give a white crystalline solid (1.12 g, 90%). 
Rf = 0.2 (petroleum ether/EtOAc = 4:1); [α]D
23
 = -4.7 (c = 0.3, MeOH; lit. no report); 
1
H 
NMR (CDCl3, 400 MHz): δ 7.76 (d, J = 7.6, 2H, 17-CH), 7.57 (t, J = 6.8, 2H, 14-CH), 
7.40 (t, J = 7.6, 2H, 16-CH), 7.33-7.28 (m, 2H, 15-CH), 7.07 (d, J = 8.1, 2H, 5-CH), 6.90 
(d, J = 8.1, 2H, 6-CH), 5.48 (d, J = 8.5, 1H, CONH), 5.05-4.95 (m, 1H, 2-CH), 4.39-4.24 
(m, 2H, 11-CH2), 4.18 (t, J = 7.2, 1H, 12-CH), 3.62 (s, 3H, OCH3), 3.16 (s, 3H, NCH3), 
3.08-3.00 (m, 1H, 3-CH), 2.95-2.86 (m, 1H, 3-CH), 1.30 (s, 9H, 9-C(CH3)3); IR (KBr) 
νmax 3300, 2974, 1716, 1654, 1504, 1448, 1284, 1159, 1105, 1043, 897, 738 cm
-1
; ES-MS: 
m/z (%): 503.3 [M]H
+







Fmoc-Weinreb amide 352 (12.0 mmol, 6.0 g) was dissolved 
in dry THF (100 mL) in an oven dry 250 mL round bottom 
flask equipped with stir bar. The solution was cooled to 0 °C, 
then LiAlH4 (550 mg, 0.15 mmol) was added in portions as a 
solid. The mixture was stirred at 0 ºC for 1 h. After this time 
the reaction mixture was quenched with a solution of 
NaHSO4 (7.0 g, 50.0 mmol) in H2O (200 mL), which was added dropwise. The mixture 
was stirred for an additional 10 min before being transferred to a separatory funnel. The 
reaction flask was washed with sat. aqueous NaCl solution (30 mL) and EtOAc (30 mL). 
The layers were separated and the aqueous layer extracted with EtOAc (100 mL). The 
organic layers were combined and washed with aqueous HCl (1.5 N, 3 × 100 mL), sat. 
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aqueous NaHCO3 solution (2 × 10 mL) and sat. aqueous NaCl solution (2 × 100 mL). The 
organic layer was dried over Na2SO4, concentrated on a rotary evaporator, dried under 
vacuum and purified by flash chromatography (petroleum ether/EtOAc = 4:1) to give the 
aldehyde as a white solid (4.6 g, 86%). 
Rf = 0.6 (petroleum ether/EtOAc = 2:1); [α]D
23
 = -9.9 (c = 0.14, MeOH; lit. no report); 
1
H 
NMR (CDCl3, 400 MHz): δ 9.63 (s, 1H, 1-CHO), 7.77 (d, J = 7.5, 2H, 17-CH), 7.58 (d, 
2H, J = 7.8, 14-CH), 7.41 (t, J = 7.5, 2H, 16-CH), 7.32 (t, J = 7.4, 2H, 15-CH), 7.02 (d, J 
= 8.2, 2H, 5-CH), 6.91 (d, J = 8.2, 2H, 6-CH), 5.32 (d, J = 6.9, 1H, CONH), 4.54-4.37 (m, 
3H, 2-CH and 11-CH2), 4.22 (t, J = 6.8, 1H, 12-CH), 3.14-3.07 (m, 2H, 3-CH2), 1.33 (s, 
9H, 9-C(CH3)3); IR (KBr) νmax 2976, 1708, 1504, 1234, 1159, 894, 758, 738 cm
-1
; 
ES-MS: m/z (%): 466.3 [M]Na
+
 (100), 444.2 [M]H
+
 (38), 484.3 [M+H2O]Na
+






Fmoc-protected aldehyde 353 (13.5 mmol, 6.0 g), a catalytic 
amount of p-TsOH (1.35 mmol, 0.26 g), and toluene (50 mL) 
were introduced into a 100 mL flask equipped with a Dean-Stark 
apparatus. After refluxing for 3 days, the solution was allowed to 
cool to room temperature and the product was precipitated as 
yellow solid. The solid was collected by filtration and washed 
with toluene. The filtrate was washed with sat. NaHCO3, NaCl and dried with anhydrous 
Na2SO4, evaporated under vacuum to give the yellow compound, which was 
recrystallized with toluene. The yellow solid was combined to give the target compound 
(4.1 g, 70%). 
[α]D
23
 = -38.7 (c = 0.4, MeOH); 
1
H NMR (DMSO, 400 MHz): δ 9.08 (s, 1H, OH), 7.81 (d, 
J = 7.5, 2H, 15-CH), 7.58 (dd, 2H, J = 7.4, 10.8, 12-CH), 7.38-7.21 (m, 5H, CONH and 
13, 14-CH), 6.96 (d, J = 8.4, 2H, 5-CH), 6.56 (d, J = 8.4, 2H, 6-CH), 4.74 (d, J = 3.7, 1H, 
1-CH), 4.13-4.02 (m, 3H, 9-CH and 10-CH2), 3.90-3.83 (m, 2H, 17-CH2), 3.79-3.72 (m, 
2H, 18-CH2), 3.69-3.61 (m, 1H, 2-CH); 2.70-2.63 (m, 1H, 3-CH2), 2.53-2.47 (m, 1H, 
3-CH2); 
13
C NMR (DMSO, 101 MHz): δ 156.3 (8-CO), 155.9 (7-C), 144.3 (11-C), 141.1 
(16-C), 130.4 (4-C), 129.1 (5-C), 128.0 (14-C), 127.5 (13-C), 125.9 (12-C), 120.5 (15-C), 
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115.3 (6-C), 104.2 (1-C), 65.8 (9-C), 65.3 (17-C), 65.0 (18-C), 55.3 (2-C), 47.1 (10-C), 
34.1 (3-C); IR (KBr) νmax 3307, 1695, 1614, 1514, 1448, 1328, 1228 cm
-1
; HRMS calcd 
for C26H25NO5 [M+Na]
+
 m/z = 454.1630 found 454.1630. 
S-4-(2-Amino-2-(1,3-dioxolan-2-yl)ethyl)phenol 342. 
Fmoc-protected acetal 354 (1.0 g, 2.32 mmol) was dissolved in 
acetonitrile (10 mL). Diethylamine (10 mL) was added and the 
mixture was stirred at room temperature for 3 h. After completed 
reaction, the solution was concentrated under vacuum and 
purified by flash chromatography (CH2Cl2/MeOH = 30:1, additional TEA was added) to 
give 342 as a yellow solid (0.33 g, 62%). 
Rf = 0.15 (petroleum ether/EtOAc = 2:1); [α]D
23
 = -15.2 (c = 0.7, MeOH). 
1
H NMR 
(CDCl3, 400 MHz): δ 7.02 (d, 2H, J = 8.5, 5-CH), 6.66 (d, J = 8.5, 2H, 6-CH), 4.75 (d, 1H, 
J = 3.6, 1-CH), 4.05-4.98 (m, 2H, 8-CH2), 3.94-3.89 (m, 2H, 9-CH2), 3.35 (s, 2H, NH2), 
3.12-3.06 (m, 1H, 2-CH), 2.87 (dd, 1H, J = 4.8, 13.8, 3-CH2), 2.55 (dd, 1H, J = 9.3, 13.8, 
3-CH2); 
13
C NMR (CDCl3, 101 MHz): δ 155.3 (7-C), 130.3 (4-C), 128.9 (5-C), 115.8 
(6-C), 105.1 (1-C), 65.4 (8-C), 65.3 (9-C), 54.9 (2-C), 37.5 (3-C); IR (KBr) νmax 3346, 
2887, 1612, 1591, 1514, 1247, 1128, 1097 cm
-1
; HRMS calcd for C11H16NO3 [M+H]
+
 




2,2-Dimethyl-(4H)-1,3-dioxin-4-one 161 (Sigma-Aldrich, 4.60 mL, 
5.00 g, 35.0 mmol) was added dropwise to a solution of LDA (47.3 
mmol, 1.35 eq.) in dry THF (100 mL) within 5 min at -78 °C. The 
resulting mixture was stirred for another 5 min. The temperature was 
gradually raised to -48 °C. A solution of C2Cl6 (14.6 g, 61.6 mmol, 1.76 eq.) in THF (40 
mL) was added dropwise within 50 min. After stirring for another 10 min, the red solution 
was quenched by the addition of ice cold diluted aqueous HCl. The layers were separated 
and the aqueous layer was extracted with Et2O (3 × 50 mL). The combined organic 
extracts were washed with H2O (15 mL) and dried over anhydrous MgSO4. The solvent 
was removed under vacuum and the residue purified by flash chromatography (petroleum 
ether/EtOAc = 4:1) to give 166 as a yellow liquid (3.1 g, 50%). 
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Rf = 0.5 (petroleum ether/EtOAc = 4:1); 
1
H NMR (CDCl3, 400 MHz): δ 5.57 (s, 1H, 
4-CH), 4.04 (s, 2H, 6-CH2), 1.74 (s, 6H, 5-(CH3)2); IR (neat) νmax 2999, 1718, 1637, 1388, 
1271, 1199, 1029 cm
-1









 (25), 177.0 [M]H
+






Diethyl phosphite (Sigma-Aldrich, 8.74 g, 63.4 mmol) was added 
dropwise to a solution of potassium tert-butoxide (7.09 g, 63.4 
mmol) in DMF (30 mL), cooled to 0 °C. After 30 min, 166 (3.73 g, 
21.1 mmol) in DMF (10 mL) was added dropwise over 20 min 
and the deep purple solution generated was stirred at 0 °C for a further 60 min. Dropwise 
addition of concentrated aqueous HCl discharged the colour and the pale brown mixture 
was filtrated through silica gel, and the silica gel washed with diethyl ether. The 
combined solvents were washed with H2O (3 × 30 mL) and the organic phase was washed 
with sat. NaCl, dried over MgSO4, concentrated under vacuum, purified by flash 
chromatography (petroleum ether/EtOAc = 1:2) to give 167 as a yellow oil (4.74 g, 48%). 
Rf = 0.4 (pure EtOAc); 
1
H NMR (CDCl3, 400 MHz): δ 5.34 (d, 1H, J = 3.7, 4-CH), 
4.14-4.06 (m, 4H, 7-CH2), 2.76 (d, J = 22.2, 6-CH2), 1.65 (s, 6H, 5-(CH3)2), 1.29 (t, J = 
7.1, 6H, 8-CH3); IR (neat) νmax 2981, 1726, 1666, 1633, 1384, 1253 cm
-1
; ES-MS: m/z 
(%): 221.2 [C8H13O5P]H
+
 (100), 239.3 [C8H13O5P+H2O]H
+









To a stirred solution of 2E,4E-hexadien-l-ol (abcr GmbH, 9.8 g, 
100 mmol) of in 20 mL of CH2Cl2 under nitrogen atmosphere at 
-10 °C was slowly added a solution of 9.20 g (34 mmol) of 
PhBr3 in 20 mL of CH2Cl2. After all the phosphorous tribromide was added, the reaction 
mixture was stirred for an additional 15-20 min before it was quenched with an ice-cold 
sat. aqueous solution of NaHCO3 (30 mL). The resulting mixture was extracted with 
pentane (350 mL), the organic phase was washed with sat. aqueous NaCl (2 × 50 mL), 
and dried over Na2SO4. After removal of the pentane and CH2Cl2 by rotary evaporation at 
room temperature, the crude bromide was transferred to a wide-mouth brown glass bottle 
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containing triphenylphosphine (Sigma-Aldrich, 28 g, 108 mmol) and dry toluene (160 
mL). The mixture was kept at room temperature for 3 days, and the resulting crystalline 
product was collected by suction filtration, rinsing the solids with a small amount of 
toluene. After pumping under vacuum at room temperature for 6 h to remove traces of 
toluene, 24.0 g of the crystalline phosphonium salt 356 was obtained (58%); 
1
H NMR (CDCl3, 400 MHz): δ 7.83-7.62 (m, 15H, ArH), 6.38-6.28 (m, 1H, 3-CH), 
5.93-5.82 (m, 1H, 4-CH), 5.69-5.58 (m, 1H, 5-CH), 5.33-5.22 (m, 1H, 2-CH), 4.74 (dd, 
2H, J = 7.6, 15.4, 1-CH2), 1.66 (d, J = 6.3, 3H, 6-CH3); IR (neat) νmax 2858, 1587, 1435, 
1109, 995, 931, 873 cm
-1






Benzoyl chloride (Sigma-Aldrich, 12.6 g, 89.5 
mmol) was added dropwise to a mixture of 
octane-1,8-diol (abcr GmbH, 19.6 g, 134 mmol) 
and TEA (9.0 g, 89.5 mmol) in dry THF (100 mL) at 0 °C. The mixture was allowed to 
warm to room temperature and stirred for 6 h. After reaction, the solution was filtrated 
and the filtrate was washed with sat. NaHCO3 and NaCl, dried over MgSO4, concentrated 
under vacuum and purified by flash chromatography (petroleum ether/EtOAc = 4:1) to 
give 364 as a colourless oil (7.8 g, 60%). 
Rf = 0.3 (PE/EA = 2:1); 
1
H NMR (CDCl3, 400 MHz): δ 8.04 (d, 2H, J = 8.1, 11-CH), 
7.57-7.54 (m, 1H, 13-CH), 7.46-7.41 (m, 2H, 12-CH), 4.31 (t, 2H, J = 6.7, 1-CH2), 3.63 (t, 
2H, J = 6.6, 8-CH2), 1.81-1.72 (m, 2H, 2-CH2), 1.59-1.52 (m, 2H, 7-CH2), 1.51-1.32 (m, 
8H, 3, 4, 5, 6-CH2); IR (neat) νmax 2928, 2854, 1716, 1450, 1284, 1159, 1271, 1109, 707 
cm
-1
; ES-MS: m/z (%): 105.0 [C7H5O]
+
 (62), 111.1 [C8H14]H
+





 (55), 233.2 [M-H2O]H
+
 (22), 251.2 [M]H
+







To a cold (-78 °C), stirred solution of oxalyl chloride 
(Sigma-Aldrich, 4.82 g, 38 mmol) in dry CH2Cl2 (40 
mL) was added a solution of DMSO (4.45 g, 57 
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mmol) dropwise in dry CH2Cl2 (30 mL) under N2. After 30 min of stirring, a solution of 
the monobenzoate of 1,8-octanediol 364 (4.8 g, 19 mmol) in dry CH2Cl2 (30 mL) was 
added over 30 min at -78 °C. The resulting cloudy solution was stirred at -78 °C for 1 h 
before TEA (9.6 g, 95 mmol) was introduced. The cold bath was removed and the mixture 
was allowed to warm to 0 °C before being quenched with a sat. aqueous solution of 
NH4Cl (50 mL). The separated aqueous phase was extracted with CH2Cl2 (3 × 50 mL). 
The organic layers were combined, dried over MgSO4, and concentrated under vacuum 
and purified by flash chromatography (petroleum ether/EtOAc = 15:1) to give 365 as a 
colourless oil (4.2 g, 86%). 
Rf = 0.5 (petroleum ether/EtOAc = 8:1); 
1
H NMR (CDCl3, 400 MHz): δ 9.74 (t, 1H, J = 
1.5, 8-CHO), 8.03 (d, 2H, J = 7.4, 11-CH), 7.57-7.51 (m, 1H, 13-CH), 7.42 (t, 2H, J = 7.8, 
12-CH), 4.30 (t, 2H, J = 6.7, 1-CH2), 2.46-2.41 (dt, 2H, J = 7.4, 1.5, 7-CH2), 1.80-1.71 (m, 
2H, 2-CH2), 1.67-1.58 (m, 2H, 6-CH2), 1.47-1.31 (m, 6H, 3, 4, 5-CH2); IR (neat) νmax 
2931, 2856, 1714, 1452, 1388, 1313, 1273, 1109 cm
-1





 (100), 289.0 [M+H2O]Na
+
 (72). 
8E,10E,12E-Tetradeca-8,10,12-trien-1-yl benzoate 369. 
Phosphonium salt 356 (2.15 g, 5.1 mmol) 
in dry THF (20 mL) was cooled with a dry 
ice-acetone bath. BuLi (2.5 M in hexanes, 
2.04 mL, 5.1 mmol) was added dropwise, and the mixture was stirred at -78 ºC for 1 h. 
Then aldehyde (1.04 g, 4.2 mmol) in THF (5 mL) was added dropwise. After the addition 
was complete, the mixture was warmed to room temperature over 1 h, then quenched with 
ice-water (25 mL), and extracted with hexane (80 mL). The hexane extract was washed 
with H2O (2 × 10 mL), sat. aqueous NaCl (2 × 10 mL), dried and concentrated. Flash 
chromatography (petroleum ether/EtOAc = 30:1) of the residue gave mixture of the title 
compound as colourless oil (0.81 g, 62%, EEE: ZEE, 62:38 by crude NMR). 
1
H NMR (CDCl3, 400 MHz): δ 8.05 (d, 2H, J = 7.6, 17-ArH), 7.58-7.53 (m, 1H, 19-ArH), 
7.47-7.41 (m, 2H, 18-ArH), 6.12-5.99 (m, 4H, 9,10,11,12-CH), 5.74-5.59 (m, 2H, 
8,13-CH), 4.32 (t, 2H, J = 6.7, 1-CH2), 2.13-2.05 (m, 2H, 7-CH), 1.82-1.72 (m, 5H, 
2-CH2 and 14-CH3), 1.49-1.29 (m, 8H, 3,4,5,6-CH2); 
13
C NMR (CDCl3, 101 MHz): δ 
166.7 (15-C), 134.3 (8-C), 132.8 (19-C), 131.8 (10-C), 130.8 (11-C), 130.6 (12-C), 130.5 
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(9-C), 129.5 (16-C), 128.8 (13-C), 128.7 (16-C), 125.8 (17-C), 65.1 (1-C), 32.8 (7-C), 
29.6 (2-C), 29.3 (6-C), 29.2 (4-C), 29.0 (5-C), 28.7 (3-C), 18.3 (14-C); IR (neat) νmax 
2928, 2854, 1716, 1450, 1313, 1269, 1174, 1111, 707 cm
-1
; HRMS: calcd for C21H28O2 
[M+Na]
+
 m/z = 335.1987, found 335.1986. 
8E,10E,12E-Tetradeca-8,10,12-trien-1-ol 370. 
Dry K2CO3 (8.72 g, 63.2 mmol) was added to 
an ice-cold solution of the acetates 369 (9.86 g, 
31.6 mmol) in MeOH (100 mL). The mixture 
was stirred at room temperature for 1 h, then quenched with ice-cold H2O (100 mL) and 
extracted with hexane (3 × 100 mL). The organic phase was washed with sat. aqueous 
NaCl, dried, concentrated. The residue was recrystallized with hexane to give the target 
compound as white solid (3.35 g, 16.1 mmol, 50%). The mother liquor was evaporated 
and dissolved in 1:1 hexane-Et2O (1 L) containing a few crystals I2 (~ 5 mg), and kept in 
laboratory light for 10 min. The solution was washed with sat. Na2S2O3 (30 mL), sat. 
aqueous NaCl (2 × 100 mL) and dried over MgSO4. After concentration and 
recrystallization as before, a further 1.05 g (15%) of pure EEE 370 was obtained. 
1
H NMR (CDCl3, 400 MHz): δ 6.12-6.00 (m, 4H, 9,10,11,12-CH), 5.73-5.62 (m, 2H, 
8,13-CH), 3.65 (t, 2H, J = 6.6, 1-CH2), 2.13-2.06 (m, 2H, 7-CH2), 1.78 (d, 3H, J = 6.6, 
14-CH3), 1.62-1.53 (m, 2H, 2-CH2), 1.45 (s, 1H, OH), 1.43-1.29 (m, 8H, 3,4,5,6-CH2); 
13
C NMR (CDCl3, 101 MHz): δ 134.3 (8-C), 131.8 (10-C), 130.7 (11-C), 130.6 (12-C), 
130.5 (9-C), 128.8 (13-C), 63.0 (1-C), 32.8 (7-C), 29.3 (2-C), 29.3 (6-C), 29.1 (4-C), 25.7 
(3-C), 18.3 (14-C); IR (neat) νmax 3373, 2926, 2848, 1465, 1371, 1062, 993, 976, 764 cm
-1
; 
HRMS calcd for C14H24O [M+Na]
+
 m/z = 231.1725 found 231.1727. 
8E,10E,12E-Tetradeca-8,10,12-trienal 345. 
To a cold (-78 °C), stirred solution of oxalyl 
chloride (1.2 g, 9.4 mmol) in dry CH2Cl2 (10 
mL) was added a solution of DMSO (1.1 g, 14.1 
mmol) dropwise in dry CH2Cl2 (10 mL) under N2. After 30 min of stirring, a solution of 
the 8E,10E,12E-tetradeca-8,10,12-trien-1-ol 370 (0.99 g, 4.7 mmol) in dry CH2Cl2 (10 
mL) was added over 30 min at -78 °C. The resulting cloudy solution was stirred at -78 °C 
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for 1 h before Et3N (2.4 g, 23.5 mmol) was introduced. The cold bath was removed and 
the mixture was allowed to warm to 0 °C before being quenched with a sat. solution of 
NH4Cl (20 mL). The separated aqueous phase was extracted with CH2Cl2 (3 × 20 mL). 
The organic layers were combined, dried over MgSO4, and concentrated under vacuum to 
afford 345 as a white solid (0.81 g, 83%). The residue was applied to freeze dryer to 
remove tiny amount of H2O inside and used for next step without further purification. 
1
H NMR (CD3CN, 400 MHz): δ 9.68 (t, 1H, J = 1.7, 1-CHO), 6.13-6.00 (m, 4H, 
9,10,11,12-CH), 5.73-5.62 (m, 2H, 8,13-CH), 2.38 (dt, 2H, J = 1.7, 7.3, 2-CH2), 
2.11-2.03 (m, 2H, 7-CH2), 1.74 (d, 3H, J = 6.6, 14-CH3), 1.60-1.53 (m, 2H, 3-CH2), 
1.41-1.29 (m, 6H, 4,5,6-CH2); 
13
C NMR (CDCl3, 101 MHz): δ 204.1 (1-CHO), 135.3 
(8-C), 132.7 (10-C), 131.8 (11-C), 131.6 (12-C), 131.5 (9-C), 129.7 (13-C), 44.3 (2-C), 
33.3 (7-C), 29.9 (6-C), 29.6 (4-C), 29.6 (5-C), 22.7 (3-C), 18.4 (14-C); IR (neat) νmax 
2926, 1718, 995 cm
-1
; HRMS calcd for C14H22O [M+Na]
+




In a flame-dried round bottom flask 
under nitrogen atmosphere, phosphonate 
167 (0.88 g, 3.2 mmol) in anhydrous 
THF (15 mL) was added dropwise 
n-BuLi (2.4 mL, 1.6 M in hexane) at -78 °C and was allowed to stir for 1 h. To this stirred 
solution, crude aldehyde 345 (0.96 g, 4.7 mmol) in THF (10 mL) was added at -78 °C. 
The resulting mixture was allowed to warm to room temperature and stirred overnight. 
The reaction was quenched with diluted HCl and extracted with hexane (3 × 20 mL). The 
organic phases were combined, washed with sat. NaHCO3, sat. aqueous NaCl, dried over 
MgSO4, concentrated under vacuum and purified by flash chromatography (petroleum 
ether/EtOAc = 15:1) to give 343 as a white solid (0.36 g, 34%). 
Rf = 0.3 (petroleum ether/EtOAc = 9:1); 
1
H NMR (CDCl3, 400 MHz): δ 6.54 (dt, 1H, J = 
6.9, 15.5, 5-CH), 6.12-6.00 (m, 4H, 14,15,16,17-CH), 5.88 (dt, J = 1.5, 15.5, 1H, 6-CH), 
5.73-5.60 (m, 2H, 13,18-CH), 5.22 (s, 1H, 4-CH), 2.22-2.15 (m, 2H, 7-CH2), 2.11-2.03 





C NMR (CDCl3, 101 MHz): δ 163.4 (3-C), 162.1 (1-C), 142.6 (6-C), 
134.1 (13-C), 131.7 (15-C), 130.8 (16-C), 130.6 (17-C), 130.5 (14-C), 128.9 (18-C), 
122.4 (5-C), 106.2 (2-C), 93.2 (4-C), 32.7 (7-C), 29.2 (12-C), 29.0 (8-C), 28.9 (11-C), 
28.3 (9-C), 25.0 (20-C), 18.3 (19-C); IR (neat) νmax 2922, 2850, 1709, 1653, 1593, 1391, 
1375, 1271, 1250, 1202, 1016, 999, 972, 905, 816 cm
-1
; HRMS calcd for C21H30O3 
[M+Na]
+




343 (0.33 g, 1.0 mmol) was added to a solution of 342 (0.21 g, 1.0 mmol) in anhydrous 
toluene (20 mL). The solution was refluxed for 2 h. After complete reaction, reaction 
mixture was concentrated under vacuum and purified by flash chromatography 
(petroleum ether/EtOAc = 2:1) to afford 371 as a white solid (0.31 g, 64%). 
Rf = 0.4 (petroleum ether/EtOAc = 1:1); [α]D
23
 = -10.3 (c = 0.4, MeOH); 
1
H NMR 
(CDCl3, 400 MHz): δ 7.44 (d, 1H, J = 9.5, CONH), 7.03 (d, 2H, J = 8.5, 5-ArH), 6.91 (dt, 
1H, J = 6.8, 15.8, 12-CH), 6.67 (d, 2H, J = 8.5, 6-ArH), 6.11-5.97 (m, 5H, 
11,20,21,22,23-CH), 5.74-5.60 (m, 2H, 19,24-CH), 4.91 (d, 1H, J = 2.2, 1-CH), 4.57-4.48 
(m, 1H, 2-CH), 4.09-3.84 (m, 4H, 26,27-CH2), 3.50 (d, 1H, J = 17.0, 9-CH2), 3.41 (d, 1H, 
J = 17.0, 9-CH2), 2.88 (dd, 1H, J = 2.9, 14.1, 3-CH2), 2.68 (dd, 1H, J = 9.5, 14.1, 3-CH2), 
2.23-2.15 (m, 2H, 13-CH2), 2.11-2.03 (m, 2H, 18-CH2), 1.76 (d, 3H, J = 7.1, 25-CH3), 
1.47-1.24 (m, 8H, 14,15,16,17-CH2); 
13
C NMR (CDCl3, 101 MHz): δ 195.7 (10-C), 
166.4 (8-C), 155.1 (7-C), 151.4 (12-C), 134.1 (19-C), 131.8 (21-C), 130.8 (22-C), 130.6 
(23-C), 130.5 (20-C), 130.1 (5-C), 129.8 (11-C), 128.9 (24-C), 128.4 (4-C), 115.4 (6-C), 
103.2 (1-C), 65.5 (26-C), 65.5 (27-C), 52.4 (2-C), 45.6 (9-C), 35.5 (3-C), 32.7 (13-C), 
32.6 (18-C), 29.2 (17-C), 29.0 (16-C), 28.9 (15-C), 27.8 (14-C), 18.3 (25-C); IR (neat) 
νmax 3363, 2922, 2852, 1659, 1607, 1545, 1514, 1441, 1261, 1229, 1146, 993, 970, 943, 
791, 727, 542 cm
-1
; HRMS calcd for C29H39NO5 [M+Na]
+







Cyclic acetal 371 (17.0 mg) was dissolved in THF (5 mL) and 5 M HCl (2 mL) was added. 
The reaction mixture was heated at 60 °C for 3 h. After completion of reaction, the 
mixture was diluted with EtOAc and washed with H2O, sat. NaHCO3, saturated aqueous 
NaCl, dried over MgSO4, concentrated under vacuum and purified by flash 
chromatography (petroleum ether/EtOAc = 3:1) to afford 372b as a yellow solid (5 mg, 
34%). The compound is not stable during NMR measurement, so only the 
1
H NMR is 
available. 
Rf = 0.5 (petroleum ether/EtOAc = 2:1); 
1
H NMR (CDCl3, 400 MHz): δ 7.35 (s, 1H, 
CONH), 7.04 (d, 2H, J = 8.4, 8-ArH), 6.87-6.76 (m, 3H, 13-CH and 9-ArH), 6.16 (d, 1H, 
J = 15.5, 12-CH), 6.10-6.00 (m, 4H, 21,22,23, 24-CH), 5.72-5.60 (m, 2H, 20,25-CH), 
5.60 (s, 1H, 4-CH), 3.62 (s, 2H, 6-CH2), 2.26 (dd, 1H, J = 6.4, 14.0, 14-CH2), 2.08 (dd, 
1H, J = 7.0, 14.0, 19-CH2), 1.76 (d, 3H, J = 7.1, 26-CH3), 1.47-1.28 (m, 8H, 
15,16,17,18-CH2); HRMS calcd for C27H33NO3 [M+Na]
+




343 (82.0 mg, 0.25 mmol) was added to a solution of 212 (63.0 mg, 0.25 mmol) in 
anhydrous toluene (10 mL). The solution was heated at 105 °C for 3 h. The reaction 
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mixture was concentrated under vacuum and the residue was purified by flash 
chromatography (petroleum ether/EtOAc = 4:1) to give 374 as a yellow solid (78.0 mg, 
59%). 
Rf = 0.4 (petroleum ether/EtOAc = 4:1); [α]D
26 
= -5.3 (c = 0.2, MeOH); 
1
H NMR (CDCl3, 
400 MHz): δ 7.09 (d, 2H, J = 8.6, 5-ArH), 7.00-6.86 (m, 2H, 13-CH and CONH), 6.78 (d, 
2H, J = 8.6, 6-ArH), 6.12-5.98 (m, 5H, 12, 21, 22, 23, 24-CH), 5.70-5.57 (m, 2H, 20, 
25-CH), 4.35-4.27 (m, 2H, 2-CH and 1-CH), 3.79-3.70 (m, 4H, 8-CH3 and 27-CH2), 
3.63-3.47 (m, 3H, 27-CH2), 3.43 (s, 2H, 10-CH2), 2.89 (dd, 2H, J = 5.9, 14.1, 3-CH2), 
2.72 (dd, 2H, J = 8.1, 14.1, 3-CH2), 2.23-2.16 (m, 2H, 14-CH2), 2.08-2.02 (m, 2H, 
19-CH2), 1.74 (d, 3H, J = 6.8, 26-CH3), 1.42-1.16 (m, 14H, 28-CH3 and 15, 16, 17, 
18-CH2); 
13
C NMR (CDCl3, 101 MHz): δ 195.2 (11-C), 165.5 (9-C), 158.0 (7-C), 150.7 
(13-C), 134.1 (20-C), 131.8 (22-C), 130.8 (23-C), 130.6 (24-C), 130.5 (21-C), 130.2 
(5-C), 130.1 (4-C), 129.9 (12-C), 128.8 (25-C), 113.7 (6-C), 102.1 (1-C), 55.1 (8-C), 52.7 
(2-C), 46.9 (10-C), 34.7 (14-C), 32.7 (3-C), 32.6 (19-C), 29.2 (18-C), 29.0 (17-C), 28.9 
(16-C), 27.9 (15-C), 18.3 (26-C), 15.3 (28-C), 15.2 (28-C); IR (KBr) νmax 3288, 3008, 
2972, 2924, 2852, 1610, 1548, 1512, 1246, 1060, 993 cm
-1
; HRMS calcd for C32H47NO5 
[M+Na]
+




343 (82 mg, 0.25 mmol) was added to a solution of 127 (45 mg, 0.25 mmol) in anhydrous 
toluene (10 mL). The solution was heated at 105 °C for 3 h. The reaction mixture was 
concentrated under vacuum and the residue was purified by flash chromatography 
(CH2Cl2/MeOH = 20:1) to give 387 as a yellow solid (68 mg, 60%). 
Rf = 0.3 (CH2Cl2/MeOH = 20:1); [α]D
23
 = -20.4 (c = 0.3, MeOH); 
1
H NMR (CDCl3, 400 
MHz): δ 7.29-7.26 (m, 1H, CONH), 7.13 (d, 2H, J = 8.6, 5-ArH), 6.94 (dt, 1H, J = 6.8, 
15.8, 13-CH), 6.83 (d, 2H, J = 8.6, 6-ArH), 6.15-5.96 (m, 5H, 12,21,22,23,24-CH), 
Experimental 
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5.72-5.58 (m, 2H, 20,25-CH), 4.19-4.09 (m, 1H, 2-CH), 3.78 (s, 3H, 8-CH3), 3.69 (dd, 1H, 
J = 3.6, 11.2, 1-CH), 3.57 (dd, 1H, J = 5.5, 11.2, 1-CH), 3.54-3.44 (m, 2H, 10-CH2), 
2.89-2.73 (m, 2H, 3-CH2), 2.27-2.19 (m, 2H, 14-CH2), 2.11-2.02 (m, 2H, 19-CH2), 1.76 
(d, 3H, J = 6.6, 26-CH3), 1.50-1.26 (m, 8H, 15,16,17,18-CH2); 
13
C NMR (CDCl3, 101 
MHz): δ 195.7 (11-C), 166.6 (9-C), 158.3 (7-C), 151.3 (13-C), 134.1 (20-C), 131.7 
(22-C), 130.8 (23-C), 130.6 (24-C), 130.5 (21-C), 130.2 (5-C), 129.9 (4-C), 129.5 (12-C), 
128.9 (25-C), 114.0 (6-C), 64.3 (1-C), 55.2 (8-C), 53.5 (2-C), 46.2 (10-C), 36.2 (14-C), 
32.7 (3-C), 32.6 (19-C), 29.2 (18-C), 29.0 (17-C), 28.9 (16-C), 27.8 (15-C), 18.3 (26-C); 
IR (KBr) νmax 3292, 2926, 2852, 1610, 1510, 1300, 1244, 1176, 1033 cm
-1
; HRMS calcd 
for C28H39NO4 [M+Na]
+




Diethyl acetal 374 (20.0 mg, 0.04 mmol) was dissolved in aqueous THF (2 mL). After 
cooling to 0 °C, concentrated HCl (37%, 1.5 mL) was added and the reaction was stirred 
for 1.5 h. After complete reaction checked by LCMS, the solution was diluted with H2O 
and extracted with EtOAc (3 × 2 mL). The organic solvents were combined and 
evaporated under vacuum to afford yellow oil (12 mg, 70%). But the compound is not 
stable during NMR measurement, thus only the LCMS and HRMS are available.  
HRMS calcd for C28H37NO4 [M+Na]
+
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